ID=H0025
URL=http://www.who.int/ncd/hgn/reppub_malta.htm
SIZE=560089
DATE=11/07/2002
TIME=17:00:09
DATASET=Biology
HTML=<html>
<head>
<title>genetic disorders</title>
<meta name="DC.title" content="genetic disorders">

<meta name="Microsoft Border" content="none">
<meta name="DC.publisher" content="World Health Organization">
<meta name="DC.rights" content="http://www.who.int/home/copyright">
<meta name="DC.format" content="text/html">
<meta name="who.pubdate" content="Wed Jun 19 08:37:12 2002">
<meta name="who.pubby" content="kerneng@who.int">

</head>
<body topmargin="0" leftmargin="0" vlink="#008080" alink="#FF0000">
<table border="0" width="640" style="border: ">
  <tr>
    <td width="640"><table height="1" width="631">
      <tr>
        <td rowSpan="2" vAlign="top" width="120"><a href="/"><img
        alt="World Health Organization" border="0" src="../images/whologo.jpg" width="120" height="80"></a></td>
        <td vAlign="top" width="500"><a href="/"><img
        alt="World Health Organization" border="0" src="../images/top_line.gif" width="500" height="12"></a></td>
      </tr>
      <tr>
        <td vAlign="top" width="500"><p align="right"><img src="../images/hgn.gif"
        alt="hgn.gif (8550 bytes)" width="500" height="70"></td>
      </tr>
      <tr>
        <td colSpan="2" vAlign="top" width="620"><img src="../images/blue.gif"
        alt="blue.gif (943 bytes)" align="right" width="620" height="12"></td>
      </tr>
</TBODY>
    </table>
    </td>
  </tr>
  <tr>
    <td width="620"><p align="right"><font face="Arial,Helvetica,Sans Serif" size="1">Last update:18 Jun 2002</font></td>
  </tr>
  <tr>
    <td width="620"><font face="Arial,Helvetica,Sans Serif" size="1"><p align="center"></font><font size="2"><strong>|
    <a href="/m/healthtopics-a-z/en/index.html">Health topics</a> |&nbsp; <a
    href="/">WHO home</a> | <a
    href="/site-search/data-who-hq-live/search.shtml">Search</a> | <a
    href="../ncd_sitemap.htm">Site map</a> | <a href="../contact_us.htm">Contact us</a> |</strong></font></td>
  </tr>
  <tr>
    <td width="620"><hr>
    </td>
  </tr>
  <tr>
    <td width="620"><font size="2"><p align="right"><a href="/">WHO Home </a>-&gt;
    <a href="index.htm">Human genetics</a> -&gt; <a href="publications.htm">Human genetics
    publications</a> -&gt; Services for the prevention and management of genetic disorders and
    birth defects in developing countries<br>
    </font><br>
    </td>
  </tr>
  <tr>
    <td width="620"><div align="center"><center><table border="0" cellPadding="3"
    cellSpacing="0" width="615">
<TBODY>
      <tr>
        <td vAlign="top" width="500" height="1"><font size="2"><i>Document reference</i><span
        lang="EN-GB" style="font-size:9.0pt;mso-bidi-font-size:10.0pt">: <em>WHO/HGN/GL/WAOPBD/99.1,
        &nbsp; </span><!--[if supportFields]><span class=manual><span lang=EN-GB
style='font-size:9.0pt;mso-bidi-font-size:10.0pt'><span style='mso-element:
field-begin'></span>PRIVATE </span></span><![endif]--><span lang="EN-GB" style="font-size:9.0pt;mso-bidi-font-size:10.0pt">ENGLISH
        ONLY, </span><span lang="EN-GB"
        style="font-size:9.0pt;mso-bidi-font-size:10.0pt;font-family:"CG Times";mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA;layout-grid-mode:line">Distr.:<span
        style="mso-spacerun: yes">&nbsp; </span>GENERAL</span></em></font><i><font SIZE="-1"> </font></i><p>&nbsp;</p>
        <p align="center"><strong>&nbsp;<font size="3" color="#8000FF">&nbsp;&nbsp;</font><span
        lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:Arial;mso-bidi-font-family:"Times New Roman";font-variant:
small-caps"><font-size="3">Services
        for the Prevention and Management<o:p></o:p> of Genetic Disorders<o:p> and Birth Defects in Developing
        Countries</span></strong></p>
        <p class="MsoHeading9" align="center"><font face="Arial Black"><em><span lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"CG Times" font-style:normal">Report
        of a joint WHO/WAOPBD meeting<o:p></span></em></font></p>
        <i style="mso-bidi-font-style:normal"><span lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"CG Times"mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman" mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA; layout-grid-mode:line"><b
        style="mso-bidi-font-weight:normal"><p align="center"></b><u>The Hague, 5-7 January 1999</u></span></i></td>
        <td vAlign="top" width="146" height="1" bgcolor="#eaeaf2"><table>
          <tr>
            <th bgColor="#000080"><font face="Arial,Helvetica,Sans Serif" size="2" color="#FFFF00"><strong>Human genetics
            shortcut</strong></font></th>
          </tr>
          <tr>
            <td><a href="hgn_news.htm"><font face="Arial,Helvetica,Sans Serif" size="2" color="#0000FF"><strong><em>News</em></strong></font></a></td>
          </tr>
          <tr>
            <td><a href="publications.htm"><font face="Arial,Helvetica,Sans Serif" size="2" color="#0000FF"><strong><em>Publications</em></strong></font></a></td>
          </tr>
          <tr>
            <td><a href="databases.htm"><font face="Arial,Helvetica,Sans Serif" size="2" color="#0000FF"><strong><em>Databases</em></strong></font></a></td>
          </tr>
          <tr>
            <td><a href="hgn_events.htm"><font face="Arial,Helvetica,Sans Serif" size="2" color="#0000FF"><strong><em>Events</em></strong></font></a></td>
          </tr>
          <tr>
            <td><a href="country_profiles.htm"><font face="Arial,Helvetica,Sans Serif" size="2" color="#0000FF"><strong><em>Country
            profiles</em></strong></font></a></td>
          </tr>
          <tr>
            <td><a href="glopartners.htm"><font face="Arial,Helvetica,Sans Serif" size="2" color="#0000FF"><strong><em>Global
            partners</em></strong></font></a></td>
          </tr>
          <tr>
            <td><a href="collcentres.htm"><font face="Arial,Helvetica,Sans Serif" size="2" color="#0000FF"><strong><em>Collaborating
            centres</em></strong></font></a></td>
          </tr>
          <tr>
            <td><a href="relatedsites.htm"><font face="Arial,Helvetica,Sans Serif" size="2" color="#0000FF"><strong><em>Related
            sites</em></strong></font></a></td>
          </tr>
        </table>
        </td>
      </tr>
      <tr>
        <td colSpan="2" vAlign="top" width="654" height="1"><table border="0" width="100%">
          <tr>
            <td width="100%"><table border="1" cellspacing="0" cellpadding="0"
            style="margin-left:-1.7pt;
 border-collapse:collapse;mso-table-layout-alt:fixed;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"
            width="593" bordercolor="#008080" bordercolorlight="#008080" bordercolordark="#008080">
              <tr>
                <td width="300" valign="top" style="width:240.95pt;padding:0cm 5.4pt 0cm 5.4pt"
                align="center" bordercolor="#008080" bordercolorlight="#008080" bordercolordark="#008080"><p
                class="MsoNormal" style="margin-top:4.5pt;mso-hyphenate:none;tab-stops:-36.0pt"><!--[if supportFields]><span
  lang=EN-GB><span style='mso-element:field-begin'></span>PRIVATE </span><![endif]--><!--[if supportFields]><span
  lang=EN-GB><span style='mso-element:field-end'></span></span><![endif]--><span
                lang="EN-GB" style="font-size:8.0pt;mso-bidi-font-size:10.0pt">This document is not a
                formal publication of the World Health Organization (WHO), and all rights are reserved by
                the Organization.<span style="mso-spacerun: yes">&nbsp; </span>The document may, however,
                be freely reviewed, abstracted, reproduced and translated, in part or in whole, but not
                for sale nor for use in conjunction with commercial purposes.<o:p></o:p>&nbsp;<o:p></o:p></span></p>
                <p class="MsoNormal" style="margin-bottom:2.7pt;mso-hyphenate:none;tab-stops:
  -36.0pt"><span
                lang="EN-GB" style="font-size:8.0pt;mso-bidi-font-size:10.0pt">The views expressed in
                documents by named authors are solely the responsibility of those authors.<o:p></o:p></span></td>
                <td width="300" valign="top" style="width:240.95pt;padding:0cm 5.4pt 0cm 5.4pt"
                align="center"><p class="MsoNormal"
                style="margin-top:4.5pt;mso-hyphenate:none;tab-stops:-36.0pt"><span lang="FR"
                style="font-size:8.0pt;mso-bidi-font-size:10.0pt;mso-ansi-language:
  FR">Ce document
                n'est pas une publication officielle de l'Organisation mondiale de la Santé (OMS) et tous
                les droits y afférents sont réservés par l'Organisation.<span style="mso-spacerun: yes">&nbsp;
                </span>S'il peut être commenté, résumé, reproduit ou traduit, partiellement ou en
                totalité, il ne saurait cependant l'être pour la vente ou à des fins commerciales.<o:p></o:p></span></p>
                <p class="MsoNormal" style="margin-bottom:2.7pt;mso-hyphenate:none;tab-stops:
  -36.0pt"><span
                lang="FR" style="font-size:8.0pt;mso-bidi-font-size:10.0pt;
  mso-ansi-language:FR">Les
                opinions exprimées dans les documents par des auteurs cités nommément n'engagent que
                lesdits auteurs.<o:p></o:p></span></td>
              </tr>
            </table>
            </td>
          </tr>
        </table>
        <p class="MsoHeading9"><u><span lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"CG Times";font-style:normal">CONTENTS<o:p></o:p></span></u><b
        style="mso-bidi-font-weight:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoFooter" style="mso-pagination:widow-orphan;tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt;layout-grid-mode:both">1.<span
        style="mso-tab-count:
1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Executive
        Summary</span></b><span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:both">......................................................................................................5<o:p></o:p></span></p>
        <p class="MsoFooter" style="mso-pagination:widow-orphan;tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt">2.<span style="mso-tab-count:1">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Introduction</span></b><span
        lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:both">................................................................................................................</span><span
        lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:10.0pt">13<b
        style="mso-bidi-font-weight:normal"><o:p></o:p></b></span></p>
        <p class="MsoNormal"><span lang="EN-GB"><b style="mso-bidi-font-weight:normal">3.<span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Genetic
        disorders and birth defects</b></span><span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:both">...........................................................................</span><span
        lang="EN-GB">14</span></p>
        <p class="MsoNormal"><span lang="EN-GB"><b style="mso-bidi-font-weight:normal">4.<span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The goals
        of genetic services</b></span><span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:both">......................................................................................</span><span
        lang="EN-GB">15</span></p>
        <p class="MsoNormal" style="margin-left:36.0pt;text-indent:-36.0pt"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal">5.<span style="mso-tab-count:
1">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Economic, demographic and
        health<o:p> </b><b style="mso-bidi-font-weight:
normal">characteristics of developing
        countries</b></span><span style="mso-tab-count:
1">..........</span><span lang="EN-GB">17</span></p>
        <p class="MsoFooter"
        style="text-indent:36.0pt;mso-pagination:widow-orphan;
tab-stops:36.0pt"><span
        lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:
10.0pt;layout-grid-mode:both">5.1.
        High fertility and reduced life expectancy</o:p></span><br>
        <span lang="EN-GB">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.2.
        Low level of urbanization<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.3. Deficient
        infrastructure<span style="mso-tab-count:2"> </span><br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.4. Poverty<span
        style="mso-tab-count:1">&nbsp; </span><br>
        </span><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><span lang="EN-GB">5.5. Poor educational levels<span style="mso-tab-count:1"> </span><br>
        </span><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><span lang="EN-GB">5.6. Health conditions<span style="mso-tab-count:1"> </span><br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.7. Access to health
        services<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.8. Influence of
        tradition and religion<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5.9. Epidemiological
        transition</span></p>
        <p class="MsoNormal" style="margin-left:36.0pt;text-indent:-36.0pt"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal">6.
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequency and impact of genetic
        disorders and birth defects <br>
        in developing countries</b></span><span style="mso-tab-count:1">..............................................................................................
        </span><span lang="EN-GB">25<b style="mso-bidi-font-weight:normal"><o:p></o:p></b></span></p>
        <p class="MsoNormal" style="margin-left:18.0pt;text-indent:18.0pt"><span lang="EN-GB">6.1.
        Congenital malformations<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6.2. Chromosome abnormalities<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6.3. Single-gene disorders<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6.4. Conditions of genetic predisposition</span></p>
        <p class="MsoNormal" style="margin-left:36.0pt;text-indent:-36.0pt"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal">7.<span style="mso-tab-count:
1">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Current situation of medical
        genetic services </b><b style="mso-bidi-font-weight:
normal">in developing countries</b></span><span
        style="mso-tab-count:1">..................</span><span lang="EN-GB">29<b
        style="mso-bidi-font-weight:
normal"><o:p></o:p></b></span></p>
        <p class="MsoNormal" style="margin-left:18.0pt;text-indent:18.0pt"><span lang="EN-GB">7.1.
        Delivery of genetic services<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7.2. Genetic education of health professionals<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7.3. Genetic education of the public and role of
        parent/patient organizations<span style="mso-tab-count:1"> </span><br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7.4. Recent developments</span></p>
        <p class="MsoNormal"><b style="mso-bidi-font-weight:normal"><span lang="EN-GB">8.<span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Definition
        and goals of genetic services</span></b><span style="mso-tab-count:1">..........................................................</span><span
        lang="EN-GB">.........35<b style="mso-bidi-font-weight:normal"><o:p></o:p></b></span></p>
        <p class="MsoNormal" style="margin-left:36.0pt;text-indent:-36.0pt"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal">9.<span style="mso-tab-count:
1">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Goals and components of
        patient/family-based genetic services</b>............................36<b
        style="mso-bidi-font-weight:
normal"><o:p></o:p></b></span></p>
        <p class="MsoNormal" style="margin-left:36.0pt"><span lang="EN-GB">9.1. Addressing the
        medical and psychosocial needs of patients and families<br>
        9.2. Genetic diagnosis<br>
        9.3. Genetic counselling</span><br>
        <span lang="EN-US" style="mso-ansi-language:EN-US">9.4. Therapeutic interventions<br>
        9.5. Psychosocial support</span></p>
        <p class="MsoNormal" style="margin-left:36.0pt;text-indent:-36.0pt"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal">10.<span style="mso-tab-count:
1">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Goals and components of population-based
        genetic services</b></span><span style="mso-tab-count:1">..................................</span><span
        lang="EN-GB">40<b style="mso-bidi-font-weight:
normal"><o:p></o:p></b></span></p>
        <p class="MsoNormal" style="text-indent:36.0pt"><span lang="EN-GB">10.1. Primary
        prevention</span>.<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span lang="EN-GB">10.2.
        Secondary prevention<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10.3. Prevention based
        on reproductive options<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10.4. Tertiary
        prevention<span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
        style="mso-tab-count:
2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></p>
        <p class="MsoNormal"><span lang="EN-GB"><b style="mso-bidi-font-weight:normal">11.<span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Organization of the
        delivery of genetic</o:p> </b><b style="mso-bidi-font-weight:
normal">services</b>..</span><span
        style="mso-tab-count:1">................................................</span><span
        lang="EN-GB">.....45</span></p>
        <p class="MsoNormal" style="text-indent:36.0pt"><span lang="EN-GB">11.1. Primary health
        care level<span style="mso-tab-count:1">&nbsp;&nbsp; </span><br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11.2. Secondary care
        level<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11.3. Tertiary care
        level: medical genetics centres<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        11.3.1. Clinical genetics evaluation and genetic counselling<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        11.3.2. Laboratory diagnosis<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        11.3.3. Research<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        11.3.4. Teaching and training<span style="mso-tab-count:1"> </span><br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        11.3.5. General organizational aspects and funding strategies<span style="mso-tab-count:1">
        </span></span></p>
        <p class="MsoNormal" style="margin-left:36.0pt;text-indent:-36.0pt"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal">12.<span style="mso-tab-count:
1">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Training and education of health professionals
        in genetics</b>.....................................54</span></p>
        <p class="MsoNormal"><span lang="EN-GB"><b style="mso-bidi-font-weight:normal">13.<span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Genetic education of
        the public</b>..</span><span style="mso-tab-count:1">..............................................................................</span><span
        lang="EN-GB">..57</span></p>
        <p class="MsoNormal"><span lang="EN-GB"><b style="mso-bidi-font-weight:normal">14.<span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Parents/patients
        organizations</b>..</span><span style="mso-tab-count:1">..............................................................................</span><span
        lang="EN-GB">...58</span></p>
        <p class="MsoNormal" style="text-indent:36.0pt"><span lang="EN-GB">14.1. Medical support
        and self help<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14.2. Objectives of
        parents/patients organizations<br>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14.3. The role of
        parents/patients organizations</span></p>
        <p class="MsoNormal"><span lang="EN-GB"><b style="mso-bidi-font-weight:normal">15.<span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Research in medical
        genetics</b>..</span><span style="mso-tab-count:1">..............................................................................</span><span
        lang="EN-GB">....61</span></p>
        <p class="MsoNormal"><span lang="EN-GB"><b style="mso-bidi-font-weight:normal">16.<span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Ethical aspects of
        genetic services</b>..</span><span style="mso-tab-count:1">.........................................................................</span><span
        lang="EN-GB">62</span></p>
        <p class="MsoNormal" style="margin-left:36.0pt"><span lang="EN-GB">16.1. Ethical
        principles applied to genetic services<br>
        16.2. Ethical principles applied to genetic counselling</span></p>
        <p class="MsoNormal"><span lang="EN-GB"><b style="mso-bidi-font-weight:normal">17.<span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>General conclusions
        and recommendations</b></span><span style="mso-tab-count:1">............................................................</span><span
        lang="EN-GB">.65<b style="mso-bidi-font-weight:normal"><o:p></o:p></b></span></p>
        <p class="MsoNormal" style="margin-left:36.0pt"><span lang="EN-GB">17.1. Need to recognize
        the burden imposed by birth defects and genetic disorders<br>
        17.2. Need for political will and commitment<br>
        17.3. Improve epidemiological knowledge about genetic disorders and birth defects<br>
        17.4.<span style="mso-spacerun: yes"> </span>Define goals of genetic services in terms
        both individual/family and public health<span style="mso-tab-count:1"> </span><br>
        17.5.<span style="mso-spacerun: yes"> </span>Improve pre- and perinatal services<span
        style="mso-tab-count:1"> </span><br>
        17.6.<span style="mso-spacerun: yes"> </span>Organize genetic services in a comprehensive
        and integrated manner, with roots in the
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; primary health care level<br>
        17.7.<span style="mso-spacerun: yes"> </span>Select programs and targets according to
        prevalence, severity and predicted outcomes<br>
        17.8.<span style="mso-spacerun: yes"> </span>Respect ethical principles and cultural
        diversity<br>
        17.9.<span style="mso-spacerun: yes"> </span>Training health professionals in medical
        genetics<br>
        17.10. Educate the public in genetics<br>
        17.11. Encourage the formation of parent/patient organizations<span
        style="mso-tab-count:1">&nbsp; </span></span></p>
        <p class="MsoFooter"
        style="margin-left:36.0pt;text-indent:-36.0pt;mso-pagination:
widow-orphan;tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:
both">18.<span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Specific
        recommendations at different stages of the reproductive cycle</span></b><span
        style="mso-tab-count:1">..............</span><span lang="EN-US"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt;layout-grid-mode:both">.75<b
        style="mso-bidi-font-weight:normal"><o:p></o:p></b></span></p>
        <blockquote>
          <p class="MsoBodyTextIndent3"><span lang="EN-GB" style="font-family:"CG Times"">&nbsp;
          18.1. Recommendations for the preconception period<span style="mso-tab-count:1"> </span></span><br>
          <span style="mso-tab-count:1">&nbsp; </span><span lang="EN-GB">18.2. Recommendations
          during pregnancy<br>
          &nbsp; 18.3. Recommendations for newborns, infants and children<span
          style="mso-tab-count:1"> <br>
          </span>&nbsp; 18.4.<span style="mso-spacerun: yes">&nbsp; </span>Recommendations for
          adults</span></p>
        </blockquote>
        <p class="MsoFooter"
        style="margin-left:36.0pt;text-indent:-36.0pt;mso-pagination:
widow-orphan;tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:
both">19.<span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Specific
        recommendations for categorical (vertical) programs</span></b><span
        style="mso-tab-count:1">..............................</span><span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:
both">77<o:p></o:p></span></p>
        <p class="MsoFooter"
        style="margin-left:24.0pt;text-indent:12.0pt;mso-pagination:
widow-orphan;tab-stops:36.0pt"><span
        lang="EN-US" style="font-size:12.0pt;
mso-bidi-font-size:10.0pt;layout-grid-mode:both">19.1.
        Prevention of congenital malformations<br>
        &nbsp;&nbsp;&nbsp; 19.2. Prevention of Down syndrome</span><br>
        <span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:
10.0pt;layout-grid-mode:both">&nbsp;&nbsp;&nbsp;
        19.3. Prevention and management of selected single-gene disorders of high prevalence and
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        impact<span style="mso-tab-count:1">&nbsp; </span><span style="mso-tab-count:
1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><br>
        &nbsp;&nbsp;&nbsp; 19.4</span><span style="mso-spacerun: yes">.<span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:
10.0pt;layout-grid-mode:both"> </span>Genetic
        education of health professionals<span style="mso-tab-count:
1">&nbsp; </span><br>
        &nbsp;&nbsp; 19.5.&nbsp; Public education in health aspects <o:p></o:p>of genetics<span
        style="mso-tab-count:1"> </span></span></p>
        <p class="MsoFooter" style="mso-pagination:widow-orphan;tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt;layout-grid-mode:both">20.<span
        style="mso-tab-count:
1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Final statement</span></b><span
        lang="EN-GB">.</span><span style="mso-tab-count:1">.......................................................................</span><span
        lang="EN-GB">.</span><span style="mso-tab-count:1">................................</span><span
        lang="EN-US" style="font-size:
12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:both">79<o:p></o:p></span></p>
        <p class="MsoFooter" style="mso-pagination:widow-orphan;tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt;layout-grid-mode:both">21</span></b><span
        lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:both">.<span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><b
        style="mso-bidi-font-weight:normal">List of Participants</b></span><span lang="EN-GB">.</span><span
        style="mso-tab-count:1">..................................................................................................</span><span
        lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:both">80<o:p></o:p></span></p>
        <p class="MsoFooter" style="mso-pagination:widow-orphan;tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt;layout-grid-mode:both">22.<span
        style="mso-tab-count:
1">&nbsp;&nbsp;&nbsp;&nbsp; </span>References</span></b><span
        lang="EN-GB">.</span><span style="mso-tab-count:1">.......................................................................</span><span
        lang="EN-GB">.</span><span style="mso-tab-count:1">........................................</span><span
        lang="EN-US" style="font-size:
12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:both">82<o:p></o:p></span></p>
        <p class="MsoFooter"
        style="margin-left:36.0pt;mso-pagination:widow-orphan;
tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:both">Figure</span></b><span
        lang="EN-GB">.</span><span style="mso-tab-count:1">.......................................................................</span><span
        lang="EN-GB">.</span><span style="mso-tab-count:1">...............................................</span><span
        lang="EN-US" style="font-size:
12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:both">94<b
        style="mso-bidi-font-weight:normal"><br>
        Tables</b></span><span lang="EN-GB">.</span><span style="mso-tab-count:1">.......................................................................</span><span
        lang="EN-GB">.</span><span style="mso-tab-count:1">..............................................</span><span
        lang="EN-US" style="font-size:
12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:both">95<o:p></o:p></span></p>
        <p><b style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt;font-family:"CG Times";mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">&nbsp;</p>
        <p><br clear="all" style="page-break-before:always">
        </span></b></p>
        <p class="MsoFooter" style="mso-pagination:widow-orphan;tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt">1. EXECUTIVE SUMMARY<o:p></o:p></span></b></p>
        <h1 style="text-align:justify"><span lang="EN-GB"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt;font-family:"CG Times";font-weight:normal">&nbsp;<o:p></o:p></span></h1>
        <p class="MsoHeading8" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;
font-family:"CG Times";font-style:normal">Introduction<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">The benefits of the enormous progress in
        medical genetics during the past two decades in the industrialized nations, have had
        little or no impact in the developing countries, where more than 80% of the world's
        population lives. In order to assess the status of genetic services in developing
        countries, the World Health Organization (WHO) and the World Alliance of Organizations for
        the Prevention of Birth Defects (WAOPD) convened a group of experts in medical genetics
        who either work in, or are familiar with the social, economic and health problems of
        developing countries. A joint WHO /WAOPBD meeting on Prevention and Care of Genetic
        Diseases and Birth Defects in Developing Countries was held in The Hague from 5 to 7
        January 1999. Its purpose was to review the current status of genetic services in the
        developing world, and make recommendations to further the implementation of programs for
        the management and prevention of genetic disorders and birth defects at the primary health
        care and community levels in those countries.</span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoFooter"
        style="text-align:justify;mso-pagination:widow-orphan;
tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:both">Goals of genetic
        services<o:p></o:p></span></b></p>
        <p class="MsoFooter"
        style="text-align:justify;mso-pagination:widow-orphan;
tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:both">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoFooter"
        style="text-align:justify;text-indent:36.0pt;mso-pagination:
widow-orphan;tab-stops:36.0pt"><span
        lang="EN-US" style="font-size:12.0pt;
mso-bidi-font-size:10.0pt;layout-grid-mode:both">Genetic
        services deal with all the medical aspects of genetic disorders, as well as of all birth
        defects and congenital malformations, regardless of their causes. Genetic services care
        for the management and prevention of those conditions. When they are targeted</span><span
        lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:10.0pt"> to individuals and
        families their goal is to enable people with a genetic disadvantage, and their families,
        to live and reproduce as normally as possible. The people need access to relevant medical
        services (diagnostic, therapeutic, counselling, rehabilitative and preventive) and social
        support systems, to help them acquire the appropriate knowledge and information to enable
        them to adapt to their unique situation and to make educated and voluntary choices on
        health and reproductive matters. <o:p></o:p></span></p>
        <p class="MsoFooter"
        style="text-align:justify;text-indent:36.0pt;mso-pagination:
widow-orphan;tab-stops:36.0pt"><span
        lang="EN-US" style="font-size:12.0pt;
mso-bidi-font-size:10.0pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoFooter"
        style="text-align:justify;text-indent:36.0pt;mso-pagination:
widow-orphan;tab-stops:36.0pt"><span
        lang="EN-US" style="font-size:12.0pt;
mso-bidi-font-size:10.0pt">When targeted to
        populations, genetic services have public health goals of reducing the burden imposed by
        genetic disorders and birth defects on the population.<o:p></o:p></span></p>
        <p class="MsoFooter"
        style="text-align:justify;text-indent:7.65pt;mso-pagination:
widow-orphan;tab-stops:36.0pt"><span
        lang="EN-US" style="font-size:12.0pt;
mso-bidi-font-size:10.0pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent" style="text-indent:0cm"><b
        style="mso-bidi-font-weight:
normal"><span lang="EN-GB" style="layout-grid-mode:both">Demographic
        and health characteristics of developing countries<o:p></o:p></span></b></p>
        <p class="MsoBodyTextIndent" style="text-indent:7.65pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent3"
        style="margin-left:0cm;text-align:justify;
text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Generalizations based on averages do not capture
        the wide range of existing realities, pertaining in most developing nations. They are
        characterized by low gross national products (10-40 times lower than average for developed
        countries), large inequalities in income distribution,<b
        style="mso-bidi-font-weight:normal"> </b>economic dependency, low levels of urbanization,
        deficient water sanitation, and poor transportation, communications and technological
        development. Education levels are low, particularly for women, and fertility is high.<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent3"
        style="margin-left:0cm;text-align:justify;
text-indent:7.65pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText" style="text-indent:36.0pt;mso-hyphenate:none"><span lang="PT-BR"
        style="font-family:"CG Times"">The average life expectancy is lower than in
        developed nations and the major portion of childhood mortality being attributable to acute
        respiratory infections, diarrhea, perinatal causes, measles and malaria, with malnutrition
        a common associated cause. However, m</span><span lang="EN-GB"
        style="font-family:"CG Times";letter-spacing:-.15pt;mso-ansi-language:
EN-GB">any
        developing countries are experiencing an epidemiological transition, with a relative
        increased role of genetic factors in health and disease. Numerous indicators are available
        pointing to the presence of a higher prevalence of genetic disorders in developing
        countries than in industrialized nations. </span><span lang="PT-BR"
        style="font-family:"CG Times"">Health services are chronically underfunded and
        characterized by deficient planning and implementation, </span><span lang="EN-GB"
        style="font-family:"CG Times";
mso-ansi-language:EN-GB">overlapping</span><span
        lang="PT-BR" style="font-family:
"CG Times""> functions, poor coordination,
        with the emphasis on individual curative medical services, rather than community-based
        preventive approaches.<o:p></o:p></span></p>
        <h4 style="text-align:justify;text-indent:7.65pt"><span lang="EN-GB"
        style="font-weight:normal">&nbsp;<o:p></o:p></span></h4>
        <h4 style="text-align:justify"><span lang="EN-GB" style="font-style:normal">Prevalence of
        genetic disorders and birth defects<o:p></o:p></span></h4>
        <p class="MsoNormal" style="text-align:justify;text-indent:7.65pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Because
        of underreporting, genetic disorders and birth defects are systematically underestimated
        in developing countries and recorded frequencies must be considered minimum estimates.
        Although the prevalence of genetic disorders and birth defects is probably higher than
        that in the industrialized nations, the burden that these conditions impose on populations
        of the developing world is greater, because of their limited resources.<b
        style="mso-bidi-font-weight:normal"> <o:p></o:p></b></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:7.65pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        haemoglobin disorders are a major public health problem in the developing world, where 90%
        of affected individuals live. Cardiovascular diseases, malignancies, mental illness,
        obesity and diabetes are increasingly affecting people in the developing countries,
        particularly in urban populations.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:7.65pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <h6 style="text-align:justify;mso-hyphenate:auto;tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt;font-family:"CG Times";mso-ansi-language:EN-US;
font-style:normal">Current
        status of genetic services<o:p></o:p></span></b></h6>
        <p class="MsoBodyTextIndent" style="mso-pagination:widow-orphan"><span lang="EN-GB"
        style="layout-grid-mode:both">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent" style="mso-pagination:widow-orphan"><span lang="EN-GB"
        style="layout-grid-mode:both">A number of deficiencies characterise genetic services in
        developing countries, in part because of:</span></p>
        <p class="MsoBodyTextIndent"
        style="margin-left:57.6pt;text-indent:-21.6pt;
mso-pagination:widow-orphan;mso-list:l169 level1 lfo74;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">The load of unmet needs in other aspects of health care;</span></p>
        <p class="MsoBodyTextIndent"
        style="margin-left:57.6pt;text-indent:-21.6pt;
mso-pagination:widow-orphan;mso-list:l169 level1 lfo74;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Genetic conditions not considered priorities by the medical profession and
        public health officials;</span></p>
        <p class="MsoBodyTextIndent"
        style="margin-left:57.6pt;text-indent:-21.6pt;
mso-pagination:widow-orphan;mso-list:l169 level1 lfo74;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Genetic services are misperceived as expensive and concerned only with rare
        diseases;</span></p>
        <p class="MsoBodyTextIndent"
        style="margin-left:57.6pt;text-indent:-21.6pt;
mso-pagination:widow-orphan;mso-list:l169 level1 lfo74;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Genetic services are more diagnostic than therapeutic, and means of their
        prevention are usually perceived as interruption of affected pregnancies; and</span></p>
        <p class="MsoBodyTextIndent"
        style="margin-left:57.6pt;text-indent:-21.6pt;
mso-pagination:widow-orphan;mso-list:l169 level1 lfo74;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">The public is largely unaware about genetic risks and the possibilities of
        prevention.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">In
        spite of these difficulties, a number of genetic services have been implemented in
        developing countries, particularly patient/family genetic services in major urban centres
        at tertiary care university hospitals. The approach has largely been individual, with
        emphasis in clinical genetics, dysmorphology, cytogenetics and prenatal diagnosis of
        chromosome anomalies. Biochemical genetics laboratories, on the other hand, are scarce.
        DNA-based diagnosis is only incipient. In a few countries there are, however,
        population-based programs for the control of genetic disorders and birth defects.</span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <h6 style="text-align:justify;mso-hyphenate:auto;tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt;font-family:"CG Times";mso-ansi-language:EN-US;
font-style:normal">Main
        conclusions and recommendations<o:p></o:p></span></b></h6>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l155 level1 lfo68;tab-stops:list 18.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">1.<span style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Need to recognize the burden imposed by genetic
        disorders and birth defects<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Notwithstanding significant variations among
        countries in the relative role of genetic and congenital factors in disease and
        disability, the consensus of the Group was that most nations in the developing world were
        already at a stage that required some attention to genetic disorders and birth defects,
        even though infectious diseases and malnutrition were not yet completely under control.
        Although scarce health resources should not be diverted from the attention of the latter,
        the Advisory Group's contention is that governments in the developing countries
        should start devoting attention and resources to the control of genetic disorders and
        birth defects. Public health authorities must acknowledge the reality that these
        conditions are indeed major causes of disease, disability, suffering and death in their
        countries, and recognize that there are approaches for their management and prevention
        that can significantly reduce their burden in a cost efficient manner.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></i></b></p>
        <p><b style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"CG Times";
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">&nbsp;</p>
        <p><br clear="all" style="mso-special-character:line-break;page-break-before:always">
        </span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt">&nbsp;<b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times""><o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l155 level1 lfo68;tab-stops:list 18.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">2.<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Need
        for political will and commitment<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Governments must demonstrate beyond rhetoric, a
        political will to improve health and wellbeing of the people by making all types of health
        services, including genetic services, available, equitable and accessible. The commitment
        must originate and be driven from the highest levels of government, and be translated into
        appropriate resource allocation.<span style="mso-spacerun: yes">&nbsp; </span>Health
        authorities should recognize that: <o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-top:0cm;margin-right:18.0pt;margin-bottom:
0cm;margin-left:18.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:
-18.0pt;mso-list:l58 level1 lfo190;tab-stops:list 18.0pt left 432.0pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span lang="EN-GB"
        style="font-family:"CG Times"">Priorities can be established so that there is no
        need to &#147;start with everything at the same time&#148;; <o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l58 level1 lfo190;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span lang="EN-GB"
        style="font-family:"CG Times"">A number of genetic services can be implemented
        without excessive financial investments; <o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l58 level1 lfo190;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span lang="EN-GB"
        style="font-family:"CG Times"">Many genetic services are cost effective; and<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l58 level1 lfo190;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span lang="EN-GB"
        style="font-family:"CG Times"">The societal costs of inaction in genetics,
        measured in terms of avoidable human suffering and burden to public health, are very high.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">The Advisory Group specifically recommends that
        Ministries of Health of developing countries allocate resources for genetic programs and
        set up a distinct Office of Genetic Services within their administrative structure to
        determine the existing burden of genetic disorders and birth defects in the population,
        the status of existing programs for their control .The Office of Genetic Services should
        organize at the level of the Ministry of Health a permanent advisory council on genetic
        services with participation of interested parties to recommend and oversee the appropriate
        steps and priorities for genetic services in the country.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l155 level1 lfo68;tab-stops:list 18.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">3.<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Improve
        epidemiological knowledge about genetic disorders and birth defects.<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Research should be stimulated to provide better
        data on the prevalence and types of birth defects, genetic diseases and genetic
        predispositions to common diseases at the national level. In addition, information on what
        impact specific genetic disorders and birth defects have on individuals, families, and
        communities should be developed. These studies would typically include data on the natural
        history of conditions, mortality, morbidity, quality of life and reproduction, utilization
        of the health care system, hospitalisations, manpower requirements for their management,
        costs of services, etc.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify"><b
        style="mso-bidi-font-weight:
normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">4.<span style="mso-spacerun: yes">
        &nbsp; </span>Define goals of genetic services in terms of individual/family wellbeing and
        of public health.<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">The basis for defining goals of genetic services
        in a particular country or community are: <o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l187 level1 lfo192;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span lang="EN-GB"
        style="font-family:"CG Times"">The existing burden of specific genetic disorders
        and birth defects and their impact upon society in human and economic terms; <o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l187 level1 lfo192;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span lang="EN-GB"
        style="font-family:"CG Times"">The burden of other health problems; <o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l187 level1 lfo192;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span lang="EN-GB"
        style="font-family:"CG Times"">The resources available and the potential of
        raising funds from external sources; <o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l187 level1 lfo192;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span lang="EN-GB"
        style="font-family:"CG Times"">The state of the art of established screening,
        diagnostic, preventive and therapeutic methodologies for particular conditions (for
        example, preconceptional folic acid supplementation for the prevention of neural tube
        defects, screening and prenatal diagnosis of thalassaemias, genetic predisposition to
        cancer, etc); and<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l187 level1 lfo192;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span lang="EN-GB"
        style="font-family:"CG Times"">The expectations of the community.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify"><b
        style="mso-bidi-font-weight:
normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify"><b
        style="mso-bidi-font-weight:
normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">5.<span style="mso-spacerun: yes">
        &nbsp; </span>Improve pre- and perinatal services.<o:p></o:p></span></i></b></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:0cm;text-align:justify;
text-indent:40.5pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:0cm;text-align:justify;
text-indent:40.5pt"><span lang="EN-GB"
        style="font-family:"CG Times"">The prevention of a number of genetic disorders
        and birth defects will follow an improvement in the quality and accessibility of
        preconception, prenatal and perinatal services. The improvement of preconception care
        should include: <o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2" style="margin-left:0cm;text-align:justify"><span
        lang="EN-GB" style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:18.0pt;text-align:justify;
text-indent:-18.0pt;mso-list:l173 level1 lfo194;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span lang="EN-GB"
        style="font-family:"CG Times"">Encouragement of procreating in the optimal age
        period (20-35 years of age); <o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:18.0pt;text-align:justify;
text-indent:-18.0pt;mso-list:l207 level1 lfo197;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span lang="EN-GB"
        style="font-family:"CG Times"">Public education about methods that allow couples
        to have children when they want them, and provision of services to make those methods
        accessible; <o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:18.0pt;text-align:justify;
text-indent:-18.0pt;mso-list:l100 level1 lfo198;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span lang="EN-GB"
        style="font-family:"CG Times"">Rubella immunization before pregnancy; <o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:18.0pt;text-align:justify;
text-indent:-18.0pt;mso-list:l188 level1 lfo199;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span lang="EN-GB"
        style="font-family:"CG Times"">Education on the avoidance of teratogens during
        gestation, particularly alcohol; <o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:18.0pt;text-align:justify;
text-indent:-18.0pt;mso-list:l128 level1 lfo200;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span lang="EN-GB"
        style="font-family:"CG Times"">Education on the need for, how and when to access
        prenatal care services.<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:0cm;text-align:justify;
text-indent:40.5pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:0cm;text-align:justify;
text-indent:40.5pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Prenatal services including facilities for
        prenatal diagnosis require to be developed and to the greatest extent possible. Each
        mother should have the opportunity of being delivered by a trained birth attendant, in a
        hospital or clinic if possible. Newborn services should allow for each neonate to undergo
        a complete physical examination prior to discharge to detect the major and common genetic
        disorders and birth defects.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify"><b
        style="mso-bidi-font-weight:
normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">6.<span style="mso-spacerun: yes">
        &nbsp; </span>Organize genetic services in a comprehensive and integrated manner, with
        roots in the primary health care level.<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Genetic services should always be comprehensive
        and combine the best possible patient care available in the country, with population-based
        prevention strategies. <o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Furthermore, genetic services must be integrated
        with related services, such as reproductive health, prenatal care, newborn care, child
        growth and development monitoring, nutrition, cancer prevention, etc. In some cases,
        genetic services will be part of specific categorical programs, such as newborn metabolic
        screening, the control of haemoglobin disorders, haemophilia or mental retardation.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Genetic
        services must be extended into primary health care settings, where genetic risks should be
        identified. In order to avoid duplication of services and ensure<span
        style="mso-spacerun: yes">&nbsp; </span>cost efficiency, genetic services should be
        regionalized, with tertiary centres responsible for specific geographic and administrative
        areas. Insertion of genetic services into the community is key to the success of any
        genetic program. Services should have an emphasis on the family and should rely on modern
        cost/efficient information technology. Continuity of care, long-term management and
        quality assurance of clinical and laboratory services are essential components.</span></p>
        <p class="MsoBodyText2" style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify"><b
        style="mso-bidi-font-weight:
normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">7.<span style="mso-spacerun: yes">
        &nbsp;&nbsp; </span>Select programs and targets according to prevalence, severity and
        predicted outcomes<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Prevention
        of congenital rubella by immunization of susceptible children should be a priority.
        Educational and social programs to prevent alcohol consumption during pregnancy will help
        prevent fetal alcohol syndrome, which has high prevalence in some population groups.
        Neural tube defects can be partially prevented through preconceptional folic acid
        supplementation, maternal serum screening programs and fetal ultrasonography. Prevention
        of Down syndrome could be accomplished to a considerable degree through community
        education and family planning to encourage procreation before 35 years of age, and,
        depending on availability of resources, implementation of maternal serum antenatal
        screening followed by prenatal diagnosis. Women of advanced maternal age who become
        pregnant could be offered prenatal diagnosis (amniocentesis, chorionic villus sampling),
        according to availability of resources. These programs require the development of
        efficient educational programs, genetic counselling and adequate fetal medicine and
        laboratory facilities.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:0cm;text-align:justify;
text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Some of the most common severe inherited
        conditions, such as haemoglobin disorders, cystic fibrosis, fragile-X syndrome,
        haemophilia and muscular dystrophies, contribute considerably to chronic morbidity in
        childhood in many developing countries. Programs for the prevention and care of affected
        children with these conditions may significantly reduce the overall burden due to chronic
        disease at the community level.<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:0cm;text-align:justify;
text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:0cm;text-align:justify;
text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Newborn metabolic screening should only be
        considered in countries with the infrastructure and resources necessary to guarantee
        efficiency and desired outcomes. Newborn metabolic screening should always be a policy
        decision by the government, which should allocate the necessary resources for its
        implementation.<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:0cm;text-align:justify;
text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify"><b
        style="mso-bidi-font-weight:
normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">8.<span style="mso-spacerun: yes">
        &nbsp; </span>Respect ethical principles and cultural diversity<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:18.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        health beliefs, traditions, religious observances and social expectations of individuals
        and communities should be assessed properly before setting program goals, and respected
        thereafter. These goals should never be set in ways to impose certain genetic tests or
        reproductive decisions on individuals. Governments should recognize that within any
        country there exists diversity of cultures and opinions about a number of issues relevant
        to genetics. These include human reproduction issues and community and individual
        approaches to the significance of disabilities.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:18.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">This
        diversity should be respected. Ethical principles of justice, autonomy, beneficence and
        respect for the dignity and basic intelligence of persons should be adhered to.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;tab-stops:54.0pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB">9.<span style="mso-spacerun: yes">
        &nbsp; </span>Train health professionals in genetics<o:p></o:p></span></i></b></p>
        <p class="MsoFooter"
        style="text-align:justify;mso-pagination:widow-orphan;
tab-stops:36.0pt"><span
        lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:
10.0pt;layout-grid-mode:both">&nbsp;<o:p></o:p></span></p>
        <p class="MsoFooter"
        style="text-align:justify;text-indent:36.0pt;mso-pagination:
widow-orphan;tab-stops:36.0pt"><span
        lang="EN-US" style="font-size:12.0pt;
mso-bidi-font-size:10.0pt">Serious efforts need to
        be undertaken in genetic education to health professionals. Undergraduate curricula of the
        health professions (primarily physicians, nurses, psychologists and social workers) should
        be modernized and the practical aspects of medical genetics included in clinical teaching.
        The relationships between genetics and public health should be addressed in the schools of
        public health. For those health professionals already in practice, continuing education
        programs to familiarize them with the modern concepts of clinical genetics are essential.
        Officials in charge of public health programs should be targeted specifically for
        continuing education in genetics.<o:p></o:p></span></p>
        <p class="MsoFooter"
        style="text-align:justify;text-indent:18.0pt;mso-pagination:
widow-orphan;tab-stops:36.0pt"><span
        lang="EN-US" style="font-size:12.0pt;
mso-bidi-font-size:10.0pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Although
        clinical geneticists and specialized laboratory personnel are scarce, efforts need to be
        directed towards training in genetics of different health professionals including
        physicians, nurses, genetic counsellors psychologists, and social workers. At the same
        time, existing clinical geneticists should be educated in public and community health.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB">10.<span style="mso-spacerun: yes">
        &nbsp; </span>Educate the public in genetics<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:3.75pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Public education about genetic disorders and
        birth defects should be attuned to the prevailing cultures, beliefs and values of the
        populations in any given community. Particular attention should be paid to the vulnerable
        groups in society (the poor, ethnic and linguistic minorities, etc). Proper use of the
        media (particularly radio and TV) is invaluable. Community meetings should be encouraged
        to discuss important issues, such as the use of alcohol in pregnancy, rubella
        immunizations, self-medications, the value of learning about one's own family medical
        history, where to go for genetic counselling, etc. Education on these topics should begin
        in high school. Educational messages require to be simple, explicit but understandable and
        couched in a manner that does not cause offence.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify"><b
        style="mso-bidi-font-weight:
normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify"><b
        style="mso-bidi-font-weight:
normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">11.<span style="mso-spacerun: yes">
        &nbsp; </span>Encourage the formation of parent/patient organizations<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Throughout the industrialized and developing
        worlds, affected individuals and their families have acquired the awareness and creativity
        to advocate for their own needs. Hundreds of parent/patient organizations have been
        instrumental in drawing attention to the need for clinical services and preventive
        programs for genetic disorders and birth defects, as well as asserting their right to be
        treated with dignity and without discrimination. A number of legislative initiatives in
        several countries have been the result of the actions of parent/patient organizations. The
        medical profession and<span style="mso-spacerun: yes">&nbsp; </span>governments should
        support the development of these independent lay organizations. It is important that they
        be truly independent and able to respond to the legitimate needs of their constituencies,
        and not be controlled by the medical establishment or government.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">2. INTRODUCTION</span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">A
        W.H.O. scientific group in 1993 reviewed the current and potential applications of genetic
        knowledge for improving human health (WHO, 1996). The group confined most of its analysis
        and recommendations to the conditions of the industrialized countries, although it
        acknowledged that genetic disorders and birth defects in developing countries occur at a
        particularly high frequency.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">In
        order to address this problem in the context of the distinct socio-economic, cultural and
        health circumstances of the developing countries, WHO joined WAOPD to convene a group of
        experts in medical genetics who either work in, or are familiar with the problems of
        developing countries, in order to analyse the situation with respect to genetic disorders
        and birth defects in those countries. The joint WHO /WAOPBD meeting on Prevention and Care
        of Genetic Diseases and Birth Defects in Developing Countries was held in The Hague from 5
        to 7 January 1999 to review the current status of genetic services in the developing
        world, and make recommendations to further the implementation of programs for the
        management and prevention of genetic disorders and birth defects at the primary health
        care and community levels in those countries.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        rationale for this meeting was that the benefits of the enormous progress in medical
        genetics during the past two decades in the industrialized countries, where less than 20%
        of the world's population lives, have had little or no impact in the Third World. The
        purposes of the meeting were to assess the status and characteristics of whatever programs
        existed in the developing world, examine the possible reasons for their deficiencies, and
        propose guidelines for the implementation of programs for the management and prevention of
        genetic disorders and birth defects that take into account the social, cultural, religious
        and economic realities of developing countries.</span></p>
        <p><span lang="EN-GB"
        style="font-size:14.0pt;mso-bidi-font-size:10.0pt;font-family:
Arial;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA;
layout-grid-mode:line">&nbsp;</p>
        <p><br clear="all" style="page-break-before:always">
        </span></p>
        <h1 style="text-align:justify"><span lang="EN-GB"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt;font-family:"CG Times"">3.
        GENETIC DISORDERS AND BIRTH DEFECTS<o:p></o:p></span></h1>
        <p class="MsoFooter"
        style="text-align:justify;mso-pagination:widow-orphan;
tab-stops:36.0pt"><span
        lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:
10.0pt;layout-grid-mode:both">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        terminology used in medical genetics is sometimes confusing and/or overlapping. A <b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal">birth defect</i></b>
        is any type of functional or structural abnormality determined largely by factors
        operating before birth, <i style="mso-bidi-font-style:normal">in utero</i>, or in the
        immediate postnatal period. Structural abnormalities are usually called <b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal">malformations</i></b>.
        Functional abnormalities are exemplified by inborn errors of metabolism, haemoglobin
        disorders, or mental retardation. The term <b style="mso-bidi-font-weight:
normal"><i
        style="mso-bidi-font-style:normal">congenital </i></b>implies present at birth. It is
        important to note that any of these birth defects may not be apparent immediately and some
        can become clinically evident only days, months or even years after birth. The causes of
        birth defects may be genetic, environmental, or mixed.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal">Genetic
        disorders</i></b> are conditions in which a defect lies in the DNA of the genes and plays
        a major role in causation of a pathological condition. Genetic disorders can be <b
        style="mso-bidi-font-weight:
normal"><i style="mso-bidi-font-style:normal">inherited </i></b>(<b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal">hereditary</i></b>),
        that is transmitted from parents to offspring, or <b style="mso-bidi-font-weight:
normal"><i
        style="mso-bidi-font-style:normal">sporadic</i></b>, a result of a new mutation.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        three categories of genetic disorders are <b style="mso-bidi-font-weight:
normal"><i
        style="mso-bidi-font-style:normal">chromosomal abnormalities, single-gene disorders and
        multifactorial conditions of gene-environment interaction.<o:p></o:p></i></b></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal">Chromosomal
        abnormalities</i></b> are characterized by an excess or deficiency of genetic material.
        The majority of these conditions are caused by random errors of cell division in the
        formation of gametes, and are usually sporadic, not hereditary. The most common is trisomy
        21 or Down syndrome; the risk of its occurrence increases with maternal age. Chromosome
        abnormalities affect at least 10% of conceptions, 90% of which end in spontaneous
        abortions. About 6 per 1000 liveborns have a chromosomal abnormality leading to congenital
        malformations, mental retardation and/or disorders of sexual differentiation.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal">Single-gene
        disorders</i></b> are caused by mutations in a single major gene. Their clinical
        manifestations are quite variable, depending on the function of the normal gene. About
        4,000 of the approximately 10,000 gene loci known thus far are associated with single-gene
        disorders (MIM). Typical examples are inborn errors of metabolism, the haemoglobin
        disorders, cystic fibrosis, and haemophilia. Individual single gene disorders range in
        frequency from 1 per 2500 to 1 per 25000 births. The global prevalence at birth of all
        single gene disorders is about 10 per 1000. </span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">These
        conditions are inherited following the patterns of dominant, recessive, autosomal or
        X-linked inheritance.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal">Multifactorial
        conditions</i></b> are due to the interaction of several genes and/or environmental
        factors. The genetic factors confer an inborn predisposition to the development of<span
        style="mso-spacerun: yes">&nbsp; </span>a particular condition in interaction with
        environmental factors. Examples of conditions in this category are some common congenital
        malformations<span style="mso-spacerun: yes">&nbsp; </span>including cleft lip and palate,
        neural tube defects and congenital heart defects. Other examples include insulin dependent
        diabetes mellitus, coronary heart disease, epilepsy, asthma and some cancers.<span
        style="mso-spacerun: yes">&nbsp; </span>The global prevalence at birth of multifactorial
        conditions ranges between 50 and 250 per 1000, depending on the inclusion criteria.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal">Environmental
        causes </i></b>of birth defects are those that interfere with the normal embryonic or
        fetal development and include physical agents (e.g.<span style="mso-spacerun: yes">&nbsp; </span>radiation,
        hyperthermia), chemicals (e.g. some medications, alcohol, tobacco and drugs, both legal
        and illicit), and infections (e.g. rubella, toxoplasmosis and cytomegalovirus).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Collectively,
        all genetic disorders and birth defects have a minimum prevalence at birth of 50 per 1000.
        The prevalence at<span style="mso-spacerun:
yes">&nbsp; </span>later ages is affected by
        the natural history of those conditions, because some are lethal early in life, whereas
        others only become manifest in adulthood. Given that genetic factors are being unveiled in
        an increasing number of common chronic conditions (cancers, coronary heart disease, mental
        illness, etc), it is likely that at least 25% of the people will develop eventually<span
        style="mso-spacerun: yes">&nbsp; </span>a condition determined totally or partially by
        genetic factors.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <h1 style="text-align:justify"><span lang="EN-GB"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt;font-family:"CG Times"">4.
        GOALS OF GENETIC SERVICES<o:p></o:p></span></h1>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Genetic
        services deal with genetic disorders, as well as all birth defects and congenital
        malformations (regardless of cause). These conditions are caused largely by genetic and/or
        environmental factors, operating before the birth of the individual, pre-conception,
        during gestation, or during the perinatal period.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Genetic
        services can be conceived with two major goals, depending on their type. Services targeted
        to individuals and families try to enable people with a genetic disadvantage, and their
        families to live and reproduce as normally as possible, assuring access to relevant
        medical services (diagnostic, therapeutic, counselling, rehabilitative and preventive) and
        social support systems, helping them to adapt to their unique situation and providing
        information to enable educated and voluntary choices in health and reproductive matters.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Genetic
        services also have public health goals of reducing the burden that genetic disorders and
        birth defects impose on the population. Public health genetic services target entire
        populations or population subgroups with specific genetic risks with measures for the
        primary, secondary and tertiary prevention of genetic disorders and birth defects. (see
        Section 10). The public health goal of genetic services should not be confused with those
        of eugenics. Eugenics is a discredited pseudo-scientific concept that improperly claims an
        ability to &#147;improve&#148; the human gene pool by enforcing social policies that limit
        the reproduction of individuals with &#147;undesirable&#148; traits, and encourages
        reproduction of individuals with &#147;desirable&#148; traits (Kevles, 1995).<span
        style="mso-spacerun: yes">&nbsp; </span>There is no scientific basis for
        &#147;improvement&#148; of the gene pool and the concept of &#147;desirable&#148; and
        &#147;undesirable&#148; traits is both arbitrary and political, usually defined by
        prejudice.<span style="mso-spacerun: yes">&nbsp; </span>Eugenic methods applied in the
        past (i.e. forced sterilization and/or social and economic sanctions) to reach these
        stated goals have not only been ineffective, but also violated fundamental human rights
        (Kevles, 1995). In the first half of the 20<sup>th</sup> century social prejudices and
        rudimentary knowledge of genetics fuelled racist &#147;eugenic&#148; policies of several
        governments with abhorrent consequences for mankind.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">It
        is currently recognized that preventive goals of medical genetics must always respect the
        reproductive rights of individuals and the social and health rights of people with
        disabilities.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Thus,
        while reducing the frequency of a particular genetic disorder is a legitimate public
        health goal, it should always be tempered by respect for the autonomous reproductive
        decisions of couples and implemented through measures that provide people with options to
        make voluntary decisions regarding genetic risks. Thus, public health genetic goals should
        be interpreted within the context of personal, cultural and societal values regarding
        reproduction, health, and respect for people with disabilities.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="Initialcode" style="mso-hyphenate:auto;tab-stops:36.0pt"><span lang="EN-GB"
        style="letter-spacing:0pt;mso-ansi-language:EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"><b style="mso-bidi-font-weight:normal"><span lang="EN-GB">5.
        ECONOMIC, DEMOGRAPHIC AND HEALTH CHARACTERISTICS OF DEVELOPING COUNTRIES<o:p></o:p></span></b></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">Approximately 80% of the world's
        population lives in countries with low gross national products (GNP) and have not reached
        the levels of economic development of industrialized nations. The term usually applied to
        these countries is that of &#147;developing&#148;, but a number of recent indicators
        suggest that the economic situation in the majority of those countries is stagnant, or
        even deteriorating (UNDP, 1998). No single indicator captures the economic, cultural,
        social and political complexities of underdevelopment. In addition to low income,
        developing nations are characterized by economic dependency, lesser urbanization, poor
        levels of technology, deficiency in qualified human resources and a number of other
        social, demographic and health correlates of poverty.</span></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">It should be noted, however, that
        generalizations about the developing world based on averages fail to capture the wide
        range of realities that characterize poverty. There are wide differences in economic and
        social development among developing countries and even diverse population groups within
        each country. Concurrently, the stereotypic image of the industrialized world can also be
        deceptive, as exemplified by significant pockets of poverty even in the economically most
        advanced nations.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        role of genetic factors in health and disease moved to the forefront in the industrialized
        countries during the past 40 years, as a consequence of the control of infectious and
        nutritional diseases and the advances in genetic technology. In contrast, for the
        populations living in the developing world, main causes of morbidity and mortality are
        still linked to environmental factors correlated with poverty, infections and
        malnutrition. An epidemiological transition, however, is taking place in many of these
        countries wherein the problems of acute diseases are gradually being controlled and
        chronic disorders are assuming an ever-increasing role in health, mandating that their
        management and prevention be recognized as a need rather than a luxury.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal">5.1. High fertility and reduced life expectancy</b><o:p></o:p></span></i></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Ninety
        percent of the 140 million births in the world in 1995 occurred in developing countries
        (UNICEF, 1998). Although their total fertility rate declined from 6.0 in 1960 to 3.2 in
        1996, it is still almost twice the 1.7 recorded in industrialized nations.<span
        style="mso-spacerun: yes">&nbsp; </span>The combination of high fertility and low life
        expectancy leads to a population age structure with a high proportion of young people (40%
        under 18 years of age, as compared with 23% in industrialized nations) (UNICEF, 1998).</span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">5.2. Low level of urbanization<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Only
        37% of the population is urbanized in developing countries, as compared with 77% in
        industrialized nations (UNICEF, 1998). This, however, is rapidly changing because of the
        movement of people from impoverished rural areas to cities.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Presently
        some of the world's largest megacities are in developing nations, e.g. Mexico City,
        Sao Paulo, and Beijing.</span></p>
        <p class="MsoFooter" style="text-align:justify;text-indent:36.0pt;tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:10.0pt">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoFooter" style="text-align:justify;text-indent:36.0pt;tab-stops:36.0pt"><i
        style="mso-bidi-font-style:normal"><span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt"><b style="mso-bidi-font-weight:normal">5.3.
        Deficient infrastructure</b><o:p></o:p></span></i></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">The percentages of population with access
        to safe water (70%) and adequate sanitation (42%) are significantly lower than in the
        industrialized nations, where they approach 100%. Transportation, communication and
        technology are also deficient.<b style="mso-bidi-font-weight:normal"><o:p></o:p></b></span></p>
        <p class="MsoFooter" style="text-align:justify;tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoFooter" style="text-align:justify;text-indent:36.0pt;tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:10.0pt">5.4. Poverty<o:p></o:p></span></i></b></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">Per capita gross national product (GNP) of
        developing nations is 10-40 times lower than that of industrialized countries. Moreover,
        the gap between the rich and poor countries has been widening. Over the past 30 years, the
        industrialized countries' share of the world's global GNP increased from 70.2%
        to 82.7%, whereas that of the countries with the poorest 20% of the world's
        population declined from 2.3% to 1.4%. (World Bank, 1993). By 1989 the income of the
        richest 20% of the world's population (living largely in the industrialized
        countries) was 60-fold higher than that of the poorest 20% (living largely in developing
        countries) (UNDP, 1998). In addition, developing countries are characterized by a greater
        inequality in the distribution of incomes between rich and poor, than that which pertains
        in the industrialized nations.</span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal">5.5. Poor
        educational levels</i></b><i style="mso-bidi-font-style:
normal"><o:p></o:p></i></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Educational
        levels in developing countries tend to be low, as measured by literacy rate (average: 71%;
        range: 57-87%, depending on the region; compared to 98% in industrialized countries) and
        the proportion of children reaching grade 5 of primary school (average: 75%; range 59-91%,
        depending on the region; compared to 99% in industrialized countries) (UNICEF, 1998). All
        educational indices are significantly lower for women.</span></p>
        <p class="MsoFooter" style="margin-left:-14.2pt;text-align:justify;tab-stops:
36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoFooter" style="text-align:justify;text-indent:36.0pt;tab-stops:36.0pt"><i
        style="mso-bidi-font-style:normal"><span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt"><b style="mso-bidi-font-weight:normal">5.6.
        Health conditions</b><o:p></o:p></span></i></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">In
        general, health standards are lower in developing countries than in the industrialized
        world. The average life expectancy is 62 years in the former, compared to 77 in the
        latter.<span style="mso-spacerun: yes">&nbsp; </span>Infant mortality varies widely among
        developing countries, ranging from the lowest of 9 /1000 live births in Cuba to the
        highest of 191 in Niger. It is under 10/1000 live births in the industrialized nations
        (UNICEF, 1998). Although the mortality of children under 5 years of age declined
        significantly in the last 25 years, its rate in developing countries is still 12 times
        that of the industrialized countries.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">In
        the mid-1990s, the World Health Organization estimated that approximately 70% of the 11.6
        million deaths of children under 5 years of age that occur annually in the developing
        countries were attributable to five illnesses: acute respiratory infections (19%),
        diarrhoea (19%), perinatal causes (18%), measles (7%) and malaria (5%), with malnutrition
        an associated cause in 54% of all the deaths (Murray &amp; Lopez, 1996). Forty-two percent
        of deaths at all ages in developing countries were potentially avoidable (communicable
        diseases, maternal and perinatal conditions, and nutritional deficiencies). In contrast in
        the industrialized nations this was the case in only 6% of deaths. Adding to this toll,
        the AIDS pandemic is currently ravaging some developing countries, particularly in
        Sub-Saharan Africa and South-East Asia. An estimated 30 million people have contracted the
        HIV and 90% of new infections occur in developing countries, where the disease has already
        reduced life expectancy in some countries by more than a decade. Moreover AIDS is
        diverting scarce resources from treatment and prevention of other diseases (World Bank,
        1997).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Prevalence
        of contraceptive usage from 1990-97 was only 54% in developing countries, compared to 72%
        in the industrialized world (UNFPA, 1998).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"><span
        style="mso-spacerun: yes">&nbsp;</span>Lack of access to safe therapeutic abortion
        continues to be a serious health issue in developing countries, independent of the
        legalities of interruption of pregnancies. It is notable that contrary to commonly held
        assumptions a sizable proportion of the population of the developing world lives in
        countries that permit induced abortion under a variety of circumstances (i.e. China,
        India, South Africa, Cuba and a few other Latin American countries) (UNFPA, 1998).
        Furthermore, legal restrictions to induced abortion in some developing countries do not
        deter its practice, but instead make abortions unsafe, forcing them to be performed in an
        environment lacking minimal medical standards and by persons without the necessary skills.
        Of the 45 million abortions annually taking place worldwide, 20 million are unsafe, and
        90% of the latter take place in developing countries, accounting for 13% of maternal
        deaths (UNFPA, 1998). Maternal mortality as a whole is alarmingly high in developing
        countries, reaching catastrophic figures in Africa, with an average of 477 per 100,000 as
        compared with 13 per 100,000 in the industrialized world (UNFPA, 1998). Obstructed labour,
        haemorrhage and postpartum infection account for almost one half of maternal mortality.</span></p>
        <p class="MsoFooter" style="text-align:justify;tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoFooter" style="text-align:justify;text-indent:36.0pt;tab-stops:36.0pt"><i
        style="mso-bidi-font-style:normal"><span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt"><b style="mso-bidi-font-weight:normal">5.7.
        Access to health services</b><o:p></o:p></span></i></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        structural and functional deficiencies of health services in the developing world have
        complex historic, political, cultural and economic roots (World Bank, 1993). Deficient
        comprehensive health planning and implementation, overlapping functions and poor
        co-ordination compound underfunding. Scarce health resources are allocated with a bias
        that favours tertiary centres in large cities at the expense of more cost-effective
        primary health care units. Specialized and high technology services are primarily
        accessible to the small wealthier segment of the population, who have expectations and
        enjoy services somewhat equivalent to those of the industrialized countries (Penchaszadeh,
        1999).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Training
        of health professionals tends to emphasize individual curative medicine rather than
        community-based preventive approaches (World Bank, 1993).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        public health sector in the developing world is chronically underfunded. In 1990 the
        average expenditure for health in developing countries was only 4% of their meagre GNP,
        compared to 9.2% in industrialized nations (World Bank, 1993). Total (public and private)
        average annual per capita health expenditure in developing countries in 1990 was US$ 41
        compared with US$1861 in the industrialized countries. These averages, obviously, mask
        significant spending inequalities between the well to do who pay high fees in the private
        for profit sector, and the majority who rely on the underfunded public sector
        (Penchaszadeh, 1999).</span></p>
        <p class="MsoFooter" style="text-align:justify;tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoFooter" style="text-align:justify;text-indent:36.0pt;tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:10.0pt">5.8. Influence of
        tradition and religion<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">In
        the developing world, the role of tradition in shaping health beliefs and patterns of
        health care is very strong. The structure of the family assigns an important authority
        role to the elders, and members of the extended family are active in decision-making
        regarding health. The various cultural meanings of disease and causal explanations affect
        decisions regarding prevention and treatment. Although religion plays an important guiding
        role everywhere in the world, its directives tend to be more rigid, authoritarian and
        conservative in the developing countries than in the industrialized ones.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Consanguinity
        has been practiced for centuries in many populations and it is deeply rooted in a web of
        social, economic and cultural factors. Although the practice has declined in
        industrialized nations, it continues to be prevalent in numerous areas of the developing
        world, particularly in parts of Africa, the Middle-East and the Indian subcontinent ,
        where it ranges from 25% to 61% (Klhat &amp; Khoury, 1991; Bittles et al, 1991; Khlat,
        1997). </span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">To a
        lesser extent, consanguineous marriages are also common in Brazil, 0.6-9%, (Freie-Maia,
        1989) and Japan, 1.6-3.9% (Imaizumi, 1986). Marriage between relatives increases the
        likelihood of homozygosity among the offspring and is associated with higher frequency of
        autosomal recessive conditions, congenital malformations, stillbirth, neonatal or
        childhood death, and mental retardation (Bittles et al, 1991; Jaber at al, 1998; WHO,
        1996). Thus, consanguinity may contribute to a limited extent to the burden of genetic
        diseases in some communities in the developing world, particularly in those that are
        experiencing a significant reduction in infant mortality. However, consanguinity has
        important social, economic and cultural roles relating to inheritance of property and land
        rights and the maintenance of social fabric, in some traditional societies. The beneficial
        effects of consanguinity perceived by these communities thus outweigh the potential
        negative health effects. Therefore efforts to discourage it would be ill advised and
        probably futile.</span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">5.9. Epidemiological transition<o:p></o:p></span></i></b></p>
        <p class="MsoBodyTextIndent" style="mso-pagination:widow-orphan;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:both">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent" style="mso-pagination:widow-orphan;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:both">Despite the general
        assessment of the developing world's health problems described above, living conditions
        are improving for many individuals in a sizable proportion of developing countries.
        Between 1960 and 1997, the average infant mortality rate in developing countries fell from
        138 to 65/1000.<span style="mso-spacerun: yes">&nbsp; </span>This reduction was
        particularly manifest in Latin America and the Caribbean (103 to 33/1000), East Asia and
        the Pacific (133 to 40/1000) and the Middle East and North Africa (154 to 48/1000).
        Simultaneously, in these nations there has been a significant decrease in the under-5
        years mortality rate (216 to 96/1000), a 48% decline in fertility rates and, between 1970
        and 1997, a nine-year increase in life expectancy. By comparison, there has been less
        progress in the least developed countries, many of which are in sub-Saharan Africa and
        South Asia (UNICEF, 1999).<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent" style="mso-pagination:widow-orphan;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:both">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">The improving health indices in some developing
        countries are indicative of social and economic progress associated with improved health
        care services and control of infectious diseases and malnutrition. Consequently,
        genetically determined disorders and birth defects have begun to constitute an increasing
        proportion of infant and general mortality and morbidity, and thus gained public health
        significance (Rimoin et al, 1996; WHO/EMRO, 1997; PAHO, 1998a, 1998b). As an expression of
        this epidemiological transition, the percentage contribution of genetic disorders and
        birth defects to the infant mortality rate is greater in countries where the latter are
        lowest, reaching 25% or more in some Middle Eastern and Latin American Countries
        (WHO/EMRO, 1997; PAHO, 1998a, 1998b).<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">Improving socio-economic indicators and health
        indices in such developing countries are also associated with urbanisation and
        modernisation in some sectors of the population. These processes result in the breakdown
        of traditional ways of living and changes in lifestyle, which in turn, when combined with
        increased longevity, result in a concomitant change in the pattern of mortality and
        morbidity in adult life. Thus common chronic multifactorial conditions with a genetic
        predisposition, including cancer, diabetes, hypertension, coronary artery disease and
        mental illness, begin to become pre-eminent in the health statistics of the middle and
        upper years of the lifespan (Penchaszadeh, 1999). As the situation further improves, late
        onset genetic diseases are expected to become increasingly evident. Thus in the 1990s,
        deaths from malignancies in Latin American countries ranged from 8 to 25% of the total as
        compared to 23% in the USA.<span style="mso-spacerun: yes">&nbsp; </span>Similarly the
        percentage of deaths due to cardiovascular diseases in this region ranged from 8 to 46%,
        which is approaching the 54%, recorded in the USA (PAHO, 1998a).<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">In each country, efforts to manage genetically
        determined disorders and birth defects would depend on local frequencies of the individual
        conditions, the health burden that they represent, and the resources available for their
        care and prevention, and the health care infrastructure (WHO, 1996). Although in
        developing countries infectious diseases and malnutrition still present a considerable
        burden, the changes described above have brought many developing nations to the stage
        where health services must give due consideration to the care and prevention of birth
        defects, genetically determined disorders and late onset complex disorders.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">The importance of genetic disorders and birth
        defects tends to be recognised in countries when their infant mortality rate falls below
        40/1000 live births (Modell &amp; Kuliev,<span style="mso-spacerun: yes">&nbsp; </span>1998).
        In order to anticipate this, health care planners should initiate appropriate strategies
        of care and prevention when an infant mortality rate of 50/1000 has been reached.<span
        style="mso-spacerun: yes">&nbsp; </span>In 1997 fully 67(47%) of the world's 142
        developing nations had an infant mortality rate &lt; 40/1000, and a further 8 (5.6%)
        countries a rate between 41 and 50/1000 live births.<span style="mso-spacerun: yes">
        &nbsp; </span>The population of those 75 countries<span style="mso-spacerun: yes">&nbsp; </span>(with
        an IMR &lt; 50/1000 live births) was 2.8 billion, or 60.5% of the developing worlds'
        peoples. In all the countries, except one, the life expectancy at birth was 65 years or
        greater (UNICEF, 1999).<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">The prevalence of genetic disorders and birth
        defects, which are recognisable in 2-3% of all newborns, varies according to geographic,
        ethnic, socio-cultural and socio-economic characteristics of a population (WHO/EMRO, 1997;
        ICBDMS, 1998). Factors that predispose to higher prevalences of these disorders in
        developing countries include:<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:39.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l104 level1 lfo73;mso-hyphenate:none;tab-stops:list 39.6pt"><span
        lang="EN-GB" style="font-family:Wingdings;letter-spacing:-.15pt">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Traditional consanguineous marriages resulting
        in a higher frequency of autosomal recessive conditions including congenital
        malformations, stillbirths, neonatal and childhood deaths and mental retardation;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:39.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l104 level2 lfo73;mso-hyphenate:none;tab-stops:list 39.6pt"><span
        lang="EN-GB" style="font-family:Wingdings;letter-spacing:-.15pt">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Advanced parental age.<span
        style="mso-spacerun: yes">&nbsp; </span>Continued child bearing into the upper end of the
        reproductive lifespan is associated with high frequencies of chromosomal abnormalities in
        women of advanced maternal age (&gt;35 years) and conditions due to new autosomal dominant
        mutations in men of advance paternal age (&gt;55 years);<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:39.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l104 level3 lfo73;mso-hyphenate:none;tab-stops:list 39.6pt"><span
        lang="EN-GB" style="font-family:Wingdings;letter-spacing:-.15pt">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Socio-economic factors.<span
        style="mso-spacerun: yes">&nbsp; </span>The increased risk of birth defects in families of
        low socio economic status has long been recognised.<span style="mso-spacerun: yes">&nbsp; </span>At
        least in part this is due to inadequate pre and post conception nutrition, including
        deficient intakes of micronutrients (folic acid and other vitamins, iodine);<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:39.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l104 level3 lfo73;mso-hyphenate:none;tab-stops:list 39.6pt"><span
        lang="EN-GB" style="font-family:Wingdings;letter-spacing:-.15pt">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Adequate health care prior to and during
        pregnancy.<span style="mso-spacerun: yes">&nbsp; </span>This can predispose to an
        increased frequency of congenital infections in particular syphilis and rubella, or birth
        defects consequent on inadequate control of diabetes, and the unsupervised intake of drugs
        and traditional medicines;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:39.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l104 level5 lfo73;mso-hyphenate:none;tab-stops:list 39.6pt"><span
        lang="EN-GB" style="font-family:Wingdings;letter-spacing:-.15pt">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Selective reproductive advantage of carriers of
        genes for haemoglobin disorders and G6PD deficiency which contribute to the high
        prevalence of these conditions in some areas of the world.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="letter-spacing:-.15pt">The observed birth prevalence of genetic disorders and birth
        defects is only the tip of the iceberg of the overall prevalence of these conditions
        (Christianson et al, 1981; WHO/EMRO,1997;<span style="mso-spacerun: yes">&nbsp; </span>Venter
        et al, 1995). Extrapolating from these studies it has been suggested that the actual
        prevalence of severe genetic disorders and birth defects by age five years in developing
        countries could reach 78.6/1000 live births (Figure 1).<span style="mso-spacerun: yes">
        &nbsp; </span>This unrecognised high prevalence of genetic disorders and birth defects has
        recently become apparent in a number of developing countries that are undergoing
        epidemiological transition.<span style="mso-spacerun: yes">&nbsp; </span>In six of ten
        Latin American countries with infant mortality under &lt;50/1000, genetic disorders and
        birth defects are now placed among the three leading causes of infant mortality (WHO,
        1998).<span style="mso-spacerun: yes">&nbsp; </span>Similarly, of ten Middle Eastern
        nations, eight had infant mortality less than 50/1000 and in four of these the proportion
        of infant mortality due to congenital anomalies was equal to or higher than the 25 %
        recorded for the United Kingdom, a typical industrialised nation (Table 1).<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="letter-spacing:-.15pt">The significance of genetic disorders and birth defects has
        also found expression in emerging morbidity statistics from this region where the
        percentage of inpatient paediatric admissions for such problems has been recorded as
        ranging from 8 to 19 percent (WHO/EMRO, 1997).</span><span lang="EN-GB"> Similarly, in
        most Latin American countries congenital anomalies have risen to the 3rd or 4th place as a
        cause of infant mortality (PAHO, 1998a). Moreover, birth defects and genetic conditions
        account for 10-25% of pediatric admissions in some urban centres, imposing their burden of
        more extensive and costly hospital stays (Barreiro et al, 1976; Penchaszadeh, 1979;
        Carnevale et al, 1985).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">In other developing countries, including some
        that have entered the phase of epidemiological transition described above, the burden of
        genetic disorders and birth defects has yet to be recognised.<span
        style="mso-spacerun: yes">&nbsp; </span>Their significance is veiled by the continuing
        prevalence of infectious diseases and malnutrition.<span style="mso-spacerun: yes">&nbsp; </span>This,
        associated with limited diagnostic capability in clinical genetics, unreliable health
        records and statistics and infant and early childhood mortality of affected individuals,
        result in failure of documentation of the majority of those deaths, which are absorbed
        into the general mortality statistics and thus are not acknowledged for what they truly
        represent (WHO, 1996).<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">6. FREQUENCIES AND IMPACT OF GENETIC DISORDERS AND BIRTH DEFECTS IN
        DEVELOPING COUNTRIES<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Deficiency
        in diagnostic capacity and unreliability of health records and statistics due to
        underreporting prevent an accurate assessment of the prevalence of genetic disorders and
        birth defects in the developing world. Recorded diagnoses typically reflect acute
        intervening illnesses rather than the basic constitutional conditions that predispose to
        morbidity and mortality and make affected children more vulnerable to infections and
        malnutrition (Penchaszadeh, 1999).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Thus,
        congenital conditions are systematically underestimated (WHO, 1996) and recorded
        frequencies must be considered minimum estimates. There are a number of indications that
        the global prevalence of birth defects and genetic diseases in developing countries is
        probably higher than that in the industrialized nations (Penchaszadeh, 1999). Moreover,
        the burden that these conditions impose on populations of the developing world is greater,
        because their limited resources are used for the most basic services.</span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">6.1. Congenital malformations<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        average prevalence at birth of recognizable congenital malformations in developing
        countries is about 2-3%, which is similar to that in the industrialized world<span
        style="mso-spacerun: yes">&nbsp; </span>(Mutchinik et al, 1988; Ciao et al, 1988; Castilla
        &amp; Lopez-Camelo, 1990; ICBDMS, 1991; Saborio, 1992; Heredero, 1992; Delport et al,
        1995; Venter et al, 1995; WHO/EMRO, 1997). Some malformations show wide geographical
        variations. Thus, neural tube defects have high prevalence at birth in Egypt (Hashem,
        1978), China (Xiao et al, 1989), Mexico (Mutchinik, 1988) and Central America (Saborio,
        1992), whereas cleft lip and palate are frequent among Amerindian and Asian populations
        (Xiao, 1988; ICBDMS, 1991) and microtia in Ecuador (Castilla &amp; Orioli, 1986).
        Interactions between environmental and constitutional factors underlie most observed
        variations in frequency among populations. In some cases, however, environmental factors
        play the major role, such as with fetal alcohol in South Africa (Baleta, 1998).</span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal">6.2. Chromosome
        abnormalities</i></b><i style="mso-bidi-font-style:
normal"><o:p></o:p></i></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Studies
        on Down syndrome show that maternal age-specific rates are similar worldwide. However,
        because of social and cultural traditions and reduced access to family planning, many
        women in developing countries continue to reproduce until advanced age (Penchaszadeh,
        1999).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        proportion of births to women over 35 years averages 11-15% in different regions of the
        developing world, compared to 9% in industrialized countries (UNFPA, 1998). Advanced
        maternal age and the reduced availability of prenatal diagnosis and selective abortion
        lead to a relatively higher birth prevalence of chromosome anomalies (6 per 1000) (WHO,
        1996) and particularly of Down syndrome (2-3 per 1000) (WHO, 1985, Modell &amp;
        Boulyjenkov, 1988; Castilla &amp; Lopez-Camelo, 1990; Zhang et al, 1991; Christianson,
        1996). The same phenomenon is behind the high proportion of babies with Down syndrome born
        to mothers of advanced age in some eastern Mediterranean countries where 50% of Down
        syndrome babies are born to mothers over 40 years of age (WHO/EMRO, 1997).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        death rate of children with Down syndrome by one year of age in South America is 34% for
        those with a congenital heart defect and 21% for those without one. The latter figure is
        about twice that for the United Kingdom (Castilla at al, 1998). In South Africa,
        two-thirds of babies with Down syndrome die by age 2 years of age (Christianson, 1996).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Sex
        chromosome abnormalities are also frequent (Temtamy et al, 1992), although their morbidity
        and mortality are much less than the autosomal aneuploidies.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">6.3. Single-gene disorders<o:p></o:p></span></i></b></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">Major single-gene disorders in the
        developing world have a global incidence similar to that of industrialized countries,
        approximately 3.5 per 1000 (WHO, 1985). The frequency of individual conditions varies in
        different regions according to ethnicity, founder effects, inbreeding, genetic drift
        and/or carrier selection (Penchaszadeh, 1999).</span></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">The haemoglobin disorders<i
        style="mso-bidi-font-style:normal"> </i>(sickle-cell disorder and thalassaemias)
        constitute a major public health problem among genetic conditions internationally, but
        particularly in the developing world which has the least resources for coping with the
        problem. Abnormal haemoglobin. genes, originated in Africa, Asia and the Mediterranean
        basin, and were maintained at high frequencies in those populations because of selective
        advantage of carriers in resistance to malaria (Serjeant, 1989; Weatherall, 1995). The
        slave trade and later migrations disseminated genes for abnormal haemoglobins worldwide.
        Approximately 250 million people (4.5% of the world population) carry a potentially
        pathological haemoglobinopathy gene and annually 300000 infants are born with a major
        hemoglobin disorders (Angastiniotis et al, 1995).</span></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">The average carrier rate of abnormal
        haemoglobins in Africa, mostly sickle cell disease, is 13.3% and the estimated prevalence
        at birth for homozygotes is 7.26 / 1000, which extrapolates to 216000 affected births
        annually, or about 75% of the world's affected children.<span
        style="mso-spacerun: yes">&nbsp; </span>Studies in Nigeria suggest an 80% mortality of
        people with sickle cell disease before 15 years of age (Angastiniotis et al, 1995).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">In
        Latin America, sickle haemoglobins predominate in the countries with the higher
        proportions of people of African origin (Caribbean islands, Panama, Brazil and Guyana)
        (Penchaszadeh, 1993). In Cuba, where African ancestors account for 30-40% of the
        population, the carrier frequency of sickle haemoglobins is 3.7% (Granda et al, 1991). In
        Brazil sickle haemoglobins have a carrier frequency of 1% in whites, 4% in those of mixed
        origin, and 7% in those of African origin (Salzano, 1985). The average thalassaemia
        carrier frequency in Brazil is about 1%, occurring primarily among descendants of Italian
        immigrants (Naoum et al, 1984; Martins et al, 1993).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">In
        Arab countries the most common abnormal haemoglobin is S, with carrier frequencies that
        range from &lt;1% to almost 20% in some areas, although both alpha- and beta-thalassaemias
        are also very frequent (El-Hazmi &amp; Warsy, 1997a). In the Mediterranean basin
        beta-thalassemia predominates (WHO, 1993).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">In
        South East Asia the average carrier frequency of beta-thalassaemia is 11.6% (Modell &amp;
        Boulyjenkov, 1988). In Thailand, up to 40% of the population carry a<span
        style="mso-spacerun: yes">&nbsp; </span>potential significant haemoglobin mutation, and
        all the major thalassaemias are common (Winichagoon et al, 1990). In China, alpha and beta
        thalassaemias are prevalent in the south and south-western provinces (Zeng Ninety five
        &amp; Huang, 1987).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Deficiency
        of glucose-6-phosphate dehydrogenase is another single gene condition frequent in areas of
        the world where malaria was and is prevalent, including the Mediterranean basin, Africa
        and the Middle East (El-Hazmi &amp; Warsy, 1996).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Most
        of the several hundred known single-gene conditions have been described in the developing
        world. A number of populations in the New World originated from a small number of migrants
        who later experienced restricted mobility for many generations, leading to pockets of
        increased endogamy. The combination of founder effects, genetic drift and geographic and
        cultural isolation has led to clusters of single gene conditions, both recessive and
        dominant (Castilla &amp; Sod, 1990; Freie-Maia, 1981; Arias 1981, Teebi, 1994). Some of
        these clusters may represent significant public health challenges, as the needs of
        hundreds of patients with severe disabling conditions in a small geographical area may
        impinge upon an already strained health services, as is the case with Huntington disease
        in Venezuela (Avila-Giron, 1973) and spino-cerebellar atrophy type 2 in Cuba (Auburger et
        al, 1990).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">In
        addition, many populations of the developing world are characterized by unusually high
        frequencies of particular single-gene conditions, such as spondylocostal dysplasia in
        Puerto Ricans (Perez-Comas &amp; Garcia-Castro, 1974), oculo-cutaneous albinism in South
        Africa (Kromberg &amp;Jenkins, 1982), and spinal muscular atrophy in Arabs (Al-Rajeh et
        al, 1993).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal">6.4. Conditions of genetic predisposition</b><o:p></o:p></span></i></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Multifactorial
        conditions with genetic predisposition include most birth defects and chronic diseases
        affecting all age groups. Prevalence of the latter becomes more apparent as childhood
        mortality due to infections and malnutrition declines and life expectancy rises. Indeed,
        although the burden of infectious diseases is still large, cardiovascular diseases,
        malignancies, mental illness, obesity and diabetes are increasingly affecting the
        developing world, particularly its urban populations (Penchaszadeh, 1999). In Saudi
        Arabia, for example, the prevalence of diabetes mellitus type 2 ranges from 1.9 to 7.2% in
        the overall adult population, but reaches 22% and 17% in males and females, respectively,
        over 45 years of age (El-Hazmi et al, 1996,1998). A similar situation is obqerved with
        obesity (El-Hazmi &amp; Warsy, 1997b).</span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">7.<span style="mso-spacerun: yes">&nbsp; </span>CURRENT SITUATION OF MEDICAL
        GENETIC SERVICES IN DEVELOPING COUNTRIES<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">7.1. Delivery of genetic services<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">In
        most countries genetic services are at an early stage of development and in many have yet
        to be established (WHO, 1996). However even in the industrialized nations, where the
        organization and funding of health services are better, there are still numerous
        technical, social, ethical, and legal challenges that act as barriers to the ultimate
        achievement of control of genetic disorders and birth defects<span
        style="mso-spacerun: yes">&nbsp; </span>(WHO, 1996). In the developing world these
        barriers also exist and are compounded by several other factors that result in serious
        challenges for the delivery of genetic services (Penchaszadeh, 1999). These include:</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l93 level1 lfo69;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">The absence of comprehensive registers and reliable statistics;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l93 level1 lfo69;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Lack of clinical expertise and awareness in health professionals;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l93 level1 lfo69;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">A considerable burden of unmet needs in other aspects of health care;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l93 level1 lfo69;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Genetic disorders and birth defects are not considered a priority by the
        medical profession and public health officials;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l93 level1 lfo69;tab-stops:0cm list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Genetic services are incorrectly perceived as expensive, inextricably linked
        to high-tech laboratory tests and concerned only with rare and esoteric diseases;</span></p>
        <p class="MsoBodyText2"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l93 level1 lfo69;tab-stops:0cm list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="font-family:"CG Times"">Genetic services are considered as
        mainly diagnostic rather than therapeutic.<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l93 level1 lfo69;tab-stops:0cm list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="font-family:"CG Times"">The means for the prevention of
        genetic disorders and birth defects is considered only in terms of selected interruption
        of affected pregnancies;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l159 level1 lfo70;tab-stops:0cm list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Genetic disorders and birth defects are seen as complex and the sole
        responsibility of medical geneticists;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l159 level1 lfo70;tab-stops:0cm list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">The public is largely unaware about genetic risks and the possibilities of
        prevention, and is developing fears towards genetics due to lack of knowledge and the
        sensationalist reaction of the media to certain topics of genetic research.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">In
        spite of the above-mentioned difficulties, a number of patient/family genetic services
        have been implemented in developing countries during the past two decades. These are
        typically set in major urban centres at tertiary care university hospitals by medical
        geneticists trained abroad. The approach has largely been individual, without much
        coordination with other health services. The emphasis has typically been in clinical
        genetics, dysmorphology, cytogenetics and prenatal diagnosis of chromosome anomalies.
        Biochemical genetics laboratories, on the other hand, are scarce. DNA-based diagnosis is
        only incipient in few centres and for a limited number of conditions (Penchaszadeh &amp;
        Beiguelman, 1997; Penchaszadeh, 1999). The practice of prenatal diagnosis shows
        significant variations among developing countries. In countries such as China, India,
        South Africa, Cuba and Cyprus, prenatal diagnosis is publicly funded for accepted
        indications and is part of comprehensive policies of prevention of genetic disorders. In
        many other developing countries, however, there is a lack of public funds for prenatal
        diagnosis, and its practice is restricted for the most part to the private sector, in
        response to the growing demand for this service by the middle and upper classes.
        Unfortunately, prenatal diagnosis in the private sector is characterized by little or no
        quality control and only perfunctory genetic counselling, making this a fragmented service
        of unpredictable quality and accessible only to those who can afford it (Penchaszadeh,
        1999).<span style="mso-spacerun: yes">&nbsp; </span>Legal restrictions to induced
        abortions, where they exist, do not seem to affect the practice of prenatal diagnosis in
        the private sector.</span></p>
        <p><span lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
"CG Times";mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA;
layout-grid-mode:line">&nbsp;</p>
        <p><br clear="all" style="page-break-before:always">
        </span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Newborn
        screening programs for phenylketonuria and congenital hypothyroidism have been introduced
        in urban centres in some developing countries. Common pitfalls of these programs are lack
        of public allocation of resources, lack of laboratory quality control and deficient
        provisions for the follow-up of abnormal initial screening results and the long-term
        treatment of affected infants (Penchaszadeh, 1999).</span></p>
        <p class="MsoBodyTextIndent" style="mso-pagination:widow-orphan"><span lang="EN-GB"
        style="layout-grid-mode:both">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent" style="mso-pagination:widow-orphan"><span lang="EN-GB"
        style="layout-grid-mode:both">In some countries with high prevalence of
        hemoglobinopathies, there are population-based prevention programs for the detection of
        carriers. These programs offer prenatal diagnosis to the couples at risk and have been
        very successful in Cuba and Cyprus (WHO, 1993). Sickle cell disease is a common problem in
        Cuba, as 3.7% of the population is heterozygous for the gene (Granda et al, 1991).<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent" style="mso-pagination:widow-orphan"><span lang="EN-GB"
        style="layout-grid-mode:both">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent" style="mso-pagination:widow-orphan"><span lang="EN-GB"
        style="layout-grid-mode:both">The sickle cell prevention program in Cuba is based on
        routine haemoglobin electrophoresis of pregnant women at 16 weeks of gestation,
        identification of carrier couples, genetic counselling and offering of amniocentesis with
        the option of voluntary termination of affected fetuses. A single laboratory in Havana
        performs all the fetal DNA tests for HbS.<span style="mso-spacerun: yes">&nbsp; </span>The
        coverage of this program is close to 90% of the pregnancies in Cuba and the population
        acceptance is high (Granda et al, 1991; Granda et al, 1994; Dorticos-Balea et al, 1997).<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent" style="mso-pagination:widow-orphan"><span lang="EN-GB"
        style="layout-grid-mode:both">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent" style="mso-pagination:widow-orphan"><span lang="EN-GB"
        style="layout-grid-mode:both">In Cyprus, 16% of the population carry the beta-thalassaemia
        trait and thalassaemia major was a main public health problem. A substantial proportion of
        financial resources for health services were consumed by the chronic treatment of affected
        patients. A plan for prevention was laid out in 1972, based in health education of the
        public, community involvement, carrier detection in the general population and genetic
        counselling (Angastiniotis &amp; Hadjiminas, 1981). The program, however, did not
        influence people's behaviour in choosing spouses or in reproduction, until prenatal
        diagnosis became available in the early 1980s. Later, a premarital certificate attesting
        that the marrying couple was tested for thalassaemia carrier status in a government
        laboratory and counselled appropriately became a requirement for marrying in church (no
        results were disclosed to third parties). A comprehensive prenatal diagnosis program
        followed. Over the ensuing years the annual birth incidence of thalassaemia homozygotes
        dropped 97% as a result of campaigns of public education, community participation, genetic
        counselling and voluntary prenatal diagnosis followed by the option of pregnancy
        termination of affected fetuses (Angastiniotis et al, 1986).<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Prenatal
        screening of neural tube defects and other fetal malformations by measurement of maternal
        serum biochemical markers has been common practice in most industrialized countries for a
        long time (Milunsky, 1998a). Latterly this has been augmented by fetal ultrasonography. </span><span
        lang="FR" style="mso-ansi-language:FR">(Ville et al, 1998).<span style="mso-spacerun: yes">
        &nbsp; </span></span><span lang="EN-GB">Among developing countries, Cuba has implemented
        population-based program for the detection of fetal anomalies based on the combination of
        the above tests in the second trimester of pregnancy. The program covers 95% of the
        pregnancies and when severe fetal malformations are detected, couples are counselled and
        given the option of pregnancy termination. As a result, prevalence of neural tube defects
        fell 90% (Rodriguez et al, 1997; Heredero, 1998).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">In
        summary, genetic services in developing countries are typically patient/family oriented
        and based in tertiary centres, without much coordination and regionalization and with wide
        variations in the quality and accessibility of services rendered. On the other hand, and
        except for the few examples cited above, population-based programs rarely exist, as
        departments of public health do not have explicit policies and resource allocations for
        the management and prevention of genetic disorders and birth defects (Penchaszadeh, 1999).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">7.2. Genetic education of health professionals<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Few
        medical schools in the developing world teach courses in clinical genetics, and most
        practicing physicians have a poor grasp of the modern applications of genetics in medical
        practice. Similar situations prevail in the training of allied health personnel, such as
        nurses and midwives. The expertise in clinical genetics remains largely confined to a very
        small number of medical geneticists concentrated in academic institutions and/or in
        private practice (Penchaszadeh, 1999). However, during the last decade, teaching of
        genetics to medical students has become a part of the medical curriculum in an increasing
        number of medical schools in several developing countries. Additionally, courses and
        workshops are being organized to train clinicians and other health personnel in medical
        genetics.</span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal">7.3. Genetic education of the public and role of
        parent/patient organizations</b><o:p></o:p></span></i></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Very
        little attention has been paid to-date to the need to educate society at large in
        developing countries about developments in human genetics and their application in health
        and wellbeing. Information about genetics usually reaches the public through the
        sensationalism and distortion of the mass media. However, in a some developing countries
        parent/patient groups have been organizing with the purpose of increasing awareness of the
        public and their governments about the plight of people with birth defects, genetic
        disorders and disabilities. Through their assertiveness and knowledge of the needs of
        affected people and their families, these organizations are bringing a humane approach to
        available genetic services and prevention programs. Concomitantly, they are raising the
        public's and governments' awareness that genetic disorders and birth defects are
        not rare, they affect a sizable proportion of the population and, most importantly,
        affected individuals and families can benefit from a number of measures such as
        improvement of the quality and accessibility of services and the adoption of a
        compassionate and non-discriminatory approach to the needs of the affected and their
        families. In many countries alliances are being formed between these lay groups and the
        medical profession. Such cooperative efforts tend to humanize and improve patient/family
        services as well as population/based prevention programs (Poortman, 1999).<b
        style="mso-bidi-font-weight:normal"><o:p></o:p></b></span></p>
        <h2 style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times";
font-style:normal">&nbsp;<o:p></o:p></span></h2>
        <h2 style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">7.4. Recent developments<o:p></o:p></span></h2>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">For
        the many reasons reviewed above, health care in general is inadequate for the majority of
        people in the developing world.<span style="mso-spacerun: yes">&nbsp; </span>This
        inadequacy has been most pronounced with respect to medical genetic services, which do not
        yet have a place among established health priorities. However, the decline in morbidity
        and mortality due to infectious diseases and malnutrition is determining an
        epidemiological transition to a growing relevance of genetic factors in disease causation.
        Furthermore, improvements in health care delivery are reducing the load of diseases that
        had been caused by inadequate prenatal and delivery care in significant segments of the
        population. Thus, infant mortality rates have fallen under 40 per 1000 in a substantial
        number of countries. This is, in turn, has led to a growing, albeit uneven, demand of
        services for the management and prevention of genetic disorders and birth defects. The
        challenge is to address the growing health issues posed by congenital and genetic
        disorders, with the scarce resources available in limited health care delivery systems, at
        the same time as there is still a high proportion of preventable, environmentally caused
        morbidity and mortality (Penchaszadeh, 1999).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">In
        spite of these obstacles and difficulties, in many regions of the developing world there
        is an increasing awareness among health professionals, public health officials and the
        public at large of the importance of genetic factors in health and disease, resulting in
        some progress in the delivery of genetic services. The region that probably leads this
        process is Latin America, where the speciality of medical genetics has been recognized in
        Mexico, Cuba, Brazil and Argentina. With a population of about 500 million, Latin America
        has an average distribution of about one physician with training in medical genetics per
        million, compared to 2.7 per million in Europe (Harris, 1997). It is also fortunate to
        have numerous centres of excellence in clinical genetics, cytogenetics and prenatal
        diagnosis, as well as for the management of hemoglobin disorders. A well-established
        congenital malformations registry, which covers 200,000 births annually in South America,
        provides reliable data on the prevalence of these anomalies in the region (Castilla &amp;
        Lopez-Camelo, 1990). Currently, a proposal to create a Latin American network of
        biochemical genetics laboratories to improve the diagnosis of inborn errors of metabolism
        is being considered (Giugliani &amp; Coelho, 1998). Molecular diagnosis is slowly
        developing for a limited number of conditions (Penchaszadeh &amp; Beiguelman, 1998a).
        Under the auspices of the Pan American Health Organization (PAHO/WHO), four meetings of
        experts in medical genetics from the region were held over the past 15 years to review and
        recommend the implementation of population based prevention programs and the delivery of
        patient/family genetic services (PAHO, 1984,1987, 1998b; Penchaszadeh &amp; Beiguelman,
        1998b).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        WHO Regional Office for the Eastern Mediterranean Region (EMR) held three meetings between
        1993 and 1996 to discuss the situation of genetic services in member states, to develop
        strategies that are appropriate to the Region, and to standardize epidemiological research
        for genetic and congenital disorders (WHO/EMRO, 1997).<span style="mso-spacerun: yes">
        &nbsp; </span>Several countries of the EMR have recognized the importance of genetic
        services and the Arab League Technical Committee sponsors annual meetings of their
        members. In South Africa, Department of Health officials are integrating
        genetic/disability services into primary health care and developing clinical guidelines
        for the management of common birth defects (Department of Health of South Africa, 1998;
        Penchaszadeh, 1998).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">8.<span style="mso-spacerun: yes">&nbsp; </span>DEFINITION AND GOALS OF
        GENETIC SERVICES<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Genetic
        services are health measures implemented to help people with genetic disadvantages to live
        and reproduce as normally as possible (WHO, 1985, 1996).<span style="mso-spacerun: yes">
        &nbsp; </span>They combine the best available medical care with prevention strategies.
        According to their nature and goals, genetic services can be targeted to individuals and
        their families (clinical genetic services) or to the population at large (public health
        genetic programs). The goals of <i style="mso-bidi-font-style:normal">individual/family
        based clinical genetic services</i> are as follows (see also Section 9):</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l76 level1 lfo209;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-size:8.0pt;mso-bidi-font-size:10.0pt;font-family:Wingdings">q<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">To address the medical and psychosocial needs of affected individuals and
        their families. The main strategies are early and accurate clinical and laboratory
        diagnosis, coordination of the multidisciplinary and long-term management of patients,
        anticipatory guidance of predicted problems based on the natural history of the condition,
        genetic counselling and psychosocial support to the patient and family.</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l76 level1 lfo209;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-size:8.0pt;mso-bidi-font-size:10.0pt;font-family:Wingdings">q<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">To maximize the probability of offspring free of genetic disease among
        individuals and/or families with increased genetic risk. The strategies to implement this
        goal are the detection of genetic risk factors as early as possible in the reproductive
        cycle (ideally preconception, although most commonly early in gestation), genetic
        counselling, genetic testing, prenatal diagnosis and offering reproductive options.</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l76 level1 lfo209;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-size:8.0pt;mso-bidi-font-size:10.0pt;font-family:Wingdings">q<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">To manage the risk that some healthy individuals have of developing a
        late-onset single-gene disorder or multifactorial condition due to gene-environment
        interaction. The strategies and instruments to achieve this goal are the detection of high
        genetic risk by family history, genetic education and counselling, and the use of
        pre-symptomatic or predisposition genetic testing followed by prevention and therapeutic
        interventions.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The <i
        style="mso-bidi-font-style:normal">population-based (public health) genetic programs</i>
        are targeted to the population at large and/or to population subgroups identified by their
        genetic risk category (e.g. specific ethnic groups). The goals of public health genetic
        programs are the primary, secondary and tertiary prevention of genetic disorders and birth
        defects at the population level. The strategies of public health genetic programs include
        prenatal screening for birth defects and chromosome abnormalities, newborn metabolic
        screening, population screening for carrier status for common recessive conditions and
        public education campaigns for the avoidance of exposure to teratogenic agents. (see also
        Section 10).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">9.<span style="mso-spacerun: yes">&nbsp; </span>GOALS AND CONPONENTS OF
        PATIENT/FAMILY-BASED GENETIC SERVICES<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>9.1. Addressing the medical and psychosocial needs of patients and families<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">The application of genetic principles to the
        practice of medicine is a development that has gained impetus and acceptance in developed
        nations since the 1960s, consequent on technological advances and an epidemiological
        transition characterized by an increased public health significance of genetic disorders
        and birth defects. Associated with this has been the evolution of clinical genetic
        services for the application of the advances in medical genetics in diagnosis, management
        and prevention of human diseases (McKusick, 1996). The likely future change of emphasis in
        the field of medical genetics from rare conditions to common complex diseases will require
        further development of medical genetic services.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">The objective of medical genetic services is to
        help people with a genetic disadvantage to live and reproduce as normally as possible
        (WHO, 1985). This definition encompasses with genetic disorders or birth defects and those
        with a genetic reproductive risk. Simultaneously it avoids any misperceived contradiction
        between treatment and prevention.<span style="mso-spacerun: yes">&nbsp; </span>This
        apparent contradiction is possibly engendered in texts by the used of the word
        "control" in relationship to hereditary diseases or genetic disorders and birth
        defects.<span style="mso-spacerun: yes">&nbsp; </span>(WHO, 1985, 1996; WHO/EMRO, 1997).<span
        style="mso-spacerun: yes">&nbsp; </span>This may suggest to some that prevention takes
        precedence in the management of these conditions.<span style="mso-spacerun: yes">&nbsp; </span>However
        a "control" programme for a hereditary disorder has been defined as "an
        integrated strategy combining the best possible patient care with prevention by community
        education, population screening, genetic counselling and the availability of prenatal
        diagnosis."<span style="mso-spacerun: yes">&nbsp; </span>(WHO, 1985; WHO/EMRO, 1997).
        Management of any medical condition should integrate treatment and prevention, and the
        above definition ensures the primacy of attention to patient's needs, in medical
        genetic programmes.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">Both in developed and developing countries,
        economic constraints, lack of appropriately educated and trained manpower, the isolation
        of medical genetic services in academic centres, and the burgeoning public demand for
        medical genetic care have resulted in inequities in genetic service delivery.<span
        style="mso-spacerun:
yes">&nbsp; </span>From the patient's perspective, barriers to
        care include lack of information, poverty, ethnicity, religion, culture, language and
        geographic location.<span style="mso-spacerun: yes">&nbsp; </span>To help overcome these
        barriers, and given the increasing inclusion of medical genetic knowledge and technology
        in all fields of medicine, the increasing demands of the public for clinical genetic
        services and information will have to be answered at the community level and be undertaken
        by primary health care practitioners.<span style="mso-spacerun: yes">&nbsp; </span>(WHO,
        1985, 1996, 1998; Paul &amp; Kavanagh, 1990; Jenkins, 1992; Bernholdt &amp; Pyeritz, 1992;
        Penchaszadeh, 1992; Qurestin &amp; Raeburn, 1993).<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">Perhaps one lesson that can be learnt from the
        industrialised countries' experience, that will most benefit the nascent medical genetic
        services in developing countries, is that from the outset these services should have a
        strong base in the community at the primary health care level. (Christianson AL et al,
        1995; Penchaszadeh, 1999)<span style="mso-spacerun: yes">&nbsp; </span>Therein, primary
        health care practitioners should receive appropriate education and training to ensure that
        they are capable of rendering the best possible patient care within the framework of their
        country's health care system.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">Patient care, in this context, includes
        diagnosis, therapeutic intervention if possible and available, genetic counselling and
        psychosocial support, with all of these implemented within the context of each country's
        cultural, religious and legal milieu.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">Care of patients with genetic disorders and
        birth defects is challenging for all providers and the outcomes for patients are limited
        even in the best of circumstances (Table 1).<span style="mso-spacerun: yes">&nbsp; </span>In
        the developing countries, where facilities are limited, the prognosis for many such
        patients is poor and often includes infant or early childhood mortality.<span
        style="mso-spacerun: yes">&nbsp; </span>Nevertheless, all these patients are still
        entitled to the best possible care available for them.<span style="mso-spacerun: yes">
        &nbsp; </span>A large part of the responsibility for care will continue to fall on the
        shoulders of primary practitioners, especially for the common genetic disorders and birth
        defects prevalent in each country.<span style="mso-spacerun: yes">&nbsp; </span>To
        facilitate this, management guidelines for specific conditions should be available,
        examples of which are those produced by WHO (WHO, 1996b, 1996c, 1996d, 1996e) and others
        available in developed countries (Bernhardt and Pyeritz 1992; Carey, 1992). It should be
        recognised that many patients and families with genetic problems have particular need for
        continuing and coordinated care from different specialities and sectors.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none"><span lang="EN-GB"
        style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:
normal"><span
        lang="EN-GB" style="letter-spacing:-.15pt">9.2. Genetic diagnosis<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">An accurate clinical diagnosis is important in
        the management of a patient with a genetic disorder or birth defect. Specific and
        definitive diagnoses help establish the aetiology, natural history, treatment and
        recurrence risks of conditions. However, even when a definitive diagnosis is not derived,
        patients can and should get the best possible care available.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">The process of making a genetic diagnosis
        should proceed in a logical sequence of <i style="mso-bidi-font-style:
normal">history
        taking</i>, <i style="mso-bidi-font-style:normal">physical examination</i> and <i
        style="mso-bidi-font-style:normal">laboratory investigation</i>.<span
        style="mso-spacerun: yes">&nbsp; </span>Common indications for genetic evaluation are
        listed in Table 2.<span style="mso-spacerun: yes">&nbsp; </span>A <i
        style="mso-bidi-font-style:normal">family history</i>, summarised in the form of a
        pedigree diagram using accepted conventional symbols, is necessary to establish a possible
        genetic cause and pattern of inheritance of the problem and to document possible
        intra-familial variability.<span style="mso-spacerun: yes">&nbsp; </span>Information
        regarding the <i style="mso-bidi-font-style:normal">pregnancy</i> including possible
        exposure to teratogens, the length and course of the gestation and the results of
        antenatal tests (e.g. sonograms) are important to assess fetal well being and risks. <i
        style="mso-bidi-font-style:normal">Birth and neonatal information</i>, including
        circumstances of delivery, anthropometric measurements (weight, length and head
        circumference), physical examination and state of wellbeing are necessary for the
        assessment of possible genetic disorders and birth defects.<span style="mso-spacerun: yes">
        &nbsp; </span>Finally, <i style="mso-bidi-font-style:
normal">subsequent history</i>
        should be obtained with respect to general health, growth, neurological development, and
        the details of any previous investigations.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB" style="letter-spacing:
-.15pt">&nbsp;<o:p></o:p></span></i></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:
-.15pt"><i style="mso-bidi-font-style:normal">Physical
        examination</i> should include physical measurements and recording of significant physical
        features (e.g. ear length, hand/palm length) and major and minor anomalies (dysmorphic
        features). The number and complexity of genetic syndromes may require special expertise on
        the part of the clinician to make the correct diagnosis. However, general physicians and
        other health professionals can be trained to suspect and diagnose genetic conditions that
        are particularly prevalent in their communities. Diagnostic guidelines and the possibility
        of consultations with specialists will enhance this capacity.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB" style="letter-spacing:
-.15pt">&nbsp;<o:p></o:p></span></i></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB" style="letter-spacing:
-.15pt">Special
        tests</span></i><span lang="EN-GB" style="letter-spacing:-.15pt"> (radiology, pathology,
        biochemical, cytogenetic, molecular and others) may be required to confirm some diagnoses.
        These tests can also be utilised as a guide to therapy (Table 3).<span
        style="mso-spacerun: yes">&nbsp; </span>gAs genetic disorders and birth defects occur in
        families, in some instances it may be necessary to conduct investigations on family
        members, after counselling and with informed consent. The costs of genetic tests, however,
        may render this process prohibitively expensive. In order to minimise costs, genetic
        diagnostic tests must be selectively applied to patients following accepted indications
        and guidelines developed in accordance of each country's context. Cost efficiency of
        genetic laboratories increase with proper regionalisation and avoidance of duplication of
        services.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><b style="mso-bidi-font-weight:normal"><i
        style="mso-bidi-font-style:
normal">9.3. Genetic Counselling</i></b><i
        style="mso-bidi-font-style:normal"><o:p></o:p></i></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:2.0pt;text-align:justify;text-indent:
-36.0pt;mso-hyphenate:none;tab-stops:-36.0pt 0cm"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>At the conclusion of the diagnostic procedure the available medical facts are
        discussed with the patient and/or the family, in the process of <i
        style="mso-bidi-font-style:
normal">genetic counselling</i>.<span
        style="mso-spacerun: yes">&nbsp; </span>Obviously this is greatly enhanced when a
        definitive diagnosis has been reached, but is not absolutely dependent thereon. Genetic
        counselling has been defined<span style="mso-spacerun: yes">&nbsp; </span>(American
        Society of Human Genetics,1975) as:<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>"A communication process, which involves an attempt of one or more
        appropriately trained persons to help the individual or the family to:<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l115 level1 lfo77;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings;letter-spacing:-.15pt">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Comprehend the medical facts including
        diagnosis, the probable course of the disorder and the available management;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l115 level1 lfo77;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings;letter-spacing:-.15pt">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Appreciate the way heredity contributes to the
        disorder and the risk of recurrence;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l115 level1 lfo77;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings;letter-spacing:-.15pt">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Understand the alternatives for dealing with
        the risk of recurrence;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l115 level1 lfo77;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings;letter-spacing:-.15pt">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Choose the course of action which seems
        appropriate to them in view of their risk, their family goals, and their ethical and
        religious standards, and act in accordance with their decision;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l115 level1 lfo77;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings;letter-spacing:-.15pt">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Make the best possible adjustment to the
        disorder in an affected family member and/or to the risk of recurrence of that disorder.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>In the 25 years after this definition was formulated in the United States, the
        concept and practice of genetic counselling has expanded in developed and developing
        countries to address not only <i style="mso-bidi-font-style:normal">retrospective</i>
        counselling after the birth of an affected child, but also <i
        style="mso-bidi-font-style:
normal">prospective</i> counselling on genetic risks at
        different stages of the life cycle, including the preconception and prenatal periods.
        Furthermore, in addition to dealing with reproductive genetic risks, genetic counselling
        is increasingly sought by healthy individuals with a genetic predisposition to late-onset
        disorders to discuss options regarding genetic susceptibility testing and preventive
        interventions.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Central to the process of genetic counselling are its educational, voluntary and
        non- prescriptive nature. The main goal is to empower individuals and couples to make
        their own informed decisions when facing genetic risks, according to their own values, and
        then support these choices. It should be recognised, however, that genetic counselling
        takes place within the context of individual countries, and is shaped by the capabilities
        of their health care system and social, cultural, religious and legal environments (WHO,
        1998).<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB" style="letter-spacing:-.15pt"><b
        style="mso-bidi-font-weight:normal"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>9.4. Therapeutic Interventions</b><o:p></o:p></span></i></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Treatment of genetic disorders and birth defects is often burdensome for the
        patient and the family and this burden tends to be heaviest in the developing countries.<span
        style="mso-spacerun: yes">&nbsp; </span>In addition it has economic implications for
        health care resources (WHO, 1985; WHO, 1996).<span style="mso-spacerun: yes">&nbsp; </span>Due
        consideration is therefore required to ensure that specific interventions are evidence
        based. .<span style="mso-spacerun: yes">&nbsp; </span>Table 3 lists the possible options
        for best care therapy for a number of common conditions, and indicates which of these can
        be undertaken at primary health care level. One of the therapeutic options available in
        the primary health care setting, that is often overlooked, is neurodevelopmental therapy
        (NDT) for patients with disabilities (intellectual, physical, auditory, or visual).<span
        style="mso-spacerun: yes">&nbsp; </span>NDT includes physical therapy, occupational
        therapy and speech therapy.<span style="mso-spacerun: yes">&nbsp; </span>In developing
        countries this can be administered by community based rehabilitation workers using
        programmes specifically designed for the circumstances in which they live and work.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB" style="letter-spacing:-.15pt"><b
        style="mso-bidi-font-weight:normal"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>9.5. Psychosocial Support</b><o:p></o:p></span></i></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The diagnosis of a genetic disorder or birth defect has lifelong implications for
        the patient and family that will result in the need for psychological, emotional and
        social support for these individuals. In a continuum of care, the primary health care
        practitioner is ideally placed to be a key provider.<span style="mso-spacerun: yes">&nbsp;
        </span>These professionals live and are a part of the same community as the patient and
        are therefore cognisant of the social, cultural, religious and economic factors that may
        influence the course of their patient's lives.<b style="mso-bidi-font-weight:normal">
        </b><span style="mso-spacerun: yes">&nbsp;&nbsp;</span>Invaluable collaboration in this
        process can be obtained from patient support groups or the arrangement of a meeting with
        another patient or parent of a child with a similar problem. Thus the concerns and
        uncertainties of patients and families can be addressed where possible, and the validity
        of their feelings acknowledged (Poortman, 1999).<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-GB">10. GOALS AND COMPONENTS OF
        POPULATION-BASED GENETIC SERVICES <o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">One
        of the goals of genetic services at the population level is the reduction of the burden of
        genetic disorders and birth defects. A number of strategies have been developed over the
        past two decades to reach this goal (WHO, 1996), focusing on primary prevention,
        prevention by reproductive options and secondary prevention.</span></p>
        <p class="MsoNormal" style="margin-left:4.5pt;text-align:justify;text-indent:
31.5pt"><u><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></u></p>
        <p class="MsoNormal" style="margin-left:4.5pt;text-align:justify;text-indent:
31.5pt"><span
        lang="EN-GB"><b style="mso-bidi-font-weight:normal"><i
        style="mso-bidi-font-style:
normal">10.1. Primary prevention</i></b><i
        style="mso-bidi-font-style:normal"><o:p></o:p></i></span></p>
        <p class="MsoNormal" style="margin-left:4.5pt;text-align:justify;text-indent:
31.5pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="margin-left:4.5pt;text-align:justify;text-indent:
31.5pt"><span
        lang="EN-GB">Primary prevention aims at reducing the incidence of specific genetic
        disorders and birth defects. Conditions most amenable to primary prevention are birth
        defects caused by environmental factors that can be removed or neutralized, and
        non-hereditary genetic disorders such as chromosomal abnormalities, in which the
        association with advanced maternal age offers a basis for prevention. General strategies
        for primary prevention include:</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l97 level1 lfo83;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Public efforts to improve health, nutrition, education and self reliance,
        particularly of women;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l174 level1 lfo84;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Avoidance of unintended pregnancies and proper birth spacing through access
        to contraception and other methods of family planning;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l174 level1 lfo84;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Improved access to and quality of prenatal care;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l192 level1 lfo86;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Improved quality of birth care;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l11 level1 lfo87;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Control of possible occupational risks.</span></p>
        <p class="MsoNormal" style="margin-left:4.5pt;text-align:justify;text-indent:
31.5pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="margin-left:4.5pt;text-align:justify;text-indent:
31.5pt"><span
        lang="EN-GB">More specific primary prevention strategies are:</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l72 level1 lfo88;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Voluntary premarital genetic screening and counselling may dissuade couples
        at risk to marry and thus could play a preventive role particularly in countries where
        abortion is not allowed. This strategy would only be ethical if it is strictly voluntary,
        implemented through non-directive genetic counselling, and not coerced through direct or
        indirect social pressures;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l91 level1 lfo89;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Pre- and periconceptional supplementation of vitamins, including folic acid,
        for women in the reproductive age group to reduce the risk of neural tube defects and
        possibly other birth defects;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l13 level1 lfo90;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Encouraging women to procreate at the ideal reproductive ages (20-35 years)
        to reduce the risk of non-dysjunction chromosomal abnormalities;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l99 level1 lfo91;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Avoidance of exposures to mutagens and teratogens (radiation, rubella,
        alcohol, tobacco, self-medications) during pregnancy.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent" style="mso-pagination:widow-orphan"><span lang="EN-GB"
        style="layout-grid-mode:both">All primary prevention is usually centrally planned and
        population based, and requires the involvement of primary health care providers as well as
        community<span style="mso-spacerun: yes">&nbsp; </span>awareness and education.<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent" style="mso-pagination:widow-orphan"><span lang="EN-GB"
        style="layout-grid-mode:both">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>10.2. Secondary prevention<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Secondary
        prevention aims at avoiding the birth of affected fetus, minimizing clinical
        manifestations of a condition after the birth of an affected infant or<span
        style="mso-spacerun: yes">&nbsp; </span>detecting the genetic predisposition for a
        condition that presents later in life. Strategies at the population level include:</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l69 level1 lfo96;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Early detection of congenital malformations by systematic physical
        examination of newborns, followed by appropriate treatment;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l70 level1 lfo97;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Newborn metabolic screening for serious diseases amenable to early and cost
        efficient treatment (e.g. congenital hypothyroidism, phenylketonuria);</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l161 level1 lfo98;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Monitoring of child growth and development for the early detection and
        treatment of genetic conditions;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l3 level1 lfo99;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Presymptomatic genetic testing for late onset conditions followed by
        surveillance and medical intervention (e.g. genetic testing of children with a parent<span
        style="mso-spacerun: yes">&nbsp; </span>affected with familial adenomatous poplyposis,
        followed by serial colonoscopies and eventual colectomy if the individual has the
        causative gene).</span></p>
        <p class="MsoNormal" style="margin-left:36.0pt;text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent" style="mso-pagination:widow-orphan"><span lang="EN-GB"
        style="layout-grid-mode:both">Newborn metabolic screening programs for certain specific
        conditions deserve special mention because they are being implemented in many countries.
        For this strategy to be cost/efficient, the disorders included in newborn screening should
        be relatively prevalent, clinically severe and screened by automated laboratory methods
        for which there are confirmatory tests. It is essential that there be a demonstrated
        benefit of their early detection and treatment measured by long term outcomes. Examples of
        such conditions are congenital hypothyroidism, phenylketonuria and sickle cell disorders.
        Newborn screening should always be a high-level health policy decision and should include
        all births in a population. Follow-up of abnormal results by confirmatory testing,
        counselling and long-term follow-up and treatment of detected cases are prerequisites as
        is public education. All steps of the program should be publicly financed. The laboratory
        infrastructure and procedures for newborn screening should be highly centralized and
        subjected to stringent quality control. The decision whether to develop a newborn
        screening program and for which conditions, should be guided by the criteria outlined
        above and may vary from country to country according to the prevalence of different
        conditions, the public health resources and the general health priorities. A medical
        genetic centre (see Section 11.3) may be an appropriate site to set the laboratory
        infrastructure for newborn screening, and particularly for the confirmation of diagnosis,
        treatment and follow-up of suspected cases, although other alternatives may be considered.<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">More recently, as environmental and
        genetic factors predisposing to common multifactorial disorders are being recognized,
        attempts are being made to identify such factors in the population. Preventive measures
        and treatment of conditions such as diabetes, obesity, coronary disease and some cancers
        can be implemented now and are likely to be even more effective in the future (WHO, 1996).
        For example, recent studies suggest that bilateral mastectomy and/or tamoxifen may be of
        value in preventing breast cancer in women with BRCA1 or BRCA2 mutations (Hartmann et al,
        1999).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal">10.3. Prevention based on reproduction options</b>.<o:p></o:p></span></i></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        technological developments in medical genetics of the last two decades have enabled the
        implementation of a novel form of prevention, which is based on reproductive options. The
        goal of the latter is to maximize the chances that individuals at increased risk of
        affected offspring will have children free of the disorder in question. This strategy is
        concerned with early detection of individuals or couples at increased genetic risk for
        having a child with a serious disorder, followed by genetic counselling and the offer of
        prenatal diagnosis. The facts that these services are always voluntary, that prior
        informed consent is required and those individuals can freely make their own reproductive
        decisions clearly distinguish this strategy from imposed eugenic policies.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Prevention
        based on reproductive options is best accomplished at the primary health care level,
        starting with the detection of genetic risk factors in the population. These include a
        positive family history for a birth defect or a genetic disorder, carrier detection of a
        recessive trait frequent in the community, maternal age, exposure to teratogens, and
        prenatal screening for neural tube defects and Down syndrome by measurement of maternal
        serum biochemical markers and/or fetal ultrasonography.<span style="mso-spacerun:
yes">
        &nbsp; </span></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Couples
        found to be at increased genetic risk are offered genetic counselling on available
        voluntary reproductive options to manage the risk. Reproductive options vary according to
        the condition in question, the personal and cultural factors involved, and what is
        available and permissible in a particular country. These may include:</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l12 level1 lfo92;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Abstention from further reproduction;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l42 level1 lfo93;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Adoption, sperm or egg donation, in vitro fertilization and preimplantation
        diagnosis;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l92 level1 lfo94;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Initiation of a pregnancy and carrying to term without prenatal diagnosis;</span></p>
        <p class="MsoNormal"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l112 level1 lfo95;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Initiation of a pregnancy and prenatal diagnosis for reassurance that the
        future child will be free of the disorder in question, or for preparing for the birth of
        an affected child, or for termination of an affected pregnancy;</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">All
        these services are voluntary and the international experience is that most couples at
        increased genetic risk of a serious genetic disorder or birth defect favour prenatal
        diagnosis to avoid the birth of an affected infant. This strategy has been successfully
        applied to the prevention of chromosome anomalies and several recessive conditions
        (thalassaemia, Tay-Sachs disease and others), both in industrialized and developing
        countries.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Among
        prevention programs based on reproductive options, the prenatal screening of pregnancies
        to detect fetuses with trisomy 21 has become a standard of prenatal care in many developed
        countries. The technologies used are measurement of fetal substances in maternal serum and
        ultrasonography, either alone or in combination, towards the end of the first trimester
        and early in the second trimester (Milunsky, 1998b, Ville, 1998). The detection rate
        varies between 50 and 80%. The caveat of these programs is that, because of the high
        sensitivity and low specificity of existing tests, they place a large number of
        pregnancies (about 5%) in a high risk category, all of which must then be offered
        amniocentesis to confirm or rule out the diagnosis. Approximately 200 amniocenteses are
        needed to confirm one case of Down syndrome. This may impose an excessive burden on health
        finances in a developing country where competing priorities exist. Thus such programs
        should only be implemented in a country that is willing to invest on the necessary
        resources to offer and perform amniocenteses in about 5% of all pregnancies. As with other
        population screening programs elsewhere, the decision to implement prenatal screening for
        trisomy 21 in a developing country will have to originate from a high health policymaking
        level and take into consideration technical, financial, cultural, legal and religious
        factors.</span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal">10.4. Tertiary
        prevention</i></b><i style="mso-bidi-font-style:
normal"><o:p></o:p></i></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Tertiary
        prevention of birth defects and genetic diseases aims at averting deterioration,
        complications, disability and dependency of the patient and the family. The strategies are
        anticipatory guidance (e.g. prevention of obesity in Down syndrome), proper interventions
        to avert complications (e.g. laminectomy to alleviate spinal cord compression in
        achondroplasia), and rehabilitation of disabilities (e.g. speech therapy, hearing aids in
        hypoacusia, physical therapy in neuromuscular diseases).<u> </u><i
        style="mso-bidi-font-style:normal">Psychosocial support</i> of affected individuals and
        their families is an essential, albeit commonly neglected, component of the care of
        genetic disorders and birth defects.</span></p>
        <p class="MsoBodyTextIndent"><i style="mso-bidi-font-style:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></i></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">In summary, the combination of
        patient/family services for diagnosis, counselling, management and prevention and
        population-based preventive programs constitute the pillars of genetic services.
        Patient/family services follow the structure of health care in steps of increasing
        complexity, at the primary, secondary and tertiary care levels, with intervention of
        allied health personnel, family practitioners, medical specialists, and clinical
        geneticists. Collaboration with other sectors including education and social welfare are
        also necessary. </span></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">Population-based programs undertaken in
        collaboration with public health departments require appropriate planning, appropriate
        resource allocation, and training of personnel at the different levels of care, with
        emphasis on the primary health care level.</span></p>
        <p class="MsoBodyTextIndent"><b style="mso-bidi-font-weight:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoBodyTextIndent"><b style="mso-bidi-font-weight:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">11.<span style="mso-spacerun: yes">&nbsp; </span>ORGANIZATION OF THE DELIVERY
        OF GENETIC SERVICES<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Among
        the key characteristics of genetic services anywhere is their multidisciplinary nature.
        Indeed, since most genetic disorders and birth defects are multisystem and lifelong,
        medical actions for their management and prevention must involve several types of health
        professionals in a coordinated fashion. The exact training needed by professionals to
        provide those services will depend on a number of factors: level of care, structure of the
        health professions in the country, rural versus urban settings, etc. Where clinical
        geneticists are available, they work in coordination with primary health care physicians,
        different medical specialists (pediatricians, obstetricians, neurologists, oncologists,
        haematologists, etc) and other health personnel (nurses, social workers, genetic
        counsellors, etc). Genetic services cannot<span style="mso-spacerun: yes">&nbsp; </span>exist
        as stand alone vertical structures but should be integrated with related medical services,
        such as preconception and prenatal care, family planning, child growth and development
        monitoring, special clinics, and rehabilitation of disabilities, to name a few. The
        clinical geneticist deals primarily with the genetic aspects of the management, including
        clinical diagnosis, genetic testing and interpretation, and genetic counselling. Prenatal
        genetic services require coordination between clinical geneticists, obstetricians and
        ultrasonographers. Because the number of clinical geneticists is limited in most
        developing countries, they should primarily be involved in training and supervision of
        other health personnel.</span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">The delivery of genetic services should be
        organized at all levels of care in a way that takes full advantage of the existing
        resources, maximizes efficiency and avoids duplication of services.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal">11.1. Primary
        health care level</i></b><i style="mso-bidi-font-style:
normal"><o:p></o:p></i></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">The primary level of care should be the backbone
        of all health actions in genetics, with emphasis in programs that employ low-level
        technology and reach a large proportion of the community. Examples of actions at the
        primary health care level are:<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l127 level1 lfo100;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="font-family:"CG Times"">Public education in genetics;<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l162 level1 lfo101;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="font-family:"CG Times"">Detection of genetic risks in the
        community by due attention and recording of family history in all patient encounters with
        the health system;<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l134 level1 lfo102;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="font-family:"CG Times"">Rubella immunization;<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l29 level1 lfo103;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="font-family:"CG Times"">Prevention of fetal alcohol effects;<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l177 level1 lfo104;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="font-family:"CG Times"">Encouragement of reproduction at
        optimal maternal ages;<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l49 level1 lfo105;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="font-family:"CG Times"">Carrier detection of recessive
        traits for disorders of high prevalence in the community (e.g., sickle-cell disease or
        others);<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l182 level1 lfo106;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="font-family:"CG Times"">Prenatal screening for maternal
        biochemical markers for Down syndrome risk;<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:57.6pt;text-align:justify;text-indent:
-21.6pt;mso-list:l182 level1 lfo106;tab-stops:list 57.6pt"><span
        lang="EN-GB" style="font-family:Wingdings">§<span
        style="font:7.0pt "Times New Roman"">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="font-family:"CG Times"">Genetic counselling for simple
        problems.<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent" style="mso-pagination:widow-orphan"><span lang="EN-GB"
        style="layout-grid-mode:both">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent" style="mso-pagination:widow-orphan"><span lang="EN-GB"
        style="layout-grid-mode:both">The sites for primary health care actions in medical
        genetics are community health centres, clinics and hospitals, physicians' offices,
        schools and community organizations. The personnel involved in medical genetic services at
        the primary level will most likely be primary care practitioners with task-oriented basic
        training in applied genetics (including physicians, nurses, and/or midwifes, depending on
        the country or community). In order to accomplish the goals stated above, there should be
        adequate links with secondary and tertiary levels of genetic care for consultation by the
        primary provider, as well as appropriate referral channels. Actions at the primary health
        care level should follow established guidelines and be supervised by the secondary and
        tertiary levels.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal">11.2. Secondary
        care level</i></b><i style="mso-bidi-font-style:
normal"><o:p></o:p></i></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        secondary care level, based in medium-size hospitals, is staffed with medical specialists
        and allied health personnel and has available general clinical laboratory, radiology and
        ultrasound facilities.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">In
        addition to all the functions typically performed at the primary health care level and
        described above, the secondary level deals with genetic problems of intermediate
        complexity, which cannot be solved at the primary health care level. Problems referred
        from the primary health care level comprise confirmation of suspected diagnoses,
        follow-ups of initial screening tests, management of specific conditions and genetic
        counselling of intermediate complexity. In some cases, fetal ultrasonography and prenatal
        diagnosis procedures can de done in this level. These services are performed by personnel
        with special training in applied genetics and genetic counselling, which can take several
        forms in different countries. For example, secondary-level genetic services in Cuba were
        initially implemented by pediatricians and obstetricians with special genetic training<span
        style="mso-spacerun: yes">&nbsp; </span>(Heredero, 1992, 1998), and later formally trained
        clinical geneticists replaced them.<span style="mso-spacerun: yes">&nbsp; </span>South
        Africa, on the other hand, resorted to specially trained nurses (Jenkins, 1990). Periodic
        outreach visits by clinical geneticists from tertiary care centres are helpful to deal
        with special problems, for education of personnel and for supervision purposes. When
        ultrasound and prenatal diagnosis procedures are offered dedicated personnel with
        appropriate training should undertake them.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <h1 style="text-align:justify;text-indent:36.0pt"><i style="mso-bidi-font-style:
normal"><span
        lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;
font-family:"CG Times"">11.3.
        Tertiary care level: medical genetics centres<o:p></o:p></span></i></h1>
        <p class="MsoBodyText"><span lang="PT-BR" style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText" style="text-indent:36.0pt"><span lang="PT-BR"
        style="font-family:"CG Times"">The tertiary level of genetic services represents
        the best care available for genetic disorders and birth defects in a country. It is
        typically a medical genetic center, usually located in a university hospital or tertiary
        health center in a major city. Such facilities are<span style="mso-spacerun: yes">&nbsp; </span>a
        referral center for the secondary levels of genetic services. Thus, adequate referral
        channels for patients and feedback mechanisms to the referring level, with information and
        guidance required for the continuing followup of the patient and his/her family, are
        essential. Ideally the medical genetic center should have a designated area of coverage,
        with a number of secondary and primary health care level units under its responsibility.
        It is assumed that this tertiary level will concentrate mostly on diagnostic services,<span
        style="mso-spacerun: yes">&nbsp; </span>provide complex counseling and care to patients
        and families with severe genetic disorders, as well as develop research and implement
        training programs in the field.<o:p></o:p></span></p>
        <p class="MsoBodyText" style="text-indent:36.0pt"><span lang="PT-BR"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText" style="text-indent:36.0pt"><span lang="PT-BR"
        style="font-family:"CG Times"">The number and complexity of tertiary genetic
        centers depend on the size of the country, the relative importance of genetic disorders
        and birth defects in the health of its population and the human and material resources
        available. They should cooperate to ensure a broad<span style="mso-spacerun: yes">&nbsp; </span>national
        base of medical genetic services without unnecessy duplication.<span
        style="mso-spacerun: yes">&nbsp; </span>Smaller and/or poorer countries may be able to
        sustain only a single such center or none at all; in the latter scenario, the more complex
        cases and/or laboratory tests can be referred out of the country.<span
        style="mso-spacerun: yes">&nbsp; </span>The following enumeration of functions performed
        by medical genetic centers describes best-case scenarios arrived at in a long process of
        service development. They should be considered ultimate goals rather than starting
        requirements . Moreover, it should be understood that a center will rarely have all the
        resources indicated.<o:p></o:p></span></p>
        <h2 style="margin-left:36.0pt;text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></h2>
        <h2 style="margin-left:36.0pt;text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">11.3.1. Clinical genetics evaluation and genetic
        counselling<o:p></o:p></span></h2>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Patients
        referred from the lower levels of care are evaluated to make a specific diagnosis, to
        provide appropriate genetic counselling and to design suitable therapeutic measures, when
        available. These services are provided by physicians trained in clinical genetics and
        other specialties, in conjunction with non-medical personnel trained in genetics,
        including nurses, social workers, psychologists and genetic counsellors. Access to
        Internet and computerized systems of syndrome identification are important diagnostic
        tools. Additional diagnostic services including pathology, radiology and ultrasonography
        must be readily available. There should also be access to consultation with other medical
        specialties, like haematology, oncology, neurology, ophthalmology. The medical genetics
        team should also be trained to provide treatments for selected conditions, like<span
        style="mso-spacerun:
yes">&nbsp; </span>inherited<span style="mso-spacerun: yes">&nbsp; </span>metabolic
        diseases.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Genetic
        counselling is provided as an integral component of genetic services, including prenatal
        counselling about genetic risks in the offspring of people who are planning a pregnancy or
        who are already pregnant.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Prenatal
        genetic diagnosis is another important service offered in medical genetic centres.
        Components of this service include genetic counselling, obstetrical procedures (ultrasound
        and sampling fetal tissue) performed in the centre or at obstetrical sites, and laboratory
        testing (see Section 11.3.2). The goal of this service is to provide prospective parents
        at risk for a particular genetic condition in their offspring, with information on the
        status of the fetus with regard to a specific condition and the alternative reproductive
        options available in the country. Prenatal diagnosis should be strictly voluntary and
        preceded by non-directive genetic counselling (WHO, 1998).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Counselling
        about teratogens can be a tool of primary prevention of birth defects when it prevents
        exposures that can lead to malformations. Exposures to potential teratogens are very
        common in developing countries, because of the widespread use of pesticides and other
        environmental pollutants and the pervasive use of unprescribed medications and home
        remedies. It is not uncommon that after exposure to a potential teratogen, prospective
        parents resort to termination of pregnancy without sound reasons for it, out of fear of
        fetal damage. In this context, counselling provides objective evidence that may prevent
        unfounded pregnancy terminations. Access to teratogen databases is advisable, as well as
        easy consultation by health professionals via telephone or electronic mail (Clavijo et al,
        1992; Schuler et al, 1993). A teratogen information service can function in a genetics
        centre, although other organizational schemes are also effective.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Finally,
        the clinical genetics unit should develop appropriate registers of genetic disorders and
        birth defects for their region and store data on the cases seen, for future follow-up of
        patients as needed as well as for research. Confidentiality and respect for the privacy of
        genetic information, however, should be strictly enforced.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <h2 style="margin-left:36.0pt;text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">11.3.2. Laboratory diagnosis<o:p></o:p></span></h2>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Most
        genetic diagnoses require specialized laboratory techniques. Although a number of such
        laboratories exist in many developing countries, appropriate regionalization and
        streamlining of their services is required to improve their utilization and
        cost/efficiency. Because of technical and economic reasons, these laboratories should be
        centralized to insure an appropriate minimum workload, quality monitoring and
        cost-efficiency. Systems for the transportation or shipment of specimens from primary and
        secondary levels of care should be implemented.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></i></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"><i
        style="mso-bidi-font-style:normal">Cytogenetic analysis</i> for chromosome abnormalities
        in blood cells, amniotic fluid and/or chorionic villi is an essential component of a
        medical genetics centre. The most common indications for chromosome analysis after birth
        are confirmation of the diagnosis of aneuploidies especially Down syndrome, multiple
        congenital anomalies of unknown origin, unexplained mental retardation, disorders of
        sexual development and infertility. During pregnancy, chromosome analysis is indicated
        when there is an increased risk for a fetal chromosome abnormality, such as advanced
        maternal age, abnormal maternal serum biochemical screening or fetal malformations
        detected by ultrasonography. Precise risk figures that constitute an indication for
        offering prenatal chromosome analysis are variable. In most industrialized countries the
        standard of practice is to offer prenatal chromosome diagnosis when the risk of a
        chromosome abnormality at birth is 0.5% (for example: maternal over 35 years) or higher.
        Individual developing countries will have to set the cut-up point for the indication of
        prenatal chromosome analysis depending on factors such as availability of the prenatal
        diagnostic services, the skill of the obstetricians, fetal risk of the procedure, the
        availability of cytogenetic laboratories and their own economic and policy considerations.</span></p>
        <p class="MsoBodyText" style="text-indent:36.0pt"><span lang="PT-BR"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText" style="text-indent:36.0pt"><span lang="PT-BR"
        style="font-family:"CG Times"">A <i style="mso-bidi-font-style:normal">biochemical
        genetics laboratory</i> is a valuable addition to the center. Simple techniques such as
        chemical screening tests in urine and chromatography/electrophoresis of amino acids,
        sugars, oligosaccharides and glycosaminoglycans are helpful in ruling out a number of
        suspected metabolic conditions. More complex techniques, such as the quantitative assay of
        amino acids, organic acids, very long chain fatty acids and assays for selected enzymes,
        depend on high-cost equipment and highly-trained personnel. Moreover, the conditions
        studied are individually very rare and the yield of positive diagnoses is low. For these
        reasons, very few such laboratories can be justified in developing countries. A
        cost-efficient strategy may be the regional development of networks of laboratories that
        complement each other and cover very large populations of one or more countries (over 20
        million).<o:p></o:p></span></p>
        <p class="MsoBodyText" style="text-indent:36.0pt"><span lang="PT-BR"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Increasingly,
        the diagnosis of genetic disorders is relying on molecular, or DNA testing. Although the
        standard laboratory of molecular genetics does not require high-cost equipment, it is
        dependent on a continuous supply of expensive consumables and the techniques are usually
        labour intensive. The decision of setting up molecular genetics testing for clinical
        purposes requires a thoughtful process and depends on considerations of cost/efficiency
        and priorities, where factors such as the existence of a genetic disease of high
        prevalence (i.e. sickle-cell disorder) or the implementation of a prevention program based
        on prenatal diagnosis of a specific genetic condition that is only diagnosable by DNA
        testing.<span style="mso-spacerun: yes">&nbsp; </span>In any case, if a DNA testing
        facility is set up, it should be highly centralized and regionalized to maximize its
        cost/efficiency and minimize duplication of resources. If two or more such facilities are
        present in a country they should cooperate to ensure the tests they offer do not overlap.
        At a minimum, the genetics centre should be able to extract DNA from blood samples and
        ship them for testing to specialized laboratories in other countries. The ability to bank
        genetic material (plasma, urine, leukocytes, fibroblasts, DNA, etc.) would be important to
        support future studies in undiagnosed cases, to allow research projects on rare diseases,
        and to enhance cooperation projects with other centres. Ethical guidelines to insure
        confidentiality and privacy of genetic information should be adhered to (WHO, 1998). (See
        Section 16).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Finally,
        in some countries the medical genetics centre may be the site for the administrative and
        laboratory components of some population screening programs, such as newborn metabolic
        screening or prenatal screening for Down syndrome (see Sections 10.2 and 10.3), although
        different organizational schemes are viable. Any program to incorporate genetics into
        health care should follow a step-wise approach, with short, medium and long term goals.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Close
        attention should be paid to cost/benefit ratios when deciding on establishing different
        types of genetic laboratories. Key principles are centralization, regionalization and
        complementation among laboratories, to avoid duplication of services. The proposal of a
        network of biochemical genetic laboratories in Latin America (Giugliani &amp; Coelho,
        1998) illustrates that complementation can also occur at the regional, supranational
        level. However, while it may be logical to concentrate most of the clinical and laboratory
        components of tertiary level genetic services in one or few sites, public health officials
        of developing countries should consider the whole context of the country or region before
        making policy decisions, as some of those components may already be operating in different
        settings.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <h2 style="margin-left:36.0pt;text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">11.3.3. Research<o:p></o:p></span></h2>
        <p class="MsoBodyText2" style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">As the improvement of knowledge on genetic
        diseases depends largely on the investigation of affected patients, genetic centres are
        the natural sites to conduct research to contribute new and valuable information,
        especially on disorders of high prevalence in their population. In addition, some research
        projects can bring further financial support to the centres and contribute to the better
        training of human resources. The genetic centre also contributes to establish guidelines
        for the transition of research findings into the practice of genetic services.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <h2 style="margin-left:36.0pt;text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">11.3.4.Teaching and training<o:p></o:p></span></h2>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Genetic
        centres are usually established in university hospitals, facilitating the teaching of
        medical genetics to undergraduate students, which contributes significantly to the
        expansion of the awareness about genetic disorders and birth defects among health
        professionals. The training of young medical doctors through residence programs is also
        highly desirable to further enable qualified personnel to work in this field. The centre
        should also be involved, whenever possible, in postgraduate courses, providing training to
        health professionals in syndrome identification, laboratory investigation, prenatal
        diagnosis and genetic counselling, among other issues. The organization of courses to
        update health professionals on the rapidly evolving field of medical genetics and the
        diffusion of information to the general public should also be addressed.</span></p>
        <h1 style="text-align:justify"><i style="mso-bidi-font-style:normal"><span lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"CG Times"">&nbsp;<o:p></o:p></span></i></h1>
        <h1 style="text-align:justify;text-indent:35.25pt"><i style="mso-bidi-font-style:
normal"><span
        lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;
font-family:"CG Times""><span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>11.3.5. General organizational principles and funding strategies<o:p></o:p></span></i></h1>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:35.25pt"><span lang="EN-GB">The
        installation of medical genetic centres in developing countries should only be conceived
        as a part of a comprehensive program designed to improve the care of these disorders. This
        is because of the large number of birth defects and genetic diseases, the rarity of any
        one condition, the complexity of the diagnostic process involved, the multidisciplinary
        nature of the care programs, and the costs involved. Ideally, these centres should be
        located in (or have easy access to) general hospitals that provide tertiary medical care.
        An association with university hospitals would enhance research and training, which could
        multiply the results of the work.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Depending
        on the size of the country, its stage of economic development and the relative impact of
        genetic disorders in health, there may be one or more tertiary level medical genetics
        centres. A single well staffed genetic centre could provide services to a population of
        5-10 million people, particularly in a regionalized health care system that ensures
        absence of duplication of services and is linked with secondary and primary health care
        levels. To overcome the usual barriers of access to tertiary care level units, the genetic
        centre should be related to the community, through a referral network of secondary and
        primary health care medical units and clinics. In turn, the genetic centre should provide
        supervision and direction to the lower levels of care. However, a genetic centre should
        not be construed as absolutely hegemonic towards the rest of genetic services or the
        health professionals working at secondary and primary levels of care. The principles to
        follow are those of <i style="mso-bidi-font-style:normal">collaboration </i>in a network
        with mutual responsibilities rather than <i style="mso-bidi-font-style:normal">authority</i>.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">To
        maintain a stable operation in the usually unstable economic environment of developing
        countries, the genetic centre should maintain a broad menu of funding options, including
        not only the health services but also research agencies, education funds, parents'
        organizations, other lay support groups and industry. There is no general rule to organize
        the funding of the genetic centre, as this issue will depend on the specific
        characteristics of each country. However, the general rule of providing patient care,
        education and research usually enlarges the range of agencies that could be asked to
        support the centre. Besides the funds that could be raised from patient services provided,
        some alternatives for fund raising can be considered:</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l44 level1 lfo108;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">The association with non-governmental organizations, such as parents'
        groups, which could raise funds for several activities of the centre, including research
        projects;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l114 level1 lfo109;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">The development of research projects that could allow the centre to apply for
        support to national and international funding agencies;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l158 level1 lfo110;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">The development of training programs that could allow the centre to apply for
        support to educational authorities and to international educational funds;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l20 level1 lfo111;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">The development of special projects such as teratogen information services
        (which could obtain support from the pharmaceutical industry) or neonatal screening (which
        could be maintained by governmental special budgets or by parents associations).</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal"><b style="mso-bidi-font-weight:normal"><span lang="EN-GB">12.<span
        style="mso-spacerun: yes">&nbsp; </span>TRAINING AND EDUCATION OF HEALTH PROFESSIONALS IN
        GENETICS<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">The latter half of the 20th century has
        witnessed rapid and remarkable advances in human and medical genetics and biomedical
        technology.<span style="mso-spacerun: yes">&nbsp; </span>This progress has resulted in an
        increasing understanding of the genetic contribution to health and disease. This is bound
        to continue and accelerate, with a likely shift of emphasis from rare genetic disorders to
        the more common multifactorial diseases, and towards new approaches of prevention and
        therapy.<span style="mso-spacerun: yes">&nbsp; </span>By the beginning of the next century
        all fields of medicine, including primary health care, will be utilising these advances in
        their practice (Harper et al, 1996; Harris &amp; Williamson, 1996)<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">Associated with these developments, in
        industrialised countries, has been the evolution of clinical and laboratory medical
        genetic services, to meet the needs of the public for genetic care and information.<span
        style="mso-spacerun: yes">&nbsp; </span>The ability of these health care systems to cope
        with the current and expected increased demands for such services, particularly in the
        field of clinical genetics is limited by lack of appropriately educated and trained
        manpower (Holtzman, 1989; Harper et al 1996).<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-spacerun:
yes">&nbsp; </span>Thus
        to ensure the future development of genetic services at all levels, including primary
        health care, medical genetics must be included in the core curriculum of under- and
        post-graduate physicians and nurses, and other allied professionals, (genetic counsellors,
        social workers, psychologists, community health care workers) who are involved in the
        provision of counselling and support.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="font-family:"CG Times";letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt;mso-hyphenate:
none"><span
        lang="EN-GB" style="font-family:"CG Times";letter-spacing:-.15pt">Education and
        training in medical genetics in developing countries is currently limited, although it has
        been initiated in several countries (WHO, 1998; WHO/EMRO 1997; Jenkins T, 1990). Given the
        increasing role that medical genetics is already playing in medicine, the delineation of
        objectives of medical genetics education for the health professions in developing
        countries cannot be ignored.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>A core medical genetics curriculum in the training of health professionals should
        have the following objectives (Baird, 1988; WHO/EMRO, 1997; Graham et al 1989; Johnston,
        1990):<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l71 level1 lfo112;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">The acquisition of a sound basic knowledge of
        genetic mechanisms in health and disease, and the role of genetic technology in medicine
        for diagnosis, treatment and prevention;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">The engendering in the student of appropriate
        attitudes towards the patient and family; <o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">The installation of a culture of lifelong
        learning in the student.<o:p></o:p></span></p>
        <p class="MsoFooter"
        style="text-align:justify;mso-pagination:widow-orphan;
tab-stops:-36.0pt"><span
        lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:
10.0pt;letter-spacing:-.15pt;layout-grid-mode:both">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>These goals can be obtained through a core curriculum that addresses the knowledge
        needed to be conversant with current developments in the field, the skills needed to apply
        this knowledge in practice and the attitudes necessary for optimal care and support of the
        patient and families.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Each country has its own characteristic pattern of common genetic disorders and
        birth defects that require to be managed within that country's social, cultural and legal
        milieu and health care framework. Until medical genetic services are well and equitably
        established in developing nations, a greater burden than usual for medical genetics care
        will be placed upon primary health care providers, including general physicians, nurses
        and non-medical personnel.<span style="mso-spacerun: yes">&nbsp; </span>As a basic
        principle these professionals should be educated and trained to manage common problems to
        the greatest extent possible, with the facilities available, at the primary health care
        level, and refer only those patients who require special care in terms of diagnosis,
        investigation and treatment.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The development of a medical genetics core curriculum for each country will require
        that these influences be accommodated and that the curriculum<span
        style="mso-spacerun: yes">&nbsp; </span>then be appropriately adapted to the needs of the
        different health care professionals.<span style="mso-spacerun: yes">&nbsp; </span>Having
        provided initial education and training for medical, nursing and paramedical personnel, it
        is necessary to develop a system of continuing professional development.<span
        style="mso-spacerun: yes">&nbsp; </span>Thereby individuals will have the opportunity to
        keep abreast of the rapid advances in the field and their appropriate application to daily
        work within the health care system.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <h6 style="text-align:justify"><span lang="EN-GB"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt;font-family:"CG Times""><span
        style="mso-spacerun:
yes">&nbsp; </span>COMPOSITION OF A CORE MEDICAL GENETIC CURRICULUM<o:p></o:p></span></h6>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:36.0pt;text-align:justify;text-indent:
-36.0pt;mso-hyphenate:none;tab-stops:-36.0pt 0cm"><b
        style="mso-bidi-font-weight:
normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Basic
        topics<o:p></o:p></span></b></p>
        <p class="MsoNormal"
        style="margin-left:36.0pt;text-align:justify;text-indent:
-36.0pt;mso-hyphenate:none;tab-stops:-36.0pt 0cm"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Basic Cytogenetics - Chromosome structure,
        function, terminology and common abnormalities.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Basic Molecular genetics - DNA, gene structure,
        function and mutation.<span style="mso-spacerun: yes">&nbsp; </span>DNA techniques and
        application.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Mendelian patterns of inheritance.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Non-Mendelian patterns of inheritance -
        multifactorial, mitrochondrial, uniparental disomy, genetic imprinting.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Congenital malformations and teratology.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Cancer genetics.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Genetic counselling.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Prenatal diagnosis and genetic screening.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Genetics and public health. Common disorders in
        the population. Consanguinity. Prevention of genetic diseases, with emphasis in primary
        prevention.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Ethical issues<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:36.0pt;text-align:justify;text-indent:
-36.0pt;mso-hyphenate:none;tab-stops:-36.0pt 0cm"><b
        style="mso-bidi-font-weight:
normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Skills<o:p></o:p></span></b></p>
        <p class="MsoNormal"
        style="margin-left:72.0pt;text-align:justify;text-indent:
-72.0pt;mso-hyphenate:none;tab-stops:-36.0pt 0cm 36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Take an adequate history.<span
        style="mso-spacerun: yes">&nbsp; </span>Includes constructing a family tree and
        identifying patterns of inheritance.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Undertake a physical examination including
        being capable of eliciting common dysmorphic features (professionals involved in clinical
        diagnosis).<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:list 18.0pt center 225.65pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Be capable of utilising the above to derive
        common genetic diagnoses (professionals involved in clinical diagnosis).<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Undertake a rational plan of investigation
        and/or care with appropriate referral when necessary.<span style="mso-spacerun: yes">
        &nbsp; </span>Management includes non-directive genetic counselling and psychosocial
        support.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:36.0pt;text-align:justify;text-indent:
-36.0pt;mso-hyphenate:none;tab-stops:-36.0pt 0cm"><b
        style="mso-bidi-font-weight:
normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Attitudes<o:p></o:p></span></b></p>
        <p class="MsoNormal"
        style="margin-left:36.0pt;text-align:justify;text-indent:
-36.0pt;mso-hyphenate:none;tab-stops:-36.0pt 0cm"><b
        style="mso-bidi-font-weight:
normal"><span lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt 0cm"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The rights of patients and families and the responsibility for upholding these,
        need to be imparted to students who will qualify to become medical genetic caregivers.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:36.0pt;text-align:justify;text-indent:
-36.0pt;mso-hyphenate:none;tab-stops:-36.0pt 0cm"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The patient's rights include:<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Respect and empathy for patients and family;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Full non-directive disclosure of information
        and counselling with respect to:<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:108.0pt;text-align:justify;text-indent:
-108.0pt;mso-hyphenate:none;tab-stops:-36.0pt 0cm 36.0pt 72.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>What is the diagnosis.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-top:0cm;margin-right:36.0pt;margin-bottom:
0cm;margin-left:108.0pt;margin-bottom:.0001pt;text-align:justify;text-indent:
-108.0pt;mso-hyphenate:none;tab-stops:-36.0pt 0cm 36.0pt 72.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The aetiology of the condition.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:108.0pt;text-align:justify;text-indent:
-108.0pt;mso-hyphenate:none;tab-stops:-36.0pt 0cm 36.0pt 72.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The prognosis/consequences of the condition.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:36.0pt;text-align:justify;mso-hyphenate:
none;tab-stops:-36.0pt 0cm 36.0pt 72.0pt"><span
        lang="EN-GB" style="letter-spacing:
-.15pt">Management of the condition, and possible
        prevention in future pregnancies.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">Full autonomy with respect to their own
        informed choices and support for these.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l153 level1 lfo117;mso-hyphenate:none;tab-stops:-36.0pt 0cm list 18.0pt left 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB" style="font-family:Symbol;letter-spacing:-.15pt">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="letter-spacing:-.15pt">The confidence that the caregiver has the
        knowledge and ability to supply refer appropriately when indicated.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB" style="letter-spacing:-.15pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">13.<span style="mso-spacerun: yes">&nbsp; </span>GENETIC EDUCATION OF THE
        PUBLIC<o:p></o:p></span></b></p>
        <p class="MsoBodyText2" style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">As it was already stated in this Report, that it
        is essential that the public be<span style="mso-spacerun:
yes">&nbsp; </span>educated
        with the appropriate knowledge necessary to take advantage of the prevention programs and
        the genetic services. As many of the outcomes of these programs depend on personal
        decisions of patients and persons at risk, the aim of public education in genetics is to
        empower people to make their own decisions in ways that maximize their wellbeing and
        health.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:18.0pt"><span lang="EN-GB"><span
        style="mso-spacerun: yes">&nbsp;&nbsp;&nbsp; </span>Educational activities in schools,
        community organizations and health care institutions are among the many possible
        alternatives. The mass media should be enlisted as allies of this endeavour. Messages
        should be simple, in language that is easily understood and free of derogatory,
        guilt-provoking or discriminatory overtones. A South-American experience of disseminating
        a &#147;Decalogue for Primary Prevention of Birth Defects&#148; (Castilla, 1999)
        constitutes a good example of public education that could be extended to other regions and
        other topics. The decalogue is worded as follows:</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l198 level1 lfo137;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Any woman of fertile age can be pregnant even if she is not aware of it;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l152 level1 lfo138;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">It is better to complete your family while you are young;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l152 level1 lfo138;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Prenatal controls are the best guarantee for the health of a pregnancy;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l152 level1 lfo138;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Get rubella vaccine before you become pregnant;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l152 level1 lfo138;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">In pregnancy, avoid all medications except the essential ones;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l152 level1 lfo138;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">In pregnancy, avoid alcoholic beverages in any quantity;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l152 level1 lfo138;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">In pregnancy, avoid smoking and smoking places;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l152 level1 lfo138;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Eat well and consume varied foods, including vegetables and fruits;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l152 level1 lfo138;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Ask if your regular job entails any risk to your pregnancy;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l152 level1 lfo138;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">In doubt, consult your physician or a specialized service.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoFooter"
        style="text-align:justify;mso-pagination:widow-orphan;
tab-stops:36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-US"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;layout-grid-mode:both">14.<span
        style="mso-spacerun: yes">&nbsp; </span>PARENTS/PATIENTS ORGANIZATIONS<o:p></o:p></span></b></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB"><b style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></i></b>Patients and their families concerned in genetic disorders and birth
        defects often face severe emotio­nal, psychosocial, physical and economic lifelong
        burdens. Standard health care services are currently not equipped to meet the needs of
        these people. Wherever they live, they need to have answers to many questions such as:</span></p>
        <p class="MsoNormal"
        style="margin-right:-50.4pt;text-align:justify;mso-hyphenate:
none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">- where to<span style="mso-spacerun: yes">&nbsp; </span>find proper care</span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">- where to<span style="mso-spacerun: yes">&nbsp; </span>obtain comprehensive,
        understandable and relevant information</span></p>
        <p class="MsoNormal"
        style="margin-right:-50.4pt;text-align:justify;mso-hyphenate:
none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">- why did this happen to them</span></p>
        <p class="MsoNormal"
        style="margin-right:-50.4pt;text-align:justify;mso-hyphenate:
none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">- could they<span style="mso-spacerun: yes">&nbsp; </span>have prevented it</span></p>
        <p class="MsoNormal"
        style="margin-right:-50.4pt;text-align:justify;mso-hyphenate:
none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">- what does it mean to their families</span></p>
        <p class="MsoNormal"
        style="margin-right:-50.4pt;text-align:justify;mso-hyphenate:
none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">- how to cope with the consequences of the disease</span></p>
        <p class="MsoNormal"
        style="margin-right:-50.4pt;text-align:justify;mso-hyphenate:
none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">- what to tell other people about their problem</span></p>
        <p class="MsoNormal"
        style="margin-right:-50.4pt;text-align:justify;mso-hyphenate:
none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">- how to<span style="mso-spacerun: yes">&nbsp; </span>get in contact with
        people involved with<span style="mso-spacerun: yes">&nbsp; </span>the same problems.</span></p>
        <p class="MsoNormal"
        style="margin-right:-50.4pt;text-align:justify;mso-hyphenate:
none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>A rough estimate by the Dutch National Health council indicates that some 10 to 35%
        of heredi­tary diseases can be prevented if the available information reaches the people
        involved in time (Poortman, 1999). Although genetic counselling services in academic
        genetic centres (see Section 11.3) usually satisfy the above mentioned concerns, most
        people in need are not aware of these services, and neither are general physicians, so
        referrals tend to be late or are never made.</span></p>
        <p class="MsoNormal"
        style="margin-right:-50.4pt;text-align:justify;mso-hyphenate:
none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-right:-50.4pt;text-align:justify;mso-hyphenate:
none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB"><b
        style="mso-bidi-font-weight:normal"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>14.1. Medical support and self help</b><o:p></o:p></span></i></p>
        <p class="MsoNormal"
        style="margin-right:-50.4pt;text-align:justify;mso-hyphenate:
none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="Initialcode"
        style="tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB" style="letter-spacing:0pt;mso-ansi-language:EN-GB"><span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Most disorders caused by mutations in a single gene are rare. In developed
        countries families often experience prolonged delays before getting a diagnosis and advice
        from the professionals about the management of the condition. Even when a timely diagnosis
        is made, lay patient support groups play an important role as a resource and a reservoir
        of practical knowledge for advice and support of its management on a day-to-day basis. In
        many parts of the developing world access to medical help for genetic disorders and birth
        defects is even more difficult because the health care systems devote their attention to
        more acute problems. The latter affect larger numbers<span style="mso-spacerun: yes">&nbsp;
        </span>of people and<span style="mso-spacerun: yes">&nbsp; </span>their management usually
        offers immediate gains through effective treatment and prevention. In developing
        countries, thus, support groups and mutual help are not<span style="mso-spacerun: yes">&nbsp;
        </span>just helpful, but essential.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-right:-50.4pt;text-align:justify;mso-hyphenate:
none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.35pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Most people, wherever they live, have little or no exposure to or knowledge about
        genetic disorders and birth defects. As a consequence, there is no reservoir of
        understanding or appreciation of what<span style="mso-spacerun: yes">&nbsp; </span>impact
        any such<span style="mso-spacerun: yes">&nbsp; </span>disorder has<span
        style="mso-spacerun: yes"> &nbsp; </span>on the affected person and his or her family. An
        affected person therefore can feel isolated<span style="mso-spacerun: yes">&nbsp; </span>and
        even<span style="mso-spacerun: yes">&nbsp; </span>rejected<span style="mso-spacerun: yes">&nbsp;
        </span>and stigmatized, because of<span style="mso-spacerun: yes">&nbsp; </span>failure<span
        style="mso-spacerun: yes">&nbsp; </span>to appreciate the genetic cause of the condition
        which leads to feelings of guilt and self-blame for the condition. Meeting others<span
        style="mso-spacerun: yes">&nbsp; </span>in the same situation is<span
        style="mso-spacerun: yes">&nbsp; </span>a source of great relief, because of acceptance
        and understanding, and also<span style="mso-spacerun: yes">&nbsp; </span>generates
        knowledge about practical management of the condition.</span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.35pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.35pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Patient support groups<span style="mso-spacerun: yes">&nbsp; </span>of developing
        countries have better access than single individuals<span style="mso-spacerun: yes">&nbsp;
        </span>to external sources of help (such as similar organisations in the industrialized
        world), which<span style="mso-spacerun: yes">&nbsp; </span>may be able to share their own
        resources or provide tangible support for their sister groups in developing countries.
        Informed, mutual self help will often lead to the development of patient groups in more
        formal ways, which in turn can result in political pressure for change, improved services
        and support and better health care for those affected.</span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.35pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></i></b></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.35pt"><span
        lang="EN-GB"><b style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>14.2. Objectives of parents/patients organisations</i></b><i
        style="mso-bidi-font-style:
normal"><o:p></o:p></i></span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.35pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.35pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Parents and patients have become united on a national, continental, and global
        level. Through disease-oriented organisations and national &#147;genetic alliances&#148;,
        they address specific concerns such as genetic causes of disability, means of prevention,
        management, public awareness, biomedical research, patenting of genetic material, and
        ethical and psychosocial aspects. Genetic coalitions have been founded in an
        ever-increasing number of developed and developing countries. In North America, Australia,
        and Western Europe, continental allian­ces of genetic support groups are well
        established. Hundreds of such groups exist in Latin America. More recently such alliances
        were founded in the Ukraine, in South Africa, and in India</span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.35pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.35pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The European Alliance of Genetic Support groups (EAGS) serves about 350 national
        support groups through nine European disease-oriented alliances and eight natio­nal
        genetic umbrella organisations. About six million families are affiliated with the member
        associations of EAGS.</span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.35pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.35pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The objectives of these organisations are:</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l21 level1 lfo150;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm list 18.0pt left 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.35pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Stimulate research into the cau­ses, prevention, and treatment of relevant
        diseases;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l21 level1 lfo150;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm list 18.0pt left 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.35pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Improve the wellbeing of patients with genetic impairments and their
        families;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l21 level1 lfo150;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm list 18.0pt left 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.35pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Improve the health status by providing<span style="mso-spacerun: yes">&nbsp; </span>quali­fied,
        accredited, accessible and affordable gene­tic services as an integral part if all health
        services;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l21 level1 lfo150;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm list 18.0pt left 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Voice the opinions of its members.</span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>At the meeting of the European Alliance of Genetic Support ­groups (EAGS) in
        London in 1995 the following<span style="mso-spacerun: yes">&nbsp; </span>consensus
        statements were developed:</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l21 level1 lfo150;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm list 18.0pt left 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Primary and secondary healthcare providers are currently not capable of
        dealing with genetic diagnosis and genetic counselling;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l21 level1 lfo150;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm list 18.0pt left 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Level of awareness of health care officials about genetics is minimal or
        entirely lacking;</span></p>
        <p class="MsoNormal"
        style="margin-left:17.85pt;text-align:justify;text-indent:
-17.85pt;mso-list:l68 level1 lfo143;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm list 18.0pt left 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Production of reliable, up to date educational materials is urgently needed
        for the professionals, the people concer­ned, and the population at large;</span></p>
        <p class="MsoNormal"
        style="margin-left:17.85pt;text-align:justify;text-indent:
-17.85pt;mso-list:l68 level1 lfo143;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm list 18.0pt left 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Appropriate and timely decisions concerning reproduction is often thwarted by
        late and inaccurate diagnosis, inef­ficient refer­ral systems and unbalanced and
        unreliable information</span></p>
        <p class="MsoNormal"
        style="margin-left:17.85pt;text-align:justify;text-indent:
-17.85pt;mso-list:l68 level1 lfo143;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm list 18.0pt left 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Research into the causes of congenital disorders has been relatively limited
        and its importance underestimated;</span></p>
        <p class="MsoNormal"
        style="margin-left:17.85pt;text-align:justify;text-indent:
-17.85pt;mso-list:l68 level1 lfo143;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm list 18.0pt left 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Impact of genetics and congenital disorders on the people concerned has been
        underestimated; adequate guidance is hard to find;</span></p>
        <p class="MsoNormal"
        style="margin-left:17.85pt;text-align:justify;text-indent:
-17.85pt;mso-list:l68 level1 lfo143;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm list 18.0pt left 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">The voice of the people concerned should be clear and heard and must be
        transmitted through the offici­al channels.</span></p>
        <p class="MsoNormal"
        style="margin-right:-50.4pt;text-align:justify;mso-hyphenate:
none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The Advisory Group recognised that the above statements (which have been endorsed<span
        style="mso-spacerun: yes">&nbsp; </span>worldwide by hundreds of parents' and patients'
        organisations concerned with genetic disorders and birth defects) is also applicable to
        developing countries. While much of the following text is based on the experience of
        patients' parents' organisations of developed countries, particularly in Europe,
        the Advisory Group felt that the principles stated apply equally to developing countries.</span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-right:-50.4pt;text-align:justify;mso-hyphenate:
none;tab-stops:-70.9pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>14.3. The role of parents/patients organisations.<o:p></o:p></span></i></b></p>
        <p class="MsoNormal"
        style="margin-right:-50.4pt;text-align:justify;mso-hyphenate:
none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>These organisations strive to make government officials and political leaders aware
        of new genetic knowledge and its applications.</span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>Parents' and patients' organisations tend to work closely with academic clinical
        genetic centres. With their support, they are able to produce comprehen­sive
        educati­onal materials for the general public, which include audio-visual presentations,
        audiotapes and lesson pac­kets of teaching materials for schools. They also produce
        television series in the context of Open University programmes; they establish public
        awareness campaigns that spread information about the availability of genetic services.
        Recent campaigns addressed the importance of folic acid as a primary preventive in the
        preconception period and described the available services making use of free publicity,
        advertisements etc. These organisations also take stands on topics such as about patenting
        of genetic material, the various international declarations pertaining to the human genome
        in the context of human rights and the need for genetic services throughout the world.</span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The media and the political leaders have shown an increasing interest in the
        opinions of parents and adult patients who have become experts themselves, because of
        their personal experiences. Another potential is their contribution to research efforts by
        encouraging their members to participate in biomedical research.</span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span></span></p>
        <p class="Initialcode"
        style="tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB" style="letter-spacing:0pt;mso-ansi-language:EN-GB"><span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>In most countries the alliances are recognised by governmental bodies. They have
        increasing political influence because of the large numbers of individuals whom they
        represent. The Advisory Group considers that parents' and patients' organisations play
        already an important role in developed and developing countries in the wellbeing of
        individuals affected with genetic disorders and birth defects. Governments and genetic
        professionals should encourage their formation and support their work.<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-right:-50.4pt;text-align:justify;mso-hyphenate:
none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="text-align:justify;mso-hyphenate:none;tab-stops:-72.0pt -36.0pt 0cm 36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">15.<span style="mso-spacerun: yes">&nbsp; </span>RESEARCH IN MEDICAL GENETICS<o:p></o:p></span></b></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">As stated previously in<span
        style="mso-spacerun: yes">&nbsp; </span>this Report, the Group feels that research is an
        important component of medical genetics in developing countries, especially as
        insufficient data are available on the epidemiology of genetic disorders and birth
        defects, the expectations of the population and the outcomes of genetic services.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Genetic research in developing countries should
        be applied in nature, and concentrate on generating knowledge regarding conditions that
        are particularly prevalent in the developing world. Emphasis should be given to
        epidemiological research on the prevalence and risk factors for genetic disorders and
        birth defects. Setting up registers of genetic disorders and birth defects will provide
        data for research as well as support and guide the implementation of care and prevention
        of these conditions. Research should take advantage of characteristics only or primarily
        found in each developing country, including particular ethnicities, exposure to specific
        environmental agents, large families, inbred populations, genetic disorders especially
        frequent in some areas.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Health services research with the purpose of
        finding new approaches to prevention and treatment of genetic disorders also deserves
        support. Psychosocial, cultural and ethical aspects of genetic services have largely been
        neglected in developing countries, where prevailing stereotypes most likely do not reflect
        the variety of opinions within a single culture.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Technological research should be directed at
        developing diagnostic and therapeutic technologies appropriate to the economic and social
        conditions and the needs of populations of developing countries.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">16.<span style="mso-spacerun: yes">&nbsp; </span>ETHICAL ASPECTS OF GENETIC
        SERVICES<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoBodyTextIndent"><span lang="EN-GB">Ethical considerations have been part of
        the practice of medicine since its inception. The traditional sources of ethical
        guidelines in medicine (respect for the dignity and autonomy of persons, beneficence,
        non-maleficence and justice) apply equally to medical genetic services worldwide.
        Moreover, the ethical concerns of medical genetics extend beyond those that medicine has
        held traditionally, as genetic information may affect an entire family rather that only an
        individual, it may predict future adverse events and presents choices that may affect
        future generations. In addition, the approach of medical genetics to patients and their
        families in genetic counselling tends to non-directive, in contrast with the directiveness
        of traditional medicine. The opportunities for prevention of genetic disorders and birth
        defects afforded by the technological advances in prediction and diagnosis, trigger novel
        ethical dilemmas, particularly in the public health applications of genetics.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Specific
        ethical dilemmas may be particularly poignant in developing countries, because of the
        circumstances described in Sections 5 and 6 of this document. Poverty, unequal
        distribution of wealth and scarcity of resources for health care pose serious ethical
        dilemmas in policy decisions regarding the place of genetic programs among competing
        priorities. Low levels of education of the public, and particularly of women, combined
        with traditional medical paternalism challenge the practice of non-directiveness and
        respect for individual autonomy. In many cultures prevailing in developing countries, the
        weight of traditions may conflict with modern views associated with the application of
        genetic technologies. A recent WHO panel of experts in medical genetics and ethics
        representing developed and developing countries proposed international guidelines to be
        followed in the implementation and practice of medical genetic services (WHO, 1998). It is
        apparent from these guidelines that, while the particular social, cultural, economic,
        legal and religious realities of individual countries must be acknowledged, most ethical
        principles in genetics are fairly universal and applicable to both developed and
        developing countries.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">16.1. Ethical principles applied to genetic services<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        following basic ethical principles should be followed in the implementation and practice
        of genetic services:</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l135 level1 lfo157;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Fair allocation of public resources for the management and prevention of
        genetic disorders and birth defects on the basis of need, defined by the magnitude and
        severity of problems to address and the benefits anticipated from actions;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l206 level1 lfo158;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Respect for human genetic and cultural diversity;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l82 level1 lfo159;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Respect for people's basic intelligence and for those whose views are in
        the minority;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l1 level1 lfo160;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Education of the public, health professionals, teachers, clergy, etc in
        genetics;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l52 level1 lfo161;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Participation of the public in the setting of goals of genetic services and
        their implementation;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l14 level1 lfo166;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Voluntary approach of genetic testing, prevention and treatment. Avoidance of
        coercion by government, society or the medical profession;</span></p>
        <p class="MsoBodyText"
        style="margin-left:18.0pt;text-indent:-18.0pt;mso-list:
l103 level1 lfo169;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol;mso-ansi-language:EN-GB">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="font-family:"CG Times";
mso-ansi-language:EN-GB">Timely
        provision of indicated services or follow-up and treatment. Refraining from providing
        tests or procedures not medically indicated. Ongoing provision of quality control of
        services;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l176 level1 lfo162;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Freedom of choice in all matters relevant to genetics. Women should be
        important decision-makers in reproductive matters;</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l32 level1 lfo170;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Prevention of unfair discrimination and/or stigmatization on the basis of
        genetic constitution; </span></p>
        <p class="MsoBodyText"
        style="margin-left:18.0pt;text-indent:-18.0pt;mso-list:
l96 level1 lfo172;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol;mso-ansi-language:EN-GB">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB" style="font-family:"CG Times";
mso-ansi-language:EN-GB">All
        genetic testing should be voluntary, preceded by adequate information and based on
        informed consent. Special caution should be exerted when testing healthy individuals for
        susceptibility to genetic and multifactorial conditions of adult onset that have no proven
        beneficial medical interventions. Testing of asymptomatic children should only be
        performed if there are potential medical or psychological benefits;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l200 level1 lfo173;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Prenatal diagnosis should be done only to give parents and physicians
        information about the health of the fetus. Its use to enforce social policies of any kind
        or for non-medical medical indications, like paternity testing or gender selection, apart
        from sex-linked disorders, is ethically unacceptable.</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l45 level1 lfo174;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">Medically indicated prenatal genetic diagnosis should be voluntary and
        available, within the context of each country, regardless of the couple's stated
        views on abortion. The prospective parents should decide whether a genetic disorder
        warrants prenatal diagnosis and/or termination of an affected pregnancy, as prenatal
        diagnosis may be used occasionally to prepare for the birth of a child with a disorder.</span></p>
        <p class="MsoNormal"
        style="margin-left:18.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l16 level1 lfo176;tab-stops:list 18.0pt"><span
        lang="EN-GB" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="EN-GB">The woman's and/or the couple's choices in a pregnancy with an
        affected fetus should be respected and protected, within the framework of the family and
        of the laws, culture and social structure of the country. The couple, not the health
        professional, should make the choice.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">16.2. Ethical principles applied to genetic counselling<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText" style="text-indent:36.0pt"><span lang="PT-BR"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText"
        style="margin-top:0cm;margin-right:9.0pt;margin-bottom:
0cm;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:27.0pt"><span
        lang="PT-BR" style="font-family:"CG Times"">The goal of genetic counselling is
        to empower individuals to make their own informed decisions pertaining to their genetic
        risks and/or the genetic risks of their offspring. This is accomplished by providing the
        individuals with accurate, full and unbiased information in a manner that is clear<span
        style="mso-spacerun: yes">&nbsp; </span>and understandable. It should take place in a
        manner that is empathetic and non-coercive. Thereafter the individuals are allowed to make
        their decisions, in their own time, in accordance<span style="mso-spacerun: yes">&nbsp; </span>with
        their own beliefs and customs, and the re-assurance that their choices will be fully
        supported by their medical attendents. These elements are the hallmark of what has been
        termed &#147;non-directiveness&#148; in genetic counselling.<span
        style="mso-spacerun: yes">&nbsp; </span>This approach has largely derived from the fact
        that todate medical genetics offers mainly diagnosis and prediction rather than treatment.
        It is likely that, as medical genetics advances and more treatments become available, the
        approach to genetic counseling may become similar to current approaches in general
        medicine, where the health professional may recommend beneficial treatments and/or
        lifestyles changes.<o:p></o:p></span></p>
        <p class="MsoBodyText" style="text-indent:36.0pt"><span lang="PT-BR"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText" style="text-indent:36.0pt"><span lang="PT-BR"
        style="font-family:"CG Times"">In summary, therefore,<span
        style="mso-spacerun:
yes">&nbsp; </span>ethical principles applied to genetic counseling
        inclide:<o:p></o:p></span></p>
        <p class="MsoBodyText"
        style="margin-left:54.0pt;text-indent:-18.0pt;mso-list:
l125 level1 lfo66;tab-stops:list 18.0pt"><span
        lang="PT-BR" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="PT-BR" style="font-family:"CG Times"">Respect for the personal values and
        culture of individuals and families.<o:p></o:p></span></p>
        <p class="MsoBodyText"
        style="margin-left:54.0pt;text-indent:-18.0pt;mso-list:
l125 level1 lfo66;tab-stops:list 18.0pt"><span
        lang="PT-BR" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="PT-BR" style="font-family:"CG Times"">Full disclosure of all information
        relevant to health with accurate and unbiased information.<o:p></o:p></span></p>
        <p class="MsoBodyText"
        style="margin-left:54.0pt;text-indent:-18.0pt;mso-list:
l125 level1 lfo66;tab-stops:list 18.0pt"><span
        lang="PT-BR" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="PT-BR" style="font-family:"CG Times"">Non coercion towards a particular
        decision<o:p></o:p></span></p>
        <p class="MsoBodyText"
        style="margin-left:54.0pt;text-indent:-18.0pt;mso-list:
l125 level1 lfo66;tab-stops:list 18.0pt"><span
        lang="PT-BR" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="PT-BR" style="font-family:"CG Times"">Protection of the privacy of genetic
        information from unjustified intrusions from third parties.<o:p></o:p></span></p>
        <p class="MsoBodyText"
        style="margin-left:54.0pt;text-indent:-18.0pt;mso-list:
l125 level1 lfo66;tab-stops:list 18.0pt"><span
        lang="PT-BR" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="PT-BR" style="font-family:"CG Times"">Informing individuals about the
        wisdom of disclosing genetic information to spouse or partner if children are intended, as
        well as the possibility of harmful effects on the marriage from disclosure.<o:p></o:p></span></p>
        <p class="MsoBodyText"
        style="margin-left:54.0pt;text-indent:-18.0pt;mso-list:
l125 level1 lfo66;tab-stops:list 18.0pt"><span
        lang="PT-BR" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="PT-BR" style="font-family:"CG Times"">Informing individuals of their moral
        duty to disclose a genetic status that may affect public safety.<o:p></o:p></span></p>
        <p class="MsoBodyText"
        style="margin-left:54.0pt;text-indent:-18.0pt;mso-list:
l125 level1 lfo66;tab-stops:list 18.0pt"><span
        lang="PT-BR" style="font-family:Symbol">·<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
        lang="PT-BR" style="font-family:"CG Times"">Non-directive approach whenever
        possible. When treatment is available a more directive stance may be advisable.<o:p></o:p></span></p>
        <p class="MsoBodyText"><span lang="PT-BR" style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText" style="text-indent:36.0pt"><span lang="PT-BR"
        style="font-family:"CG Times"">Policymakers of all countries should take these
        principles into consideration in formulating policies for the management and prevention of
        genetic conditions and birth defects. Concurrently, close dialog between the health
        professions and the public should be fostered to allay fears of misuse or abuse of genetic
        information.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">17. GENERAL CONCLUSIONS AND RECOMMENDATIONS<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><i
        style="mso-bidi-font-style:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">17.1. Need to recognize the burden imposed by genetic disorders and birth
        defects<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">The key and obvious first step to address a
        problem is to recognize its existence. As this report has documented extensively, genetic
        disorders and birth defects constitute a significant public health problem in most of the
        developing world. A number of factors (biological, medical, cultural, social) contribute
        to their occurrence and to their impact on health and wellbeing. The burden of these
        conditions in the developing world is dynamic, with an ongoing epidemiological transition
        from infections and malnutrition, on the one hand, to genetic disorders and birth defects
        as the principle causes of disease and disability. It is recognised that there is a
        significant variation among developing countries in the relative role of genetic disorders
        and birth defects in disease and disability. The consensus of the Group was however that
        most nations in the developing world have reached the stage in which some attention needs
        to be paid to genetic disorders and birth defects, even if infectious diseases and
        malnutrition are not yet completely controlled. Although scarce health resources should
        not be diverted from the prevention and care of infections and malnutrition, the
        Group's contention is that governments in the developing countries should also devote
        attention and resources to the management and prevention of genetic disorders and birth
        defects. For this to happen, public health authorities must acknowledge the reality that
        these conditions indeed are major causes of disease, disability, suffering and death in
        their countries, and recognize that there are approaches for their management and
        prevention that can significantly reduce their burden in a cost efficient manner.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">17.2. Need for political will and
        commitment<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">For genetic services to be implemented in a
        meaningful way and to benefit a sizable proportion of populations in need, governments
        must demonstrate beyond rhetoric, a political will to improve health and wellbeing of the
        people by making all types of health services, including genetic services, available and
        accessible. <o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">The commitment must come from the highest levels
        of government, and be translated into appropriate resource allocation. Moreover, by the
        nature and factors involved in genetic disorders and birth defects, the approach to their
        management and prevention are necessarily multidisciplinary and multisectorial, with
        involvement of health, social welfare, education, nutrition and other agencies. Generating
        political will and commitment from government authorities will require lobbying and
        educational efforts on the part of the medical community and non-governmental
        organizations such as parents/patients groups.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Cost/benefits analyses will help authorities to
        realize that:<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">- Priorities can be established so that there is
        no need to &#147;start with everything at the same time&#148;;<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-right:9.0pt;text-align:justify;tab-stops:
13.5pt 418.5pt"><span
        lang="EN-GB" style="font-family:"CG Times"">- A number of genetic services can
        be implemented without large financial investments;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">- Many genetic services are cost/effective;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="margin-right:18.0pt;text-align:justify;tab-stops:
423.0pt"><span
        lang="EN-GB" style="font-family:"CG Times"">- Costs of inaction in genetics to
        society, measured in terms of avoidable human suffering and burden to public health, are
        much higher.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">The Advisory Group specifically recommends that
        Ministries of Health of developing countries allocate resources for genetic programs and
        set up a distinct Office of Genetic Services within their administrative structure. This
        office should be directed by an individual with appropriate expertise in genetic services
        and would have the following tasks:<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:54.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l194 level1 lfo38;tab-stops:list 54.0pt"><span
        lang="EN-GB" style="font-family:"CG Times"">(a)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp; </span>Determine the
        existing burden of genetic disorders and birth defects in the population<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:54.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l194 level1 lfo38;tab-stops:list 54.0pt"><span
        lang="EN-GB" style="font-family:"CG Times"">(b)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp; </span>Determine the status of
        existing programs for the prevention and care of genetic disorders and birth defects,
        their human and material resources, their distribution, their financial needs and
        outcomes.<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:54.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l194 level1 lfo38;tab-stops:list 54.0pt"><span
        lang="EN-GB" style="font-family:"CG Times"">(c)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp; </span>Organize at the
        level of the Ministry of Health a permanent advisory council on genetic services with
        participation of interested parties, including clinical geneticists, other relevant
        medical specialties, public health specialists, paramedical personnel and parents/patients
        organizations. This advisory council would be instrumental in recommending the appropriate
        steps and priorities for genetic services in the country.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify"><b
        style="mso-bidi-font-weight:
normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">17.3. Improve epidemiological
        knowledge about genetic disorders and birth defects.<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">In order to improve the knowledge of the impact
        of genetic disorders in developing countries, epidemiological research should be
        stimulated to provide better data on the prevalence and types of birth defects, genetic
        diseases and genetic predispositions to common diseases at the country level. Population
        and/or hospital based registries of congenital malformations are good sources of
        epidemiological data on genetic disorders and birth defects detectable at birth. Special
        registries of specific conditions, such as haemophilia, thalassaemia, skeletal dysplasias,
        inborn errors of metabolism and others, can provide data on which to base policies for the
        management and prevention of these conditions. Epidemiological studies should be
        standardized to enable international comparisons and include the demographic and social
        characteristics of countries and their influence on the prevalence of genetic disorders
        and birth defects and on the delivery of services. Consanguinity, founder effects,
        cultural and geographic isolation must be studied to assess their influence on the
        prevalence of specific conditions and, particularly on geographical clusters of genetic
        diseases.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">In addition to standard epidemiological data, it
        is useful to develop information on what impact specific genetic disorders and birth
        defects have on individuals, families, and communities. These studies would typically
        include data on the natural history of conditions, mortality, morbidity and survival,
        quality of life and reproduction,utilization of the health care system, hospitalizations,
        manpower requires for their management, costs of services, etc.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">The above recommendations should be implemented
        by Ministries of Health and academic institutions, in the form of established data
        gathering programs or specific research projects.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">17.4. Define goals of genetic
        services in terms of both individual/family wellbeing and public health.<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Genetic programs and services have two
        complementary objectives. They alleviate suffering and help individuals and families
        touched by or at risk for a genetic disorder or birth defect, to benefit from medical
        interventions. Additionally, through public health genetic programs, they aim to reduce
        the burden of these conditions in the population. In establishing genetic services there
        has to be a balance between individual and public health goals. The latter should never
        override autonomous reproductive decisions by individuals. In other words, public health
        goals should not be confused with the concept of eugenics, wherein population genetic
        goals, however defined, are imposed by coercion and discrimination (see section on ethical
        principles). Reliance on education, non-directive counselling and respect for
        peoples' reproductive decisions should not interfere with success in genetic programs
        in industrialized as well as developing countries. Public health authorities have to be
        aware and accept the fact that occasionally an individual's decision may be a
        direction apparently contrary to an implicit or explicit public health goal (i.e. when a
        couple decides to continue a pregnancy with an affected fetus).<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">The basis for defining goals of genetic services
        in a particular country or<span style="mso-spacerun: yes">&nbsp; </span>community are:<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:54.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l43 level1 lfo40;tab-stops:list 54.0pt"><span
        lang="EN-GB" style="font-family:"CG Times"">a)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>the
        existing burden of specific genetic disorders and birth defects and their impact upon
        society in human and economic terms;<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:54.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l43 level1 lfo40;tab-stops:list 54.0pt"><span
        lang="EN-GB" style="font-family:"CG Times"">b)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>the
        burden of other health problems;<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:54.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l43 level1 lfo40;tab-stops:list 54.0pt"><span
        lang="EN-GB" style="font-family:"CG Times"">c)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>the
        resources available and the potential of raising funds from external sources;<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:54.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l43 level1 lfo40;tab-stops:list 54.0pt"><span
        lang="EN-GB" style="font-family:"CG Times"">d)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>the
        state of the art of established screening, diagnostic, preventive and therapeutic
        methodologies for particular conditions (for example, preconceptional folic acid
        supplementation for the prevention of neural tube defects, screening and prenatal
        diagnosis of thalassaemias, genetic predisposition to cancer, etc);<o:p></o:p></span></p>
        <p class="MsoBodyText2"
        style="margin-left:54.0pt;text-align:justify;text-indent:
-18.0pt;mso-list:l43 level1 lfo40;tab-stops:list 54.0pt"><span
        lang="EN-GB" style="font-family:"CG Times"">e)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>the
        expectations of the community.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Whenever setting goals for genetic services it is
        important to bear in mind that by their very nature, these services accomplish primary,
        secondary and tertiary prevention objectives at the same time.<span
        style="mso-spacerun: yes">&nbsp; </span>For example, the diagnosis of fragile-X syndrome
        in a child with mental retardation enables secondary and tertiary prevention strategies to
        minimize the impact of that condition on the child and his family; at the same time, it
        may set in motion primary prevention measures, such as genetic counselling for the family
        to give options to avoid recurrences in the same couple or other relatives at risk.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">17.5. Improve pre- and perinatal
        services.<o:p></o:p></span></i></b></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:0cm;text-align:justify;
text-indent:40.5pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:0cm;text-align:justify;
text-indent:40.5pt"><span lang="EN-GB"
        style="font-family:"CG Times"">The prevention of a number of birth defects will
        follow an improvement in the quality and accessibility of preconception, prenatal and
        perinatal services. The improvement of preconception care should include:<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:58.5pt;text-align:justify;
text-indent:-18.0pt;mso-list:l189 level1 lfo41;tab-stops:list 58.5pt"><span
        lang="EN-GB" style="font-family:"CG Times"">a)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>improvement
        of preconception and prenatal nutrition<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:58.5pt;text-align:justify;
text-indent:-18.0pt;mso-list:l189 level1 lfo41;tab-stops:list 58.5pt"><span
        lang="EN-GB" style="font-family:"CG Times"">b)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>encouragement
        to procreate in the optimal age period (20-35 years of age);<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:58.5pt;text-align:justify;
text-indent:-18.0pt;mso-list:l189 level1 lfo41;tab-stops:list 58.5pt"><span
        lang="EN-GB" style="font-family:"CG Times"">c)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>public
        education about methods that allow couples to have children when they want them, and
        provision of services to make those methods accessible;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:58.5pt;text-align:justify;
text-indent:-18.0pt;mso-list:l189 level1 lfo41;tab-stops:list 58.5pt"><span
        lang="EN-GB" style="font-family:"CG Times"">d)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>rubella
        immunization before pregnancy;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:58.5pt;text-align:justify;
text-indent:-18.0pt;mso-list:l189 level1 lfo41;tab-stops:list 58.5pt"><span
        lang="EN-GB" style="font-family:"CG Times"">e)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>avoidance
        of teratogen exposures during <o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2" style="margin-left:40.5pt;text-align:justify"><span
        lang="EN-GB" style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:58.5pt;text-align:justify;
text-indent:-18.0pt;mso-list:l189 level1 lfo41;tab-stops:list 58.5pt"><span
        lang="EN-GB" style="font-family:"CG Times"">f)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>gestation,
        particularly alcohol;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:58.5pt;text-align:justify;
text-indent:-18.0pt;mso-list:l189 level1 lfo41;tab-stops:list 58.5pt"><span
        lang="EN-GB" style="font-family:"CG Times"">g)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>accessible
        prenatal care;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:58.5pt;text-align:justify;
text-indent:-18.0pt;mso-list:l189 level1 lfo41;tab-stops:list 58.5pt"><span
        lang="EN-GB" style="font-family:"CG Times"">h)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>proper
        delivery care;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:58.5pt;text-align:justify;
text-indent:-18.0pt;mso-list:l189 level1 lfo41;tab-stops:list 58.5pt"><span
        lang="EN-GB" style="font-family:"CG Times"">i)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>enhancement
        of newborn services by increasing the proportion of babies born in institutions, and by
        insuring that they have a complete physical examination to detect congenital malformations
        such as congenital hip dysplasia, cleft palate, congenital heart defects and others whose
        outcome can be improved by early intervention;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:58.5pt;text-align:justify;
text-indent:-18.0pt;mso-list:l189 level1 lfo41;tab-stops:list 58.5pt"><span
        lang="EN-GB" style="font-family:"CG Times"">j)<span
        style="font:7.0pt "Times New Roman"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>newborn
        metabolic screening of relevant conditions.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">17.6. Organize genetic services in a
        comprehensive and integrated manner, with roots in the primary health care level.<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">The key to the implementation of genetic services
        is the application to genetics of the strategy advocated by WHO for health care in
        general, that is of extending primary health care to all segments of the population, while
        linking the primary health care level with secondary and tertiary levels in a regionalized
        manner that makes the best possible use of existing resources.<span
        style="mso-spacerun: yes">&nbsp; </span>Genetic services should always be comprehensive,
        that is, they should combine the best possible patient care available in the country, with
        population-based prevention strategies such as public education, screening and control of
        genetic risks and genetic counselling (WHO, 1996; WHO/EMRO, 1997). Furthermore, genetic
        services cannot exist in a vacuum. They must be integrated with related services, such as
        reproductive health, prenatal care, newborn care and child growth and development
        monitoring, nutrition, cancer prevention, etc. In some cases, genetic services will be
        part of specific categorical programs, such as newborn metabolic screening, the control of
        haemoglobin disorders, haemophilia or mental retardation.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">A
        key ingredient for success of genetic programs in the developing countries is the
        extension of genetic services coverage into primary health care settings, where genetic
        risks should be identified. In order to avoid duplication of services and to be as cost
        efficient as possible, genetic services must be regionalized, with tertiary centres
        responsible for specific geographic and administrative areas. Programs at secondary and
        primary health care levels should be supervised by tertiary centres in a collaborative
        rather than authority mode.</span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">What
        is practically needed is the organization of different programs according to the needs and
        resources of individual countries. Organization of such programs is facilitated by their
        integration within existing primary health programs. Such integration is more feasible and
        cost-effective than establishing a new vertical genetic program. Insertion of genetic
        services into the community is key to the success of any genetic program. This approach of
        <i style="mso-bidi-font-style:normal">community genetics</i> was outlined by the World
        Health Organization and has led to the formulation of strategies appropriate for the
        developing world (WHO, 1996). The idea is that the health personnel in charge of primary
        health care be trained to address also the genetic components of prevention and care.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Genetic
        services should have an emphasis in the family and should rely on modern cost/efficient
        information technology, such as internet. Care should be coordinated among different
        specialties and disciplines, and provide for continuity of care and long-term management.
        Quality assurance of clinical and laboratory services should not be considered a luxury
        but rather an essential component of genetic services.</span></p>
        <p class="MsoBodyText2" style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times""><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span><o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">17.7. Select programs and targets
        according to prevalence, severity and predicted outcomes<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Preventive
        actions should focus on specific conditions that have a significant impact on<span
        style="mso-spacerun: yes">&nbsp; </span>health because of their prevalence and severity,
        and the feasibility of their prevention. In this regard, prevention of congenital rubella
        by immunization of susceptible children should be a priority. Educational and social
        programs to prevent alcohol consumption during pregnancy will help prevent fetal alcohol
        syndrome, which has high prevalence in some population groups. Neural tube defects can be
        partially prevented through preconceptional folic acid supplementation, maternal serum
        screening programs and fetal ultrasonography.</span></p>
        <p class="MsoNormal" style="margin-left:4.5pt;text-align:justify;text-indent:
31.5pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="margin-left:4.5pt;text-align:justify;text-indent:
31.5pt"><span
        lang="EN-GB">Primary prevention of Down syndrome could be accomplished to a considerable
        degree through community education and family planning to encourage procreation before 35
        years of age. Prevention by reproductive options would require, depending on availability
        of resources, a program of prenatal screening based on maternal serum biochemical markers
        and/or ultrasound followed by prenatal diagnosis. Similarly, women of advanced maternal
        age who become pregnant could be offered prenatal diagnosis, according to availability of
        resources. These programs are strictly voluntary and require the development of efficient
        educational programs, genetic counselling and adequate fetal medicine and laboratory
        facilities. All programs should have standardized protocols for evaluating their
        effectiveness.</span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:0cm;text-align:justify;
text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:0cm;text-align:justify;
text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Some of the most common severe inherited
        conditions, such as haemoglobin disorders, cystic fibrosis, fragile-X syndrome,
        haemophilia and muscular dystrophies, contribute considerably to chronic morbidity in
        childhood in many developing countries. Programs for the prevention and care of affected
        children with these conditions may significantly reduce the overall burden due to chronic
        disease at the community level.<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:0cm;text-align:justify;
text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2"
        style="margin-left:0cm;text-align:justify;
text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Newborn metabolic screening should only be
        considered in countries with appropriate infrastructure and resources that guarantee
        efficiency and desired outcomes. Conditions to include in a newborn screening program
        should be clinically severe, relatively prevalent, capable of being screened and diagnosed
        with simple and low cost methods, and subject to treatment that will clearly be more
        beneficial if started immediately after birth. The condition that most clearly fits all
        these criteria is congenital hypothyroidism. Newborn metabolic screening should always be
        a policy decision by the government, which should allocate the necessary resources to its
        implementation, including a funded centralized laboratory, follow-up and confirmation of
        initial abnormal initial screen results, and long term treatment of affected children.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">17.8. Respect ethical principles and
        cultural diversity<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        health beliefs, traditions, religious observances and social expectations of individuals
        and communities should be assessed properly before setting program goals, and respected
        thereafter. These goals should never be set in ways to impose certain genetic tests or
        reproductive decisions on individuals. Governments should recognize that within any
        country there exists diversity of cultures and opinions about a number of issues relevant
        to genetics, such as human reproduction issues as well as about the significance of
        disabilities. This diversity should be respected. Ethical principles of justice, autonomy,
        beneficence and respect for the dignity and basic intelligence of persons should be
        adhered to.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;tab-stops:54.0pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt;tab-stops:54.0pt"><span
        lang="EN-GB">It should be stressed that the major ethical issues in present medical
        genetic practice are inadequate services, deficient genetic knowledge of medical and
        para-medical practitioners and inequitable access to existing services. Accepted ethical
        guidelines of public health programs in genetics stipulate that genetic testing should
        always be voluntary, respecting the autonomous decisions of the patients, and should be
        preceded by proper information in the form of non-directive genetic counselling (WHO,
        1998).<span style="mso-spacerun: yes">&nbsp; </span>Public health goals cannot override
        the cultural and personal values and beliefs of individuals and their reproductive rights,
        and oppose stigmatization and discrimination of affected persons (WHO, 1998<b
        style="mso-bidi-font-weight:normal">).</b></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">17.9. Training health professionals in medical genetics<o:p></o:p></span></i></b></p>
        <p class="MsoFooter"
        style="text-align:justify;mso-pagination:widow-orphan;
tab-stops:36.0pt"><span
        lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:
10.0pt;layout-grid-mode:both">&nbsp;<o:p></o:p></span></p>
        <p class="MsoFooter"
        style="text-align:justify;text-indent:36.0pt;mso-pagination:
widow-orphan;tab-stops:36.0pt"><span
        lang="EN-US" style="font-size:12.0pt;
mso-bidi-font-size:10.0pt">Serious efforts should
        be undertaken in genetic education for health professionals. Undergraduate curricula of
        the health professions (primarily physicians, nurses, psychologists and social workers)
        requires to be continually updated and the practical aspects of medical genetics included
        in clinical teachings. The relationships between genetics and public health, largely
        neglected in most health professional circles, should be addressed in the schools of
        public health of developing countries. For those health professionals already in practice,
        continuing education programs are essential to familiarize them with the modern concepts
        of clinical genetics. Officials in charge of public health programs should be targeted
        specifically for continuing education in genetics.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Training
        of health professionals in genetics can be implemented by the already existing medical
        geneticists in developing countries, usually concentrated in tertiary care institutions,
        affiliated with academic institutions and research centres. When the human resources in
        any particular country are insufficient for this task, manpower should be pooled at a
        regional level, so that teaching materials are developed and shared in countries with
        similar backgrounds and health problems. Training partnerships should be developed not
        only among developing countries, but also between developing and developed countries. An
        initiative worth undertaking is the joint development of medical genetics curricula that
        address the needs of developing countries, and that target separately primary health care
        physicians, pediatricians, obstetricians, nurses and public health officials. The Internet
        is ideally suited for this type of endeavour. One of the objectives of this training
        should be that, with proper supervision, genetic counselling becomes a tool that most
        health professionals are able to apply in practice.</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">Another
        aspect to consider is the training of clinical geneticists and specialized laboratory
        personnel, whose number is clearly insufficient to provide all the genetic services needed
        in the developing countries.<span style="mso-spacerun: yes">&nbsp; </span>However, few
        developing countries have the manpower to engage in, and the resources to devote to, this
        highly specialized training. Therefore, rather than training additional such personnel,
        efforts should be directed towards training in genetics of different health professionals
        such as physicians, nurses, psychologists, and social workers. Nonetheless, it is
        important that existing academic clinical geneticists be educated in public and community
        health, so that they recognize the social and population impact of the services they
        provide.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">17.10. Educate the public in genetics<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">It is well recognized that, both in the
        industrialized as well as developing countries, there are serious misconceptions about
        birth defects, genetic disorders and the role of medical genetics in their management and
        prevention. As individuals and families increase their active participation in health and
        reproductive decisions, it is essential that the public at large be educated in the
        clinical and social aspects of genetic services. Education empowers people to take control
        of their health and their lives. This is particularly true for women, whose educational
        standards are much lower than those of men in the developing world. It is well known that
        the mother's educational level is the single most important predictive factor in the
        health and survival of children in the developing world.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Public education about genetic disorders and
        birth defects should be attuned to the prevailing cultures, beliefs and values of the
        populations in any given community. Particular attention should be paid to the vulnerable
        groups in society (the poor, ethnic and linguistic minorities, etc). <o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Proper use of the media (particularly radio and
        TV) is invaluable. Community meetings should be encouraged to discuss important issues,
        such as the use of alcohol in pregnancy, rubella immunizations, self-medications, the
        value of learning about one's own family medical history, where to go for genetic
        counselling, etc. Education on these topics should include high schools. Educational
        messages should be simple and in a language that is not derogatory or discriminatory.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Education in genetics should also target other
        relevant professionals such as lawyers, judges and legislators, and political authorities
        who very frequently make decisions regarding genetic problems.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Journalists, as key players in the dissemination
        of medical genetics knowledge to the general public, should be enlisted as allies in this
        endeavour and be offered training in relevant genetic topics.<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB" style="font-family:"CG Times"">17.11. Encourage the formation of
        parent/patient organizations<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">Throughout the industrialized and developing
        worlds, affected individuals and their families are acquiring awareness and creativity to
        advocate for their own needs. Hundreds of parent/patient organizations have been
        instrumental in bringing attention to the need for clinical services and preventive
        programs for genetic disorders and birth defects, as well as asserting their right to be
        treated with dignity and without discrimination. A number of legislative initiatives in
        several countries have been the result of the actions of parent/patient organizations. The
        medical profession and the governments should support the development of these independent
        organizations. It is important that these organizations be truly independent and able to
        respond to the legitimate needs of their constituencies, and not be controlled by the
        medical establishment or the government.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-GB">18.<span style="mso-spacerun: yes">
        &nbsp; </span>SPECIFIC RECOMMENDATIONS AT DIFFERENT STAGES OF THE REPRODUCTIVE CYCLE<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:36.0pt"><span lang="EN-GB"><span
        style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>A number of recommendations for the management and prevention of genetic disorders
        and birth defects in the developing world have been proposed over the past 15 years. Some
        of these recommendations have emphasized comprehensive and non-categorical programs (PAHO,
        1984; WHO, 1985; Penchaszadeh, 1992; WHO, 1996; WHO/EMRO, 1997; Penchaszadeh and
        Beiguelman, 1998; PAHO, 1998; Penchaszadeh, 1999), while others have focused on primary
        prevention of birth defects of environmental origin (Castilla, 1999).</span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        Group recommended that the following programs be given priority in the field of genetic
        disorders and birth defects in the developing world. It was recognized that actual
        priorities are to be determined by each country according to needs and resources. It was
        also noted that any program should have identifiable targets and expected outcomes. The
        measures recommended are conceived along the different stages of the life cycle, as
        follows:</span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>18.1. Recommendations for the preconception period<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <h4 style="text-align:justify"><span lang="EN-GB"
        style="font-weight:normal;
font-style:normal">a. Improve access and quality of
        reproductive health services, including family planning and encouragement for women to
        complete their reproduction by 35 years of age</span><span lang="EN-GB">.</span></h4>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB">b.
        Insure adequate nutrition and vitamin supplementation (especially folic acid) to women in
        reproductive age.</span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB">c.
        Expand rubella immunization to eliminate rubella infection in pregnancy.</span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB">d.
        Standardize family history taking at the primary health care level for the detection of
        genetic risk factors and referral of high-risk patients for genetic counselling.<b
        style="mso-bidi-font-weight:normal"><o:p></o:p></b></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="margin-left:18.0pt;text-align:justify;text-indent:
36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:
normal"><span
        lang="EN-GB">18.2. Recommendations during pregnancy<u><o:p></o:p></u></span></i></b></p>
        <p class="MsoNormal"
        style="margin-left:54.0pt;text-align:justify;text-indent:
-54.0pt;tab-stops:54.0pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal"
        style="margin-left:54.0pt;text-align:justify;text-indent:
-54.0pt;tab-stops:54.0pt"><span
        lang="EN-GB">a. Adequate prenatal care, nutrition and delivery services</span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm"><span lang="EN-GB">b. Raise
        awareness of the need to avoid exposure to teratogens, specially alcohol, tobacco,
        radiation and unnecessary and unsupervised medications</span></p>
        <p class="MsoNormal" style="margin-left:4.5pt;text-align:justify;text-indent:
-4.5pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="margin-left:4.5pt;text-align:justify;text-indent:
-4.5pt"><span
        lang="EN-GB">c. Manage maternal conditions that can affect the health of the fetus, such
        as diabetes and<span style="mso-spacerun: yes">&nbsp; </span>hypertension</span></p>
        <p class="MsoNormal" style="margin-left:4.5pt;text-align:justify;text-indent:
-4.5pt"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="margin-left:4.5pt;text-align:justify;text-indent:
-4.5pt"><span
        lang="EN-GB">d. Implement programs for the detection of increased risk of neural tube
        defects, other congenital malformations and chromosome anomalies by maternal serum
        screening and fetal ultrasonography, followed by the offer of prenatal diagnosis.</span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm"><span lang="EN-GB">e.
        Implement programs for the detection of increased risk of selected single-gene disorders
        that are specially prevalent in the population (i.e., sickle cell disease, thalassaemia),
        followed by the offer of genetic counselling and prenatal diagnosis.</span></p>
        <p class="MsoNormal" style="text-align:justify"><u><span lang="EN-GB">&nbsp;<o:p></o:p></span></u></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">18.3. Recommendations for newborns, infants and children<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB">a.
        Implement systematic physical examination of newborns to detect congenital malformations,
        particularly of those whose outcome can be improved by early intervention (such as
        congenital hip dysplasia, cleft lip and palate).</span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB">b.
        Metabolic screening of newborns<span style="mso-spacerun: yes">&nbsp; </span>for
        conditions that are clinically severe, prevalent, easy detectable at birth and<span
        style="mso-spacerun: yes">&nbsp; </span>derive clear benefit when treatment begins in the
        newborn period. The clearest example of such condition is congenital hypothyroidism.</span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB">c.
        Monitoring of child growth and development for the early detection of genetic disorders
        and intervention for secondary and tertiary prevention.</span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">d. Psychosocial support and genetic counselling
        for families of children affected with congenital malformations, Down syndrome and
        single-gene disorders of high prevalence and severity in the community.<o:p></o:p></span></p>
        <p class="MsoNormal" style="margin-top:12.0pt;text-align:justify;text-indent:
36.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:
normal"><span
        lang="EN-GB">18.4. Recommendations for adults<o:p></o:p></span></i></b></p>
        <p class="MsoBodyText2" style="margin-top:12.0pt;text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">a. Promote healthy lifestyles to prevent chronic
        diseases, such as cancer and coronary occlusion.<o:p></o:p></span></p>
        <p class="MsoNormal" style="margin-top:12.0pt;text-align:justify"><span lang="EN-GB">b.
        Detect individuals at risk of developing late-onset genetic diseases and offer genetic
        counselling and presymptomatic testing if medical intervention is feasible and beneficial.</span></p>
        <p class="MsoNormal" style="margin-top:12.0pt;text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-GB">19.<span style="mso-spacerun: yes">
        &nbsp; </span>SPECIFIC RECOMMENDATIONS FOR CATEGORICAL (VERTICAL) PROGRAMS<o:p></o:p></span></b></p>
        <p class="MsoBodyText2" style="text-align:justify;tab-stops:0cm"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;tab-stops:0cm"><span lang="EN-GB"
        style="font-family:"CG Times""><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>The following categorical programs were selected by the Group as examples of high
        priority in most developing countries, recognizing that each country should set its own
        priorities after careful analysis of their reality.<o:p></o:p></span></p>
        <p><span lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
"CG Times";mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">&nbsp;</p>
        <p><br clear="all" style="mso-special-character:line-break;page-break-before:always">
        </span></p>
        <p class="MsoBodyText2" style="text-align:justify;tab-stops:0cm">&nbsp;<span lang="EN-GB"
        style="font-family:"CG Times""><o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB"><span style="mso-tab-count:1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>19.1. Prevention of congenital malformations<o:p></o:p></span></i></b></p>
        <p class="MsoBodyTextIndent2" style="margin-left:0cm;text-align:justify;
tab-stops:0cm"><span
        lang="EN-GB" style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2" style="margin-left:0cm;text-align:justify;
tab-stops:0cm"><span
        lang="EN-GB" style="font-family:"CG Times"">a) Expand rubella immunization
        programs with the aim of covering all children.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm"><span lang="EN-GB">b)
        Implement programs to raise awareness of the need to avoid exposure of pregnant women to
        known teratogens, such as alcohol, tobacco, radiation and unnecessary or unsupervised
        medications.</span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm"><span lang="EN-GB">c)
        Evaluate the feasibility of folic acid fortification of foods for the prevention of neural
        tube defects.</span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify;tab-stops:0cm"><span lang="EN-GB"
        style="font-family:"CG Times"">d) Expand the accessibility of ultrasonography
        for the detection of severe fetal malformations.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm 54.0pt"><u><span lang="EN-GB">&nbsp;<o:p></o:p></span></u></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm 54.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB"><span style="mso-spacerun: yes">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>19.2. Prevention of Down syndrome<o:p></o:p></span></i></b></p>
        <p class="MsoBodyTextIndent2" style="margin-left:0cm;text-align:justify;
tab-stops:0cm"><span
        lang="EN-GB" style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent2" style="margin-left:0cm;text-align:justify;
tab-stops:0cm"><span
        lang="EN-GB" style="font-family:"CG Times"">a) Encourage women, through public
        education and family planing programs, to complete reproduction by age 35.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm"><span lang="EN-GB">b)
        Increase accessibility<span style="mso-spacerun: yes">&nbsp; </span>to genetic counselling
        and voluntary prenatal diagnosis to pregnant women of advanced maternal age</span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:0cm"><span lang="EN-GB">c) Study
        the feasibility of implementing prenatal screening programs for Down syndrome risk, by
        maternal serum markers and fetal ultrasonography, followed by prenatal diagnosis.</span></p>
        <p class="MsoBodyTextIndent3"
        style="margin-left:0cm;text-align:justify;
tab-stops:54.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent3"
        style="margin-left:0cm;text-align:justify;
tab-stops:54.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:
normal"><span
        lang="EN-GB" style="font-family:"CG Times""><span style="mso-spacerun: yes">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>19.3. Prevention and management of selected single-gene disorders of high
        prevalence and impact.<o:p></o:p></span></i></b></p>
        <p class="MsoBodyTextIndent3"
        style="margin-left:0cm;text-align:justify;
tab-stops:72.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:
normal"><span
        lang="EN-GB" style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoBodyTextIndent3"
        style="margin-left:0cm;text-align:justify;
tab-stops:72.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">a) Conduct studies to determine the most
        prevalent severe single gene disorders in the population and their impact on morbidity and
        mortality (e.g. haemoglobin disorders, cystic fibrosis, fragile X syndrome, etc).<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent3"
        style="margin-left:0cm;text-align:justify;
tab-stops:72.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent3"
        style="margin-left:0cm;text-align:justify;
tab-stops:72.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">b) Implement carrier detection programs for these
        conditions, coupled with genetic counselling and voluntary prenatal diagnosis. At the same
        time, implement services for the care of affected individuals and provide psychosocial
        support to patients and their families.<o:p></o:p></span></p>
        <p><span lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
"CG Times";mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA;
layout-grid-mode:line">&nbsp;</p>
        <p><br clear="all" style="mso-special-character:line-break;
page-break-before:always">
        </span></p>
        <p class="MsoBodyTextIndent3"
        style="margin-left:0cm;text-align:justify;
tab-stops:54.0pt">&nbsp;<span lang="EN-GB"
        style="font-family:"CG Times""><o:p></o:p></span></p>
        <p class="MsoBodyTextIndent3"
        style="margin-left:0cm;text-align:justify;
tab-stops:54.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:
normal"><span
        lang="EN-GB" style="font-family:"CG Times""><span style="mso-spacerun: yes">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </span>19.4. Genetic education of<span style="mso-spacerun: yes">&nbsp; </span>the health
        professionals<o:p></o:p></span></i></b></p>
        <p class="MsoBodyTextIndent3"
        style="margin-left:0cm;text-align:justify;
tab-stops:72.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:
normal"><span
        lang="EN-GB" style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoBodyTextIndent3"
        style="margin-left:0cm;text-align:justify;
tab-stops:72.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">a) Develop and implement educational curricula
        with emphasis on clinical and public health aspects of genetics at undergraduate levels
        for students of medicine, nursing, psychology, social work and public health.<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent3"
        style="margin-left:0cm;text-align:justify;
tab-stops:72.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent3"
        style="margin-left:0cm;text-align:justify;
tab-stops:72.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">b) Develop and implement genetic education for
        practicing family<span style="mso-spacerun:
yes">&nbsp; </span>physicians and allied
        health personnel.<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent3"
        style="margin-left:0cm;text-align:justify;
tab-stops:72.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyTextIndent3"
        style="margin-left:0cm;text-align:justify;
tab-stops:72.0pt"><span lang="EN-GB"
        style="font-family:"CG Times"">c) Encourage multidisciplinary<span
        style="mso-spacerun: yes">&nbsp; </span>educational workshops among clinical geneticists,
        public health professionals and patient/parents organizations.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB"><span style="mso-spacerun: yes">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>19.5.
        Public education in health aspects of genetics<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></i></b></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB">a)<b
        style="mso-bidi-font-weight:normal"><i style="mso-bidi-font-style:
normal"> </i></b>Develop
        and implement educational and awareness programs addressed to the general public about
        prevention and care of genetic diseases.</span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;tab-stops:54.0pt"><span lang="EN-GB">b)
        Encourage the formation of patient/parents organizations related to birth defects and
        genetic diseases.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <h2 style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times";
font-style:normal">20.<span
        style="mso-spacerun: yes">&nbsp; </span>FINAL STATEMENT<o:p></o:p></span></h2>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The<span
        style="mso-spacerun: yes">&nbsp; </span>WHO Expert Group convened in The Hague under the
        auspices of WHO and WAPBD should consider the above recommendations as a<span
        style="mso-spacerun: yes">&nbsp; </span>starting point to define the proposals that will
        emerge from this meeting, adding the proposed strategy to carry out each recommendation.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;text-indent:36.0pt"><span lang="EN-GB">The
        fate of genetic services in the developing world ultimately rests upon the wisdom and
        political will of statesmen, public health officials, and medical educators. For the right
        to health care to be meaningful, it should include prevention and care of genetically
        determined conditions. Genetic health professionals in developing countries must act in
        conjunction with public health officials, other health professionals, patient-oriented
        organizations and other community organizations to achieve an adequate allocation of
        resources for health care in general and genetic services in particular, making equity the
        highest priority.</span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">21.<span style="mso-spacerun: yes">&nbsp; </span>LIST OF PARTICIPANTS<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:center 8.0cm"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Professor O.O. Akinyanju, College of Medicine,
        University of Lagos, P.M.B. 12003, Lagos, Nigeria [fax: +234 1 618 778 - e-mail:
        oluphysic@cyberspace.net.ng]<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Dr J.M. Cantú Garza, Chief, Genetics Division,
        Centro de Investigación Biomédica de Occidente, Instituto Mexicana del Seguro Social,
        Siena No. 1068 Lomas de Providencia, Guadalajara, Jalisco, Mexico [fax: +523 6188 069 -
        e-mail: jmcantu@koch.mb.udg.mx]<o:p></o:p></span></p>
        <p class="Initialcode"><span lang="EN-GB"
        style="letter-spacing:-.1pt;mso-ansi-language:
EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Professor E. Castilla,
        ECLAMC/Dept.Genetica/FIOCRUZ, C.P. 926, 20010-970 Rio de Janeiro, Brazil [fax: +55 21 260
        4282 - e-mail: castilla@centroin.com.br]<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Professor A.L. Christianson, Head, Department of
        Human Genetics and Developmental Biology, Faculty of Medicine, University of Pretoria,
        P.O. Box 667, Pretoria 0001, South Africa [fax: +27 12 323 2788 - e-mail: <a
        href="mailto:christal@medic.up.ac.za]"><span style="letter-spacing:0pt">christal@medic.up.ac.za]</span></a>,
        <b style="mso-bidi-font-weight:normal">Co-Rapporteur<o:p></o:p></b></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Professor M.A.F. El-Hazmi, Department of Medical
        Biochemistry, College of Medicine and King Khalid University Hospital, P.O. Box 2925,
        Riyadh 11461, Saudi Arabia [fax: +966 1 467 2575 - e-mail: mohsen@ksu.edu.sa]<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Professor D.D. Farhud, Head, Unit of Human
        Genetics &amp; Anthropology, University of Tehran, School of Public Health &amp; Institute
        of Public Health Research, P.O. Box 1310, Tehran, Islamic Republic of Iran [fax: +98 21
        880 3003 - e-mail:<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Professor E.K. Ginter, National Research Centre
        for Medical Genetics, Moscow 115478, The Russian Federation [fax: +7 095 324 0702 -
        e-mail: ginter5@glasnet.ru]<o:p></o:p></span></p>
        <p class="Initialcode"><span lang="EN-GB"
        style="letter-spacing:-.1pt;mso-ansi-language:
EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Professor R. Giugliani, Hospital de Clinicas de
        Porto Alegre, Rua Ramiro Barcelos 2350, Porto Alegre, RS, Brazil [fax: +55 51 316 8010 -
        e-mail: <a href="mailto:rgiugliani@hcpa.ufrgs.br]"><span style="letter-spacing:0pt">rgiugliani@hcpa.ufrgs.br]</span></a>,
        <b style="mso-bidi-font-weight:normal">Co-Rapporteur<o:p></o:p></b></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Professor H. Hamamy, Professor of Medical
        Genetics, Mustansiriya College of Medicine, Baghdad, Iraq (currently in Egypt) [fax: +203
        483 0900 - e-mail: alwan@who.sci.eg]<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Professor Rodney Harris, The Cottage, Catherine
        Road, Bowdow, GB-Altrincham WA14 2TD, UK [fax: +44 161 272 8837 - e-mail:
        rodney.harris@man.ac.uk]<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Dr L. Heredero, Director, Centro Nacional de
        Genética Médica, Calle 31 esquina a 146, Cubanacan, Playa, Havana, Cuba [fax:<span
        style="mso-spacerun: yes">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>e-mail:
        lhere@infomed.sld.cu]<o:p></o:p></span></p>
        <p class="Initialcode"><span lang="EN-GB"
        style="letter-spacing:-.1pt;mso-ansi-language:
EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Dr Wilson H.Y. Lo, Institute of Basic Medical
        Sciences, PUMC, 5 Dong Dan San Tiao, Beijing 100005, People's Republic of China<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Professor Victor Penchaszadeh, Director,
        Division of Medical Genetics, Beth Israel Medical Center, First Avenue at 16th Street, New
        York, NY 10003, USA [fax: +1 212 420 3440 - e-mail: <a
        href="mailto:vpenchaszadeh@bethisraelny.org]"><span style="letter-spacing:
0pt">vpenchaszadeh@bethisraelny.org]</span></a>,
        <b style="mso-bidi-font-weight:
normal">Chairman and Rapporteur</b><o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Dr Chintana Sirinavin, Department of Medicine
        and Molecular Genetics Unit, Office for Research and Development, Faculty of Medicine,
        Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand [fax: +662 411 2004 -
        e-mail:<span style="mso-spacerun: yes">&nbsp; </span>]<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Dr Leo ten Kate, Professor of Clinical Genetics,
        Academisch Ziekenuis, Vrije Universiteit, Afdeling Klinische Genetica, Postbus 7057,
        NL-1007 MB Amsterdam, The Netherlands<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">[fax: +31 20 444 0769 - e-mail:
        lp.tenkate@azvu.nl]<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Professor Ishwar Verma, Head, Department of
        Medical Genetics, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi 110060, India [fax:
        +91 11 685 4434 -<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">e-mail: icverma@giasdL01.vsnL.net.in]<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:
-.1pt"><b style="mso-bidi-font-weight:normal">WAOPBD
        SECRETARIAT</b><o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Dr Michael Katz, President, World Alliance of
        Organizations for the Prevention of Birth Defects, March of Dimes Birth Defects
        Foundation, National Office, 1275 Mamaroneck Avenue, White Plains, NY 10605 [fax: +1 914
        997 4560 - e-mail: katzmi@pipeline.com]<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Mr Y. Poortman, Vereniging Spierziekten
        Nederland, Lt. Gen. van Heutszlaan 6, NL-3743&nbsp;JN Baarn, The Netherlands [fax: 31 35
        6027 440 - e-mail: vsn@vsn.nl]<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Professor Irmgard Nippert, Member of the Board
        of the WAOPBD, Institut für Hummangenetik, Westfalische Wilhelms Universitat Munster,
        Vesaliusweg 12-14, D-48149, Munster, Germany <o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Professor W. Wertelecki, Secretary/Treasurer of
        the WAOPBD, Department of Medical Genetics, University of South Alabama, AL 36688-0002,
        USA<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-GB" style="letter-spacing:
-.1pt">WHO
        SECRETARIAT<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Dr V. Boulyjenkov, Human Genetics, Division of
        Noncommunicable Diseases, CH-1211&nbsp;Geneva&nbsp;27, Switzerland [fax: +41 22 791 47 69
        - e-mail: boulyjenkovv@who.ch and richsteink@who.ch] <o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-GB" style="letter-spacing:
-.1pt">OBSERVERS<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Dr H. Harris, Manchester, UK<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Dr J. Howse, President of the March of Dames,
        USA<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Dr Ch. Howsen, Director of International
        Programmes and Science Officer, March of Dames, USA<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">Mrs I. Roelofsz-Beltman, Deputy Director of
        VSOP, The Netherlands<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify;mso-hyphenate:none;tab-stops:-36.0pt"><span
        lang="EN-GB" style="letter-spacing:-.1pt">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">&nbsp;<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><b style="mso-bidi-font-weight:
normal"><span
        lang="EN-GB">22.<span style="mso-spacerun: yes">&nbsp; </span>REFERENCES<o:p></o:p></span></b></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Al-Rajeh S, Bademosi O,
        Ismail H, Awada A et al(1993). A community survey of neurological disorders in Saudi
        Arabia. The Thugbah Study. Neuroepidemiology 1993;12:164-178.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">American Society of
        Human Genetics Ad Hoc Committee on Genetic Counseling (1975). Genetic Counseling. Am J Hum
        Genet 27:240-242.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Angastiniotis MA, Hadjiminas MG (1981).<span
        style="mso-spacerun: yes">&nbsp; </span></span><span lang="EN-GB">Prevention of
        thalassaemia in Cyprus.<span style="mso-spacerun: yes">&nbsp; </span></span><span
        lang="FR" style="mso-ansi-language:
FR">Lancet 1981; 1:369-370.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Angastiniotis MA, Kyriakidou S, Hadjiminas M (1986).<span
        style="mso-spacerun: yes">&nbsp; </span></span><span lang="EN-GB">How thalassaemia was
        controlled in Cyprus.<span style="mso-spacerun: yes">&nbsp; </span>World Health Forum
        1986; 7:291-297.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Arias S (1981).<span
        style="mso-spacerun: yes">&nbsp; </span>Osteochondrodysplasia Irapa type: an ethnic marker
        gene in two subcontinents.<span style="mso-spacerun:
yes">&nbsp; </span>Am J Med Genet
        1981; 8:251-253.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Auburger G,<span
        style="mso-spacerun: yes">&nbsp; </span>Orozco Diaz G, Ferreira Capote R, Gispert Sanchez
        S et al. (1990) Autosomal dominant ataxia: Genetic evidence for locus heterogeneity from a
        Cuban founder-effect population. Am J Hum Genet 1990; 46: 1163-1177.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Avila-Giron R (1973).<span
        style="mso-spacerun: yes">&nbsp; </span>Huntington chorea 1872-1972 in: Barbeau A, Chase
        TN, Paulson GW (Eds).<span style="mso-spacerun: yes">&nbsp; </span>Adv Neurol Vol. I;
        261-266.<span style="mso-spacerun: yes">&nbsp; </span>Graven Press, New York, 1973.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Baird PA (1988).
        Towards an ideal human genetics curriculum in medical schools. Am J Hum Genet 1988; 44:
        166-167.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Baleta A. Fetal alcohol
        syndrome rife in South Africa. </span><span lang="FR" style="mso-ansi-language:
FR">Lancet
        352: 295, 1998<b style="mso-bidi-font-weight:normal">.<o:p></o:p></b></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Barreiro CZ, Negrotti T, Penchaszadeh VB (1976).<span
        style="mso-spacerun:
yes">&nbsp; </span></span><span lang="EN-GB">Prevalence of genetic
        disease in a paediatric referral hospital. Excerpta Med Intl Congr Series 1976; 397:60.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Bernhardt BA, Pyeritz
        RE (1992). The organisation of genetic services. Ped Clin N Am 1992; 39(1): 1-11. </span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="Initialcode" style="mso-hyphenate:auto;tab-stops:36.0pt"><span lang="EN-GB"
        style="letter-spacing:0pt;mso-ansi-language:EN-GB">Bittles AH, Mason WM, Greene, Rao NA
        (1991). Reproductive behaviour and health in consanguineous marriages. Science
        1991;252:789-794.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Carey JC. Health
        supervision and anticipatory guidance for children with genetic disorders( including
        trisomy 21, trisomy 18, and neurofibromatosis1)(1992). Ped Clin N Am 1992; 39(1): 25-53.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Carnevale A, Hernandez
        M, Reyes R, Paz F, Sosa C (1985). The frequency and economic Burden of genetic disease<span
        style="mso-spacerun: yes">&nbsp; </span>in a<span style="mso-spacerun: yes">&nbsp; </span>paediatric
        hospital in Mexico City. Am J Med Genet 1985;<span style="mso-spacerun: yes">&nbsp; </span>20:665-675.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Castilla EE (1999). How
        to apply epidemiological information from malformations registries to the practice of
        primary prevention of birth defects and the care of the affected. Paper presented at the
        joint WHO/WAOPBD meeting on Prevention and Care of Genetic Disorders and Birth Defects in
        Developing Countries. The Hague, Netherlands, 5-7 January, 1999.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Castilla EE, Orioli IM
        (1986). Prevalence rates of microtia in South America. </span><span lang="FR"
        style="mso-ansi-language:FR">Int J Epidemiol 1986;15:364-368.<o:p></o:p></span></p>
        <p class="MsoFooter" style="text-align:justify;tab-stops:36.0pt"><span lang="FR"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;mso-ansi-language:FR">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Castilla EE and
        Lopez-Camelo JS (1990).<span style="mso-spacerun: yes">&nbsp; </span>The Surveillance of
        Birth Defects in South America: I. The Search for Time Clusters: Epidemics. Ad.
        Mutagenesis 1990; p191-210.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Castilla EE, Sod R
        (1990). The surveillance of birth defects in South America: II. The search for geographic
        clusters: Endemics. Adv Mutag Res 1990; 2:211-230.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Castilla EE, Rittler M,
        Dutra MG, Lopez-Camelo JS, campaña H, Paz JE, Orioli IM, ECLAMC-Downsurv Group (1998).
        Survival of children with Down syndrome in South America.<span style="mso-spacerun: yes">
        &nbsp; </span>Amer J Med Genet 79:108-111.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Christianson AL (1996).
        Down syndrome in sub Saharan Africa. J Med Genet 33:89-292.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Christianson Al, Gericke GSD, Venter PA, du Toit JL<span
        style="mso-spacerun: yes">&nbsp; </span>(1995). </span><span lang="EN-GB">Genetics,
        primary health care and the Third World. S Afr Med J 85: 6-7.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Christianson RE, Van
        den Bergh BJ, Milkovich L, Oechsli FW (1981). Incidence of congenital anomalies among
        white and black live births with long-term follow up. Am J Public Health, 71:1333-1341.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Clavijo HA, Schuler L,
        Sanseverino MT, Giugliani R (1992). An information service on teratogenic agents in
        Brazil. World Health Forum 13:2/3:196.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Delport SD,
        Christianson AL (1995). Congenital anomalies in black South African liveborn neonates at
        an urban academic hospital. S Afr Med 1995; 85-11-15.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Department of Health of
        South Africa (1997). White Paper for the Transformation of the Health System in South
        Africa. Government Gazette, 16 April 1997, Vol 382, No. 17910. Pretoria, South Africa.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Department of Health of
        South Africa (1998). Subdirectorate of Human Genetics.<span style="mso-spacerun: yes">
        &nbsp; </span>National Guidelines the management and prevention of genetic disorders,
        birth defects and disabilities . Pretoria, South Africa, 1999.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Dorticos-Balea A, Martin-Ruiz M, Hechevarria-Fernandez P,
        Robaina-Castellanos MS, et al.<span style="mso-spacerun: yes">&nbsp;&nbsp; </span></span><span
        lang="EN-GB">(1997). Reproductive behaviour of couples at risk for sickle cell disease in
        Cuba: A follow-up study.<span style="mso-spacerun: yes">&nbsp; </span></span><span
        lang="FR" style="mso-ansi-language:FR">Prenat Diagn 17:737-742.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">El-Hazmi MAF (1992). </span><span lang="EN-GB">Genetic
        diseases in Arabia- A model for national awareness and care programmes. Saudi Med J
        13:514-520.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">El-Hazmi MAF (1994). An
        integrated model for care and control of blood genetic disorders. Proceedings of the
        Symposium on The Medical Genetics in the Setting of Middle Eastern Populations&#148;,
        Ryad, Saudi Arabia.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">El-Hazmi MAF, Warsy AS
        (1996). Genetic disorders among Arab populations. Saudi Med J 17(2):108-123.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">El-Hazmi MAF, Warsy AS
        (1997a). Haemoglobinopathies in Arab Countries. In: Teebi AS, Farag TI (eds): Genetic
        Disorders among Arab Populations. 1997, New York, Oxford. Oxford University Press, pp
        83-110.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">El-Hazmi MAF, Warsy AS
        (1997b). Prevalence of obesity in Saudi population. Ann Saudi Med 17:302-306.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">El-Hazmi MAF, Warsy AS,
        Al-Swailem AR, Al-Swailem AM, Sulaimani, R, Al-Meshari AA (1998). Diabetes mellitus as a
        health problem in Saudi Arabia and its complications. Med Health J 4:58-67.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Freie-Maia A (1981).
        Historical note. The extraordinary handless and footless families of Brazil: 50 years of
        acheiropodia. Am J Med Genet 1981;9:31-41.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Freire-Maia N (1989).<span
        style="mso-spacerun: yes">&nbsp; </span>Genetic effects in Brazilian populations due to
        consanguineous marriages. Am J Med Genet 1989; 35:115-117.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Graham JM, Rotter JI,
        Riccardi VM, Baird PA, Benkendorf J, Bodurtha J, Childs B, Davidson R, Rhuether CA, Laing
        K, Murray RF, Nadler H, Nance WE, Nesbitt M, Scriver CR, Short EM, Summitt RL, Toriello HV
        (1989). Report on the task force on teaching<span style="mso-spacerun: yes">&nbsp; </span>human
        genetics in North American medical schools. Am J Hum Genet 1989; 44: 161-165. </span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Giugliani R, Coelho JC (1998). </span><span lang="EN-GB">Diagnosis
        of inborn errors of metabolism. In: Penchaszadeh VB &amp; Beiguelman B, eds.: Medical
        Genetic Services in latin America. WHO publication WHO/HGN/CONS/MGS/98.4 Geneva.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Granda H, Gispert S,
        Dorticos A, Martin M, et al (1991).<span style="mso-spacerun: yes">&nbsp; </span>Cuban
        programme for prevention of sickle cell disease.<span style="mso-spacerun: yes">&nbsp; </span></span><span
        lang="FR" style="mso-ansi-language:
FR">Lancet 1991; 337:152-154.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Granda H, Gispert S, Martinez G, Gomez M, et al.<span
        style="mso-spacerun:
yes">&nbsp; </span></span><span lang="EN-GB">Results from a
        reference laboratory for prenatal diagnosis of sickle cell disorders in Cuba.<span
        style="mso-spacerun:
yes">&nbsp; </span>Prenatal Diagnosis 1994; 14:659-662.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Harper PS, Hughes HE,
        Raeburn JA (1996). Clinical genetic services into the 21<sup>st</sup> century. J Royal
        Coll Phys of Lond 1996; 30(4): 296-301.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Hartmann LC, Schaid DJ,
        Woods JE, Crotty TP et al (1999). Efficacy of bilateral prophylactic mastectomy in women
        with a family history of breast cancer. N Engl J Med 340:77-84.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Hashem N (1978).
        Population indices and markers of value as prospective monitors for prevention of genetic
        morbidity. Proceedings First International Congress on Preventable Aspects of Genetic
        Morbidity. Cairo, Al-Ahram Press, 1978 Cairo.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Harris R (1997).
        Preface and Overview. Genetic Services in Europe.<span style="mso-spacerun:
yes">&nbsp; </span>A
        comparative study of 31 countries by the Concerted Action on Genetic Services in Europe.
        Eur J Hum Genet 1997; 5(suppl 2):1-21.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Heredero L (1992).
        Comprehensive national genetic program in a developing country- Cuba. In: Kuliev A,
        Greendale K, Penchaszadeh VB, Paul NW (Eds): Genetic Services Provision: An International
        Perspective. Birth Defects Orig Art Ser 1992; 28 (3) 52-57.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Heredero L (1998) in:
        Penchaszadeh VB, Beiguelman B (Eds). Medical Genetic Services in Latin America.<span
        style="mso-spacerun: yes">&nbsp; </span>WHO publication WHO/HGN/CONS/MGS/98.4. Geneva,
        1998.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Holtzman, N (!989).
        Proceed with Caution: Predicting Genetic Risks in the Recombinant Era. Baltimore: The
        Johns Hopkins University Press.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">ICBDMS (1991).
        Congenital Malformations Worldwide. A Report from the International Clearinghouse for
        Birth Defects Monitoring Systems, Elsevier, Amsterdam, 1991.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">ICBDMS (1998). World
        Atlas of Congenital Malformations. International Clearinghouse for Birth Defects
        Monitoring Systems.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Imaizumi Y (1986).<span
        style="mso-spacerun: yes">&nbsp; </span>A recent survey of consanguineous marriages in
        Japan. Clin Genet 1986; 30:230-233.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Jaber L, Halpern GJ,
        Shohat M (1998). The impact of consanguinity worldwide. Community Genet 1998;1:12-17.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Jenkins T (1990).
        Medical genetics in South Africa. J Med Genet 1990; 27:760-779.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Johnston AW (1990).
        Teaching of clinical genetics in Britian: a report from the Royal College of Physicians of
        London. J Med Genet 1990; 27: 707-709.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Khlat M (1997).
        Endogamy in the Arab world. In: Teebi AS, Farag TI (eds): Genetic Disorders among Arab
        Populations. 1997, New York, Oxford. Oxford University Press<span
        style="mso-spacerun: yes">&nbsp; </span>pp 63-77.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Kevles DJ (1995). In
        the Name of Eugenics. Harvard University Press, Cambridge.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Khrouf<span
        style="mso-spacerun: yes">&nbsp; </span>N, Spang R, Podgorna T, Miled SB, Moussaoui M,
        Chibani M (1986). Malformations in 10,000 consecutive births in Tunis. Acta Paediatr
        Scand, 75:534-539.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Khlat M, Khoury M
        (1991).<span style="mso-spacerun: yes">&nbsp; </span>Inbreeding and diseases: Demographic,
        genetic and epidemiologic perspectives. </span><span lang="FR"
        style="mso-ansi-language:FR">Epidemiol Rev 1991; 13:28-41.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Kromberg JGR, Jenkins T (1982).<span
        style="mso-spacerun: yes">&nbsp; </span></span><span lang="EN-GB">Common birth defects in
        South African Blacks. S Afr Med J 1982; 62:599-602.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Kromberg JGR, Christianson AL, Duthie-Nurse G, Zwane E,
        Jenkins T (1992).<span style="mso-spacerun: yes">&nbsp; </span></span><span lang="EN-GB">Down
        Syndrome in the Black population. S Afr Med J 1992; 81:337.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Kromberg JGR, Jenkins T (1982).<span
        style="mso-spacerun: yes">&nbsp; </span></span><span lang="EN-GB">Albinism in the South
        African Negro II. Prevalence. S Afr Med J 1982; 61:383-386.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Kuliev A, Greendale K,
        Penchaszadeh VB, Paul NW (Eds) (1992). Genetic Services Provision: An International
        Perspective. Birth Defects Orig Art Ser 1992; 28 (3) 17-26.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Manga N, Jenkins T, Lane AB (1997). </span><span
        lang="EN-GB">The molecular basis of transferase galactosemia in the South African Black
        population. SA Society of Human Genetics Congress, Pilanesberg, 18-21 May 1997. Abstract
        Book: 43.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Martins CSB, Ramalho
        AS, Sonati MF, Goncalves MS, Costa FF (1993). Molecular characterization of
        beta-thalassemia heterozygotes in Brasil. J Med Genet 1993;30:797-798.</span></p>
        <p class="MsoBodyText2" style="margin-top:12.0pt;text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">McKusick VA (1996). History of medical genetics.
        In: Rimoin D, Connor JM, Pyeritz RE (eds): Emery and Rimoin's Principles and Practice
        of Medical Genetics. Churchill-Livingstone, pp 1-30.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Milunsky A (1998a).
        Maternal serum screening for neural tube and other defects. In: Milunsky A (ed): Genetic
        Disorders and the Fetus. Baltimore and London, 1998, The Johns Hopkins University Press,
        pp 635-701.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Milunsky A (1998b).
        Multianalyte maternal serum screening for chromosomal defects. In: Milunsky A (ed):
        Genetic Disorders and the Fetus. Baltimore and London, 1998, The Johns Hopkins University
        Press, pp 702-149.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Modell B, Bulyzhenkov V
        (1988). Distribution and control of some genetic disorders. World Health Statistics
        Quarterly, 1988: vol. 41; No. 3/4, pp: 209-218.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Murray C, Lopez A
        (1996), eds. The Global Burden of Disease. Cambridge, Massachussets, The Harvard School of
        Public Health; 1996, p. 176.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Mutchinick O, Lisker R,
        Rabinsky V (1988). The Mexican Program of Registration and Epidemiologic Surveillance of
        External Congenital Malformations (SPA). Salud Publica Mex 1988; 30:88-100.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Naoum PC, de Mattos LC, Curi PR (1984).<span
        style="mso-spacerun: yes">&nbsp; </span></span><span lang="EN-GB">Prevalence and
        geographic distribution of abnormal hemoglobins in the state of Sao Paulo, Brazil.<span
        style="mso-spacerun: yes">&nbsp; </span>Bull Pan Am Health Org 1984; 18:127-138.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">PAHO (1984). Pan
        American Health Organization.<span style="mso-spacerun: yes">&nbsp; </span>Prevention and
        Control of Genetic Diseases and Congenital Defects. Report of an Advisory Group.
        Scientific Publ. 460. Washington, DC: PAHO; 1984.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">PAHO (1988). </span><span
        lang="FR" style="mso-ansi-language:FR">Organizacion Panamericana de la Salud.<span
        style="mso-spacerun: yes">&nbsp; </span>Ejecución de Actividades de Salud de Genetica en
        America Latina y el Caribe. Informe de un Grupo de Expertos.<span
        style="mso-spacerun: yes">&nbsp; </span></span><span lang="EN-GB">Havana, Cuba, 9-11
        October, 1987. Internal Publication, Panamerican Health Organization, Washington, DC.
        1988.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">PAHO (1998a). Health
        Conditions in the Americas. Washington, DC: Pan American Health Organization; 1998.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">PAHO (1998b).
        Consultation on the Development of PAHO Strategy on Congenital Disorders. Washington, DC,
        7-8 October, 1998.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Penchaszadeh VB (1979).<span
        style="mso-spacerun: yes">&nbsp; </span>Frequency and characteristics of birth defects
        admissions to a pediatric hospital in Venezuela:<span style="mso-spacerun: yes">&nbsp; </span>Am
        J<span style="mso-spacerun: yes">&nbsp; </span>Med Genet 1979; 3:359-369.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Penchaszadeh VB (1992).
        Implementing comprehensive genetic services in developing countries. The case of Latin
        America. In: Kuliev A, Greendale K, Penchaszadeh VB, Paul NW (Eds). Genetic Services
        Provision: An International Perspective. Birth Defects Orig Art Ser 1992; 28 (3) 17-26.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Penchaszadeh, V.B.
        (1993). Genetic services for the hemoglobinopathies in Latin America. Paper presented at
        the the WHO/TIF meeting on The Prevention and Control of the Hemoglobinopathies. Nicosia,
        Cyprus, 3-4 April, 1993.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Penchaszadeh, VB
        (1998): Report of WHO Consultation on Policy Guidelines on Prevention and Care of Genetic
        Disorders in South Africa. Pretoria, South Africa, October 1998.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Penchaszadeh, VB
        (1999): Delivery of genetic services in developing countries. In : Khoury M, Burke W,
        Thompson E (Eds). Genetics and Public Health in the 21<sup>st</sup> Century. Oxford
        University Press, New York, In Press, 1999.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Penchaszadeh VB,
        Beiguelman B (1998a).<span style="mso-spacerun: yes">&nbsp; </span>Medical Genetic
        Services in Latin America.<span style="mso-spacerun: yes">&nbsp; </span>WHO publication
        WHO/HGN/CONS/MGS/98.4. Geneva, 1998.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Penchaszadeh VB,
        Beiguelman B (1998b).<span style="mso-spacerun: yes">&nbsp; </span>Medical genetic
        services in Latin America. Report of a meeting of experts. Pan Am J Public Health 1998 In
        Press.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Penchaszadeh VB,
        Heredero L, Punales-Morejon D, Rojas I, Perez ET (1997). Genetic counseling training in
        Cuba. Am J Hum Genet 1997; 61(4) Supplement A1099.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Perez-Comas A,
        Garcia-Castro JM (1974). Occipito-facial-cervico-thoracic-abdomino-digital dysplasia;
        Jarcho-Levin syndrome of vertebral anomalies: report of six cases and review of the
        literature. J Pediat 85:388-391, 1974.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoBodyText2" style="text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">Poortman Y (1999). Parent/patient organizations
        in promoting genetic services. Paper presented at the joint WHO/WAOPBD meeting on
        Prevention and Care of Genetic Disorders and Birth Defects in Developing Countries. The
        Hague, Netherlands, 5-7 January, 1999.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <h4 style="text-align:justify"><span lang="EN-GB"
        style="font-weight:normal;
font-style:normal">Qureshi N,<span style="mso-spacerun: yes">
        &nbsp; </span>Raeburn JA (1993). Clinical genetics meets primary health care. BMJ 1993;
        307: 816-817.<o:p></o:p></span></h4>
        <p class="MsoBodyText2" style="margin-top:12.0pt;text-align:justify"><span lang="EN-GB"
        style="font-family:"CG Times"">Rimoin D, Connor JM, Pyeritz RE (1996) (eds):
        Emery and Rimoin's Principles and Practice of Medical Genetics.
        Churchill-Livingstone.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Rodriguez L, Sanchez R, Hernandez J, Carrillo L, et al
        (1997).<span style="mso-spacerun: yes">&nbsp; </span></span><span lang="EN-GB">Results of
        12 years' combined maternal serum alpha-fetoprotein screening and ultrasound fetal
        monitoring for prenatal detection of fetal malformations in Havana City, Cuba.<span
        style="mso-spacerun: yes">&nbsp; </span></span><span lang="FR"
        style="mso-ansi-language:FR">Prenat Diagn 1997; 4:301-304.<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Saborio M (1992). </span><span lang="EN-GB">Experience in
        providing genetic services in Costa Rica. In: Kuliev A, Greendale K, Penchaszadeh VB,
        Paul, NW (Eds): Genetic Services Provision: An International Perspective. Birth Defects
        Orig Art Ser 1992;28 (3) 96-102.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Salzano FM (1985).<span
        style="mso-spacerun: yes">&nbsp; </span>Incidence, effects, and management of sickle cell
        disease in Brazil. Am J Pediat Hem/Onc 1985;7:240-244.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Schuler L, Sanseverino
        MT, Clavijo HA, Ashton-Prolla P, Boianowsky K, Pecis F, Costa FS, Tatto E, Wong V, Santos
        CMV, Giugliani R (1993). Preliminary report on the first Brazilian Teratogen Information
        Service (SIAT). Braz J Genet 16:1085-1095.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Serjeant GR (1989).<span
        style="mso-spacerun: yes">&nbsp; </span>Geography and the clinical picture of sickle-cell
        disease. Ann NY Acad Sci 1989; 565:109-119.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Teebi AS (1994).
        Autosomal recessive disorders among Arabs. An overview from Kuwait. J Med Genet 30:797.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Temtamy SA, GhaliI, Salam MA et al. </span><span
        lang="EN-GB">(1992) Karyotype/phenotype correlation in females with short stature. Clin
        Genet 41:147-151.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">UNDP (United Nations
        Development Program). Human Development Report 1998. New York and Oxford: Oxford
        University Press; 1998.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">UNFPA (United Nations
        Population Fund). The State of World Population. New York: United Nations Population Fund;
        1998.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">UNICEF. The State of
        the World's Children 1998. Oxford and New York: Oxford University Press; 1998.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Venter PA, Christianson
        AL, Hutamo CM, Makhura MP, Gericke GS. Congenital anomalies in rural black South African
        neonates - a silent epidemic? S Afr Med J 1995; 85: 15-20.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Ville YG, Nicolaides
        KH, Campbell S (1998). Prenatal diagnosis of fetal malformations by ultrasound. In:
        Milunsky A (ed): Genetic Disorders and the Fetus. Baltimore and London, 1998, The Johns
        Hopkins University Press, pp 750-811.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Weatherall DJ, Clegg
        JB, Higgs DR, Wood WG (1995).<span style="mso-spacerun: yes">&nbsp; </span>The
        hemoglobinopathies. In: Scriver CR, Beaudet AL, Sly WS, Valle D (Eds): The Metabolic and
        Molecular Basis of Inherited Disease, New York. McGraw-Hill, 1995; pp3417-3484</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">World Bank (1993).
        World Development Report, 1993. New York, Oxford University Press; 1993.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">World Bank (1997).
        Confronting AIDS. Public Priorities in a Global Epidemic. New York, Oxford University
        Press, 1997.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">WHO (1983). Community
        Control of Hereditary Anemias.<span style="mso-spacerun: yes">&nbsp; </span>Memorandum
        from a WHO meeting. Bull World Health Org<span style="mso-spacerun: yes">&nbsp; </span>61:63-80.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">WHO (1985).<span
        style="mso-spacerun: yes">&nbsp; </span>Community approaches to the control of hereditary
        diseases.<span style="mso-spacerun: yes">&nbsp; </span>Report of a WHO Advisory Group on
        Hereditary Diseases. Geneva, 3-5 October 1985. Unpubl WHO document HMG/AG/85.10.
        Hereditary Diseases Programme. Geneva, WHO 1985.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">WHO (1993). Report of
        the 7<sup>th</sup> Meeting of the WHO Working Group on the Control of Hereditary Anaemias.
        Nicosia, Cyprus, 3-4 April 1993. (WHO/HDP/TIF/HA/93.1).</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">WHO (1996). Report of a
        WHO Scientific Group. Control of Hereditary Diseases: WHO Technical<span
        style="mso-spacerun: yes">&nbsp; </span>Report Series 865, Geneva, 1996.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">WHO (1996b) Guidelines
        for the development of a national programme for haemophilia.<span
        style="mso-spacerun: yes">&nbsp; </span>Pub WHO/HGN/WFH/GL/96.1.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">WHO (1996c).
        Haemophilia: Facts for health care professionals. Pub WHO/HGN/WFH/EM/96.4.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">WHO (1996d). Guidelines
        for the diagnosis and management of cystic fibrosis. Pub WHO/HGN/ICF(M)a/GL/96.2.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">WHO (1998). Proposed
        international guidelines on ethical issues in medical genetic and genetic services. Report
        of a WHO meeting on ethical issues in medical genetics. Geneva, 15-16 December 1997.<span
        style="mso-spacerun: yes">&nbsp; </span>Pub. WHO/HGN/GL/ETH/98.1.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">WHO/EMRO (1997).
        Community Control of Genetic and Congenital Disorders.<span style="mso-spacerun: yes">
        &nbsp; </span>Technical Publications Series, No 24. Alexandria WHO Regional Office for the
        Eastern Mediterranean, 1997.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Winichagoon P,
        Fucharoen S, Thonglairoam V, Tanapotiwirai V, Wasi P. (1990) Thalassemia in Thailand. Ann
        N Y Acad Sci 1990;612:31-42.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Xiao KZ, et al (1988). </span><span lang="EN-GB">Consecutive
        three-year birth defects monitoring in Sichuan province. Heredity and Disease 1988;
        5(2):65-68.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Xiao KZ, et al (1989).<span style="mso-spacerun: yes">
        &nbsp; </span></span><span lang="EN-GB">Epidemiology of neural tube defects in China.<span
        style="mso-spacerun: yes">&nbsp; </span>Natl<span style="mso-spacerun: yes">&nbsp; </span>Med
        J China 1989; 69(1):189-191.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="FR"
        style="mso-ansi-language:
FR">Zeng YT, Huang SZ (1987).<span style="mso-spacerun: yes">
        &nbsp; </span></span><span lang="EN-GB">Disorders of haemoglobin in China.<span
        style="mso-spacerun: yes">&nbsp; </span>J Med Genet 1987; 24:578-583.</span></p>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">&nbsp;<o:p></o:p></span></p>
        <p><span lang="FR"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
"CG Times";mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
mso-ansi-language:FR;mso-fareast-language:EN-US;mso-bidi-language:AR-SA;
layout-grid-mode:line">&nbsp;</p>
        <p>Zhang SZ, et al (1991).<span style="mso-spacerun: yes">&nbsp; </span></span><span
        lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;
font-family:"CG Times";mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA;layout-grid-mode:line">The
        prevalence of chromosome diseases in the general population of Sichuan, China.<span
        style="mso-spacerun:
yes">&nbsp; </span>Clinical Genetics 1991; 39:81-88.<br>
        </span></p>
        <p align="center"><img src="gendis1.jpg" alt="wpe1.jpg (12593 bytes)" width="384" height="291"></p>
        <h4 align="left"><font size="3"><b style="mso-bidi-font-weight:normal"><span lang="EN-GB"
        style="font-size:9.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
  letter-spacing:-.05pt">Table
        1: Epidemiological Transition in the Eastern Mediterranean region</span></b><span
        lang="EN-GB"
        style="font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:"Times New Roman""><o:p></span></font></h4>
        <table border="1" width="100%" height="436">
          <tr>
            <td width="8%" rowspan="2" height="108">Country</td>
            <td width="40%" colspan="5" height="21"><p align="center">Socio-Economic Indicators</td>
            <td width="52%" colspan="7" height="21"><p align="center">Health Indices</td>
          </tr>
          <tr>
            <td width="8%" height="83" align="center"><font size="1">GNP per Capita (US$)<br>
            1995</font></td>
            <td width="16%" colspan="2" height="83" align="center"><font size="1">Adult female
            Literacy (%) 1980-1995</font></td>
            <td width="8%" height="83" align="center"><font size="1">% of population with access to
            safe water 1990-97</font></td>
            <td width="8%" height="83" align="center"><font size="1">% of population with access to
            adequate sanitation 1990-97</font></td>
            <td width="16%" colspan="2" height="83" align="center"><font size="1">Life espectancy
            1970-1997</font></td>
            <td width="15%" colspan="2" height="83" align="center"><font size="1">Fertility 1970-1997</font></td>
            <td width="7%" height="83" align="center"><font size="1">IMR per 1000 (Date documented)</font></td>
            <td width="7%" height="83" align="center"><font size="1">Lethal CA per 1000 (date
            documented)</font></td>
            <td width="7%" height="83" align="center"><font size="1">CA/IMR % (Date documented)</font></td>
          </tr>
          <tr>
            <td width="8%" height="20"><span lang="FR"
            style="font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-ansi-language:
  FR">Bahrain<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">7840<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">60<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">79<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">94<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">97<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">62<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">73<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">7.1<o:p></o:p></td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:10.0pt;
  font-family:"Times New Roman""><span
            lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">3.0<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">21.1(1991)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">5.3(1991)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">25.2('91)<o:p></o:p></span></td>
          </tr>
          <tr>
            <td width="8%" height="20"><span lang="FR"
            style="font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-ansi-language:
  FR">Egypt</o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">1080<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">26</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">39<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">87</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">88</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">51</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">66</span></td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">7.0<o:p></o:p></td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:10.0pt;
  font-family:"Times New Roman""><span
            lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">3.4<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">33.8(1990)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">1.5(1990)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">4.3('90)<o:p></o:p></span></td>
          </tr>
          <tr>
            <td width="8%" height="20"><span lang="FR"
            style="font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-ansi-language:
  FR">Iran<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">1033<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">37<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">59</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">90</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">81</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">55</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">69</span></td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">7.<o:p>2</td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:10.0pt;
  font-family:"Times New Roman""><span
            lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">4.8<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">45
            &nbsp; (1988)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">3.3(1990)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">10.1('90)<o:p></o:p></span></td>
          </tr>
          <tr>
            <td width="8%" height="20"><span lang="FR"
            style="font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-ansi-language:
  FR">Irak<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">1036</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">25<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">45</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">81</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">75</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">55</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">62</span></td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">7.2</td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:10.0pt;
  font-family:"Times New Roman""><span
            lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">5.3<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">51
            &nbsp; (1985)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">3.8(1985)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">7.5('85)<o:p></o:p></span></td>
          </tr>
          <tr>
            <td width="8%" height="20"><span lang="FR"
            style="font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-ansi-language:
  FR">Kuwait</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">18720</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">59</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">75<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">-</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">-</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">66</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">76</span></td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">7.3<o:p></o:p></td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:10.0pt;
  font-family:"Times New Roman""><span
            lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">2.8<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">10.7(1993)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">3.6(1993)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">31.8('93)<o:p></o:p></span></td>
          </tr>
          <tr>
            <td width="8%" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">Morocco</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">1290</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">16</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">31<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">65</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">58</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">52</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">66</span></td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">7.2</td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:10.0pt;
  font-family:"Times New Roman""><span
            lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">3.2</span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">54
            &nbsp; (1990)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">1.7(1991)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">3.2('91)<o:p></o:p></span></td>
          </tr>
          <tr>
            <td width="8%" height="20"><span lang="FR"
            style="font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-ansi-language:
  FR">Oman</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">4950</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">-<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">46<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">85</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">78</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">47</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">91</span></td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">7.2</td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:10.0pt;
  font-family:"Times New Roman""><span
            lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">7.2<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">25
            &nbsp; (1993)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">4.0(1993)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">21.6('93)<o:p></o:p></span></td>
          </tr>
          <tr>
            <td width="8%" height="20"><span lang="FR"
            style="font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-ansi-language:
  FR">Qatar</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">11590<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">65</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">80<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">100</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">97<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">61</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">72</span></td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">7.0<o:p></o:p></td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:10.0pt;
  font-family:"Times New Roman""><span
            lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">3.8<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">11.8(1992)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">3.7(1992)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">31.7('92)<o:p></o:p></span></td>
          </tr>
          <tr>
            <td width="8%" height="20"><span lang="FR"
            style="font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-ansi-language:
  FR">Syria</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">1060</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">34</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">56<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">86</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">67</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">56</span></td>
            <td width="8%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">69</span></td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">7.3<o:p></o:p></td>
            <td width="8%" valign="middle" align="center" height="20"><p
            style="font-size:9.0pt;mso-bidi-font-size:10.0pt;
  font-family:"Times New Roman""><span
            lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">4.1<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">34
            &nbsp; (1990)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">4.0(1992)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="20"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">11.8('92)<o:p></o:p></span></td>
          </tr>
          <tr>
            <td width="8%" height="32"><span lang="FR"
            style="font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-ansi-language:
  FR">United
            Arab Emirates</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">17390</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">6<o:p>4</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">80</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">97</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">92</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">61</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">75</span></td>
            <td width="8%" valign="middle" align="center" height="32"><p
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">7.9<o:p></o:p></td>
            <td width="8%" valign="middle" align="center" height="32"><p
            style="font-size:9.0pt;mso-bidi-font-size:10.0pt;
  font-family:"Times New Roman""><span
            lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">3.5<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">10.9(1992)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">2.9(1992)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">26.8('92)<o:p></o:p></span></td>
          </tr>
          <tr>
            <td width="8%" height="32"><span lang="FR"
            style="font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-ansi-language:
  FR">Developing
            Countries</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">1222</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">46<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">62</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">71</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">44</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">53</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">63</span></td>
            <td width="8%" valign="middle" align="center" height="32"><p
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">6.0<o:p></o:p></td>
            <td width="8%" valign="middle" align="center" height="32"><p
            style="font-size:9.0pt;mso-bidi-font-size:10.0pt;
  font-family:"Times New Roman""><span
            lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">3.1<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">65
            &nbsp; (1997)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="32">-</td>
            <td width="7%" valign="middle" align="center" height="32">-</td>
          </tr>
          <tr>
            <td width="8%" height="32"><span lang="FR"
            style="font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-ansi-language:
  FR">Industrialised
            Countries</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">27086<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">96<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">-<o:p></o:p></span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">-</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">-</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">72</span></td>
            <td width="8%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">78</span></td>
            <td width="8%" valign="middle" align="center" height="32"><p
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">2.8<o:p></o:p></td>
            <td width="8%" valign="middle" align="center" height="32"><p
            style="font-size:9.0pt;mso-bidi-font-size:10.0pt;
  font-family:"Times New Roman""><span
            lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">7.1<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="32"><span lang="EN-GB"
            style="font-size:9.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman"">6.0(1997)<o:p></o:p></span></td>
            <td width="7%" valign="middle" align="center" height="32">-</td>
            <td width="7%" valign="middle" align="center" height="32">-</td>
          </tr>
        </table>
        <div align="center"><center><table border="0" cellspacing="0" cellpadding="0"
        style="border-collapse:collapse;
 mso-table-layout-alt:fixed;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"
        width="400">
          <tr style="height:3.75pt">
            <td width="671" valign="top"
            style="width:503.2pt;border:none;
  border-top:solid windowtext .25pt;padding:0cm 5.4pt 0cm 5.4pt;height:3.75pt"></td>
          </tr>
        </table>
        </center></div><h4 align="left" style="text-align:center"><span lang="EN-GB"
        style="font-size:12.0pt;
mso-bidi-font-size:10.0pt;font-family:"CG Times""><o:p></o:p></span></h4>
        <p class="MsoNormal"
        style="text-align:justify;line-height:200%;mso-hyphenate:
none;tab-stops:-36.0pt"><b
        style="mso-bidi-font-weight:normal"><span lang="EN-GB"
        style="font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"CG Times"">TABLE
        2<span style="mso-spacerun: yes">&nbsp; </span>:<span style="mso-tab-count:1">
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Reasons for Presentation of Patients<o:p></o:p>for Medical
        Genetic Care</span></b><br>
        <span lang="EN-GB" style="letter-spacing:-.15pt">The presence of birth
        defect(s)/dysmorphic features<o:p></o:p><br>
        Mental retardation<o:p></o:p><br>
        Neuro-developmental regression<o:p></o:p><br>
        Neonatal lethargy/coma, anorexia, vomiting, acidosis, ketosis, or a combination thereof.<o:p></o:p><br>
        Abnormal patterns of growth<o:p></o:p><br>
        Abnormal sexual development, amenorrhoea, aspermia<o:p></o:p><br>
        Unexplained partial or complete hearing and/or visual loss<o:p></o:p><br>
        Unexplained neurodegeneration<o:p></o:p><br>
        Unexplained abnormalities of skin, hair and bones<o:p></o:p><br>
        Unexplained anaemias or bleeding disorder<o:p></o:p><br>
        Abnormal newborn screening test for an inborn error of metabolism<o:p></o:p><br>
        Family history of a specific condition<o:p></o:p><br>
        Indications for prenatal diagnosis (e.g. advanced maternal age)<o:p></o:p><br>
        Fetal abnormality indicated by prenatal diagnosis<o:p></o:p><br>
        Ethnic background indicates a risk of a specific disorder (e.g. Tay-Sachs disease) <o:p></o:p><br>
        Consanguinity<o:p></o:p><br>
        Exposure of a pregnant woman to a teratogen</span></p>
        <h4
        style="margin-left:72.0pt;text-align:justify;text-indent:
-72.0pt;line-height:200%;mso-hyphenate:none;tab-stops:-36.0pt 0cm 36.0pt"><b
        style="mso-bidi-font-weight:
normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Table
        3<span style="mso-spacerun: yes">&nbsp; </span>:<span style="mso-tab-count:1"> </span>Options
        for Best Possible<span style="mso-spacerun: yes">&nbsp; </span>Care in Common Genetic
        Disorders and Birth Defects<o:p></o:p></span></b></h4>
        <table border="1" width="100%">
          <tr>
            <td width="100" align="left"><font size="2"><strong><span lang="EN-GB"
            style="letter-spacing:
  -.15pt">CONDITION</span></strong></font></td>
            <td width="25%"><font size="2"><strong><span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";letter-spacing:-.15pt;mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">SPECIFIC
            COMPLICATIONS</span></strong></font></td>
            <td width="125"><font size="2"><strong><span lang="EN-GB"
            style="letter-spacing:
  -.15pt">INVESTIGATIONS</span></strong></font><table border="1"
            cellspacing="0" cellpadding="0"
            style="border-collapse:collapse;
 mso-table-layout-alt:fixed;border:none;mso-border-alt:solid windowtext .5pt;
 mso-padding-alt:0cm 5.4pt 0cm 5.4pt"
            height="26">
              <tr>
                <td width="170"
                style="width: 127.55pt; border: .5pt none; padding-left: 5.4pt; padding-right: 5.4pt; padding-top: 0cm; padding-bottom: 0cm"
                height="24"></td>
              </tr>
            </table>
            </td>
            <td width="125"><font size="2"><strong><span lang="EN-GB"
            style="font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"CG Times";mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">THERAPEUTIC
            INTERVENTION</span></strong></font></td>
          </tr>
          <tr>
            <td width="100" align="left"><font size="3"><strong><span lang="EN-GB"
            style="font-size:10.0pt;font-family:
"CG Times";mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">Spina
            bifida</span></strong></font></td>
            <td width="25%"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Spinal
            lesion<br>
            Hydrocephalus<br>
            Developmental delay<br>
            Paraplegia</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Incontinence</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB"><br>
            Brain scan<br>
            Developmental*/ psychometric assesment<o:p></o:p></span></p>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA"><p>Urological
            evaluation</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Surgery/
            Palliative care*<br>
            Surgey<br>
            NDT*<o:p></o:p></span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Prevention
            UTI*/ Self catheterisation*</span></td>
          </tr>
          <tr>
            <td width="100" align="left"><font size="3"><strong><span lang="EN-GB"
            style="font-family:"CG Times"">Cleft lip/Palate</span></strong></font></td>
            <td width="25%"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Feeding
            problems</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Speech
            problems</span></td>
            <td width="125"><span lang="EN-GB"
            style="font-size:10.0pt;font-family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">Audiological/
            Speech evaluation</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Surgery
            /Buccal plate</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">NDT*</span></td>
          </tr>
          <tr>
            <td width="100" align="left"><font size="3"><strong><span lang="EN-GB"
            style="font-size:10.0pt;font-family:
"CG Times";mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">Tallipes
            Equinovarus</span></strong></font></td>
            <td width="25%"><span lang="EN-GB"
            style="font-size:10.0pt;font-family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">Abnormal
            foot position</span></td>
            <td width="125"><span lang="EN-GB"
            style="font-size:10.0pt;font-family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">X-rays*</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Manipulation*
            / Plaster of paris*</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Surgery</span></td>
          </tr>
          <tr>
            <td width="100" align="left"><font size="3"><strong><span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA"></span><span
            lang="EN-GB" style="font-family:"CG Times"">Undescended testes</span><span
            lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA"></span></strong></font></td>
            <td width="25%"><span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA"></span></td>
            <td width="125">&nbsp;</td>
            <td width="125"><span lang="EN-GB"
            style="font-size:10.0pt;font-family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">Surgery</span></td>
          </tr>
          <tr>
            <td width="100" align="left"><font size="3"><strong><span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA">Achondroplasia</span></strong></font></td>
            <td width="25%"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Short
            stature<br>
            Spinal gibbus<br>
            Spinal cord compression</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Hydrocephalus</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">DNA<br>
            X-rays*<br>
            X-rays*</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Brain
            scan</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Counselling
            on spinal posture*<br>
            Surgery</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Surgery</span></td>
          </tr>
          <tr>
            <td width="100" align="left"><p style="text-align:justify" align="right"><font size="3"><strong><span
            lang="EN-GB">Neurofibromatosis<o:p></o:p></span><span lang="EN-GB"
            style="font-size:10.0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">
            (NFI)</span></strong></font></td>
            <td width="25%"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Tumors<br>
            Plexiform neurofibroma<br>
            Optic glioma<br>
            Seizures<br>
            Learning disability / Mental retardation</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Long
            bone bowing</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">DNA<br>
            X-rays*<br>
            Opthalmological assessment<br>
            EEG<br>
            Developmental* / Psychometric assessment</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">X-rays*</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Surgery<br>
            Surgery<br>
            Anticonvulsant therapy*<br>
            NDT*</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Surgery</span></td>
          </tr>
          <tr>
            <td width="100" align="left"><font size="3"><strong><span lang="EN-GB">Thalassaemia</span></strong></font></td>
            <td width="25%"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Chronic
            aneamia<br>
            Splenomegaly<br>
            Hepatomegaly</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Iron
            overload</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Heamoglobin
            electrophoresis / DNA<br>
            Full blood count* </o:p></span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Iron
            studies </span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Blood
            transfusion*/ Haematinics*<br>
            Splenectomy</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Desferioxamine*</span></td>
          </tr>
          <tr>
            <td width="100" align="left"><font size="3"><strong><span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA">Haemochromatosis</span></strong></font></td>
            <td width="25%"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Iron
            overload<br>
            Cirrhosis<br>
            Diabetes<br>
            Cardiac failure</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Arthiritis</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">DNA<br>
            Iron studies<br>
            Liver function tests<br>
            Glucose tolerance test<br>
            ECG* / X-rays* / Ultrasound / Angiogram</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">X-rays*</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Venesection<br>
            Diet* / Insulin* / Diabetic medications*<br>
            Cadiac failure therapy*</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Anti-inflammatories*</span></td>
          </tr>
          <tr>
            <td width="100" align="left"><font size="3"><strong><span lang="EN-GB"
            style="font-size:10.0pt;font-family:
"CG Times";mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">FragileX-syndrome</span></strong></font></td>
            <td width="25%"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Mental
            retardation</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Behavioural
            problems</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">DNA</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Developmental*
            / Psychometric assessment</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">NDT*</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Behavioural
            management*</span></td>
          </tr>
          <tr>
            <td width="100" align="left"><font size="3"><strong><span lang="EN-GB">Haemophilia A</span></strong></font></td>
            <td width="25%"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Bleeding<br>
            Diathesis</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Joint
            Arthiroses</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">DNA<br>
            PI / PTT<br>
            Factor VIII assay</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">X-rays*</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Factor
            VIII replacement*</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Physiotherapy*
            / Surgery</span></td>
          </tr>
          <tr>
            <td width="100" align="left"><font size="3"><strong><span lang="EN-GB">Down syndrome</span></strong></font></td>
            <td width="25%"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Mental
            retardation<br>
            Congenital heart defect<br>
            Ocular abnormalities<br>
            Recurrent infection<br>
            Serous otitis media / Hearing loss</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Hypothyroidism</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Chromosomes<br>
            Developmental* / Psychometric assessment<br>
            ECG* / X-rays* / Ultrasound / Angiogram<br>
            Opthalomological evaluation<o:p></o:p><br>
            Auditory / Speech evaluation</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Thyroid
            function test</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">NDT*<br>
            Cardiac failure therapy* / Surgery<br>
            Surgery (cataracts) / Glasses<br>
            Antibiotics*<br>
            NDT*</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Thyroid
            hormones</span></td>
          </tr>
          <tr>
            <td width="100" align="left"><font size="3"><strong><span lang="EN-GB"
            style="font-size:10.0pt;font-family:
"CG Times";mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">Turner
            syndrome</span></strong></font></td>
            <td width="25%"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Short
            stature<br>
            Learning disablility<br>
            Primary amenorrhoea / Infertility</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Congenital
            heart defect</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Chromosomes<o:p></o:p><br>
            Psychometric assessment</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">ECG*
            / X-rays* / Ultrasound / Angiogram</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Growth
            hormones<br>
            NDT*<br>
            Hormone replacement</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Cardiac
            failure therapy* / Surgery</span></td>
          </tr>
          <tr>
            <td width="100" align="left"><font size="3"><strong><span lang="EN-GB"
            style="font-size:10.0pt;font-family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">Trisomy
            18 syndrome</span></strong></font></td>
            <td width="25%"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Growth
            deficiency<br>
            Congenital heart defect</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Early
            death</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Chromosomes</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Growth
            monitoring*</span></td>
            <td width="125"><span lang="EN-GB"
            style="font-size:10.0pt;font-family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">Palliative
            care*</span></td>
          </tr>
          <tr>
            <td width="100" align="left"><font size="3"><strong><span lang="EN-GB"
            style="font-size:10.0pt;font-family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">Fetal
            alcohol syndrome</span></strong></font></td>
            <td width="25%"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Growth
            deficiency<br>
            Mental retardation<br>
            Behavioural abnormalities</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Congenital
            cardiac defects</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Clinical
            diagnosis<br>
            Growth monitoring*<br>
            Developmental* / Psychometric assessment<br>
            Psychological assessment</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">ECG*
            / X-rays* / Ultrasound / Angiogram</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">NDT*<br>
            Neuro-behavioural therapy</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Cardiac
            failure therapy* / Surgery</span></td>
          </tr>
          <tr>
            <td width="100" align="left"><font size="3"><strong><span lang="EN-GB"
            style="font-size:10.0pt;font-family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">Fetal
            rubella syndrome</span></strong></font></td>
            <td width="25%"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Growth
            deficiency<br>
            Microcephaly<br>
            Mental retardation<br>
            Visual defects<br>
            Deafness</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Congenital
            heart defects</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="ES-TRAD"
            style="mso-ansi-language:ES-TRAD">Rubella virus IgM / IgG<o:p></o:p></span><br>
            <span lang="EN-GB">Growth monitoring*<br>
            Developmental* / Psychometric assessment<br>
            Opthalmological assessment<br>
            Auditory / Speech assessment</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">ECG*
            / X-rays* / Ultrasound / Angiogram</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">NDT*<br>
            Surgery (cataract) / Glasses<br>
            NDT* / Hearing aids</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Cardiac
            failure therapy* / Surgery</span></td>
          </tr>
          <tr>
            <td width="100" align="left"><font size="3"><strong><span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA">Congenital
            hypothyroidism</span></strong></font></td>
            <td width="25%"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Growth
            deficiency<br>
            Mental retardation</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Umbilical
            hernia</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Neonatal
            screening* / Thyroid function tests<br>
            Growth monitoring*</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Developmental*
            / Psychometric assessment</span></td>
            <td width="125"><p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">Thyroxine*<br>
            NDT*</span><br>
            <span lang="EN-GB"
            style="font-size:10.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA">Surgery</span></td>
          </tr>
        </table>
        <p class="MsoNormal" style="text-align:justify"><span lang="EN-GB">* Can be undertaken at
        primary health care level<br>
        For the above conditions clinical diagnosis, genetic counselling and psycho-social support
        are possible at primary health care level.</span></td>
      </tr>
</TBODY>
      <tr>
        <td colSpan="2" vAlign="top" width="654" height="0"><hr>
        <h5 align="center">| <a href="/">WHO Home</a> |<br>
        | <a href="../asthma/index.htm">Asthma</a> | <a href="../cancer/index.htm">Cancer</a> | <a
        href="../cvd/index.htm">Cardiovascular diseases</a> | <a href="../dia/index.htm">Diabetes</a>
        | <a href="index.htm">Human genetics</a> | <a href="../orh/index.htm">Oral health</a> | <a
        href="http://www5.who.int/tobacco/">Tobacco use</a> | <a href="../noma/index.htm">Noma</a>
        |<br>
        </h5>
        <h5 align="left"><font size="2">Contact us: <a href="mailto:ncdinfo@who.int">ncdinfo@who.int</a>
        .<br>
        Copyright </font><font size="1"><a class="Asmall"
        href="/home/copyright/index.en.html">© WHO/OMS, 2001</a> </font></h5>
        </td>
      </tr>
    </table>
    </center></div></td>
  </tr>
</TBODY>
</table>
<p>&nbsp;</p>
</body>
</html>

